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Abstract 
Abstract 
This thesis describes the design and synthesis of bifunctional drugs combining a 
nucleoside (d4U) and non-nucleoside (HI-236) reverse transcriptase inhibitor linked 
via different spacers between C-5 of the NRTI and 0-1 of the NNRTI. 
Three targets were successfully synthesized in a divergent manner from uridine in 13 
steps for the butyne target and 19 steps for targets bearing PEG-propyne units using 
Sonogashira coupling as a key step. The most challenging step of the synthesis 
involved Boc deprotection and thiourea condensation in the final step, which suffered 
from anomeric cleavage with loss of the sugar moiety. As a result, the target with a 
three-carbon propynyl spacer could not be accessed. 
Progress towards the synthesis of a bifunctional system bearing a saturated and 
more flexible tether is highlighted in Chapter 4. The key reactions included 
Sonogashira coupling of iodo nucleosides, 2',3'-dideoxygenation of the vicinol diol, 
phenolic alkylation and condensation of amine with thiourea reagent. The synthesis 
surmounted several challenges, with chemoselective distinction of unsaturation via 
late introduction of the d4U double bond using Corey-Winter methodology as the 
highlight. 
Preliminary biological results indicate that the d4U-butyne-HI-236 bifunctional to have 
the smallest EC50 anti-HIV activity of any NRTI-spacer-NNRTI bifunctional inhibitor 
synthesized to date. The work presented in this thesis has established a synthetic 
platform for the production of a library of active bifunctional compounds used to 
probe the two drug target sites of HIV-1 reverse transcriptase synergistically. 
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Chapter 1 : Introduction 
CHAPTER 1 
Introduction 
1.1 Human Immunodeficiency Virus (HIV) 
HIV, the causative agent of AIDS, is a single-stranded RNA that belongs to the family 
of Retroviridae. Its genetic information is not encoded as DNA, but as RNA and 
therefore is reverse-transcribed into DNA. The HIV virus comprises two distinct 
viruses as HIV-1 and HIV-2, which differ in origin and gene sequence. HIV-1 carries 
a vpu gene whereas HIV-2 carries the vpx gene. These strains of HIV share similar 
molecular structures in that they contain a single-stranded RNA genome and both 
viruses cause AIDS with a similar spectrum of symptoms. Like all viruses, HIV-1 is an 
intracellular parasite and cannot multiply without the host cel1. 1 
1.2 Epidemiology of HIV/AIDS 
About 40.3 million people are living currently (2005) with HIV/AIDS and the great 
majority are in the developing world. With a population of about 600 million, sub-
Saharan Africa accounts for over two-thirds of the world's HIV-infected people, 
including 80% of the world's HIV-infected women and children. In 2005, 
approximately 3.1 million AIDS deaths occurred globally, at least 2.4 million of them 
in sub-Saharan Africa. In South Africa, AIDS has orphaned an estimated 660,000 
children,2 with the epidemic being concentrated in the eastern and southern parts of 
the continent. 3 The epidemic's toll continues to mount even in countries already 
experiencing high HIV prevalence rates. Six countries, all in Southern Africa, have 
prevalence rates higher than 20%: Swaziland (38.8%), Botswana (37.3%), Lesotho 
(28.9%), Zimbabwe (24.6%), South Africa (21.5%) and Namibia (21.3%).2 
1.3 Structure of HIV-1 
The HIV-1 structure involves outer and inner cores. The outer core consists of a lipid 
bilayer acquired from the host cell, while the inner core contains two proteins, p24 
- 1 -
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Chapter 1 Introduction 
and p17, as matrix proteins surrounding the nucleocapsid containing the genetic 
material. A single virion has an icosahedral shape with a knobby-looking envelope. 
The knobs are comprised of the envelope glycoproteins (gp) 120 and 41 .4. Beneath 
the envelope is the viral matrix (p17), which, aside from structural maintenance, 
enables the DNA copy of the viral genome to be transmitted to the host nucleus. 
Inside this is the p24-capsid. It encapsuiates nine genes: gag, pol, emf, tat, rev, nef, 
vif, vpu and vpr, which carry all the information needed to make new viruses (Fig. 
1.1),5 
........:. . 
",,'e, ... n""",<>,,_ 
- ... ""~ -~. 
-
~" 
..... -. 
• 
• • 
Fig 1.1 Structure and Ille cycle 01 HIV-1 VifUS 
1,4 Life-Cycle of HIV 
HIV begins its infection of a susceptible host cell by binding to the C04 receptor on 
the host cell (Fig , 1.2) , CD4 is present on the suliace of many lymphocytes, which 
are a critical part of the body's immune system 6 Two chemokine receptors: CCR5 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter l ' Introduction 
and CXCR4 are coreceptors needed for HIV to enter the cell.! The HIV glycoprotein 
120 interacts with the CD4 molecule on the suliace of the target cell . Following CD4 
binding, a central material change in the HIV gp120/gp41 complex is induced by 
Interaction of gp120 with chemokine receptors CCR5 or CXCR4, The chemokine 
receptors, CCR5 and CXR4 are co-receptors for macrophage-tropic HIV-1 (R5-HIV-
1) and T-cell line-tropic HIV-1 (X4-HIV-1). respectively, The change In conformation 
exposes gp41 allowing it to initiate fusion of the membranes." This is a complex 
process that has been investigated exhaustively leading to development of the fusion 
inhibitor Fuzeon n• (Enfuvirtide, T-20) ,b 
-
Fig. 1.2 The three steps of HIV cell entry. 
Following fusiOll of the virus with the host cell, HIV enters the cell. Partial uncoating 
of the viral core occurs and the RNA-genetic material of the virus, is released into the 
host cell cytoplasm where it undergoes reverse transcriptioo into DNA An enzyme in 
HIV called reverse transcriptase (RT) is necessary to catalyze this conversiOll of viral 
RNA into DNA. Initially the viral enzyme (RT) copies the viral RNA genome into a 
single minus strand of DNA5 via polymerisation of deoxynucleoside triphosphates into 
a complementary DNA (cDNA) strand using an RNA template. like other DNA 
poIymerases, this enzyme can only add nucleotides to the 3' end of a pre·existing 
primer, base-paired to the template. Once a cDNA copy of mRNA is synthesized, the 
mRNA is removed by ribOlluclease (RNase H). The single-stranded DNA (ssDNA) is 
then converted by RT to double·stranded DNA (dsDNA) The entire process yields a 
dsDNA molecule thai is longer than the template RNA and which has a long terminal 
repeat (LTR) at each end. Once the genetic material of HIV has been changed into 
DNA. this viral DNA enters the host cell nucleus (a process facilitated by the HIV 
proteins vpr and MAl where it can be integrated into the genetic material of the cell. 
The enzyme integrase catalyzes this process." 
~ 3 ~ 
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Chapter 1: Introduction 
Activation of the host cells using RNA polymerase " results in the transcription of 
viral DNA into messenger RNA (mRNA), which is then translated into viral proteins. 
The proteins pass through the Golgi apparatus where they are glycosylated into 
gp120 and gp41 HIV envelope proteins. The gag and gag-pol polyproteins associate 
with the inner surface of the plasma membrane and interact with gp41 present in the 
plasma membrane. As p55 and p160 polyproteins accumulate on the inner surface of 
the plasma membrane, they aggregate and commence assembly to form the virion. 
As assembly continues, the structure extrudes from the cell. The virus buds from the 
cell and acquires a lipid coat, carrying the gp120 and gp41 proteins. During (or soon 
after) the budding of the new HIV particle from the host cell membrane, the viral 
proteinase in p160 becomes active, resulting in the cleavage of p160 and p56 into 
the various subunits and generating the mature form of HIV.5 
1.5 HIV Pathogenesis 
AIDS results from selective depletion of CD4-positive helper T-lymphocytes.8 The 
function of CD4 cells is to help COB-positive cytotoxic T -lymphocytes (CTL or killer 
cells) to destroy other cells expressing foreign antigens and also to enhance antibody 
production by B-Iymphocytes. Thus, CD4 cells represent a key component of the 
immune system. In the healthy individual, about 1200 CD4 cells circulate per ~L 
blood; when CD4 counts drop below 400/~L, opportunistic infections start to occur.1 
HIV eventually kills the helper T-cells that are vital for the immune system, and the 
decline in CD4+ T-cells eventually has a great effect on humoral response functions, 
specifically the functioning of the B-cells. The helper T -cells activate both the 
cytotoxic T-cells and the B-Iymphocytes. Helper T-cell depletion inhibits the B-cells 
from differentiating into plasma cells and memory cells, thus imparing the immune 
system's ability to fight against foreign antigens that have entered the body.9 A 
person with a CD4 level below 200/~L is considered to be in the AIDS phase of the 
disease. 
1.6 The Reverse Transcriptase Enzyme (RT) 
HIV-1 RT is a dimer of two related chains; a 66-kD subunit (p66) and a 51-kD subunit 
(p51), which is derived from p66 by proteolytic cleavage. The p66 subunit contains 
- 4 -
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the polymerase and RNase H active sites as well as the NNRTI binding pock.et (Fig. 
1.3). The p51 polypeptide corresponds to the polymerase subdomain of p66, and 
comprises the first 440 amino aCids of p66 11 The subdomalns within the polymerase 
domain of each subunit have been named fingers, palm, thumb and connection. The 
additional 120 residues at the carboxyl terminus of p66 comprise the RNase H 
domain, The arrangement of the subdomains in the two subunits is dramatically 
different. In p66, the subdomains are arranged to fonn a cleft in which the template-
primer binding cleft and active site residues are buried. There is, therefore, only one 
functiona l polymerase active site per p66/p51 heterodimer. 12 
The RT enzyme is an essential viral enzyme, which is responsible for converting the 
genomic single-stranded RNA of HIV into double-stranded DNA (dsDNA), which 
subsequently becomes integrated into the host genome. HIV-1 RT IS a 
multifunctional enzyme that exhibits two distinct enzymatic activities: (i) a DNA 
polymerase activity that can use either RNA or DNA as a template and (ii) an 
endonucleolytic ribonuclease H (RNase H) activity that specifically degrades the RNA 
strand of a RNA-DNA hybridB Reverse transcription is carried out using the 
following catalylic activilles: 
(i) RNA-dependent DNA polymerisabon to form an RNA-DNA hybrid 
(ii) RNase H degradation of the RNA strand from the RNA-DNA hybrid 
(iii) DNA-dependent DNA polymerisation to form a dsDNA 
As a result of its crucial role In the life cycle of HIV, it has been considered to be a 
good drug targe\. 1 ~ 
, 
""" 'J 
ftu" " " 
,.. .... " 
''"'' , .... , 
Fig. 1.3. (a) Structure of the HIV-1 reve rse transcripta~e enzyme adapted from Huang et aI." (b) 
RNA-directed synthesIs followed by DNA-directed ~ynthesis 
b 
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Chapter 1: I ntrod uction 
1.7 HIV-1 Reverse Transcriptase Inhibitors 
Drugs that inhibit the functions of the Reverse Transcriptase enzyme are referred to 
as reverse transcriptase inhibitors. They are classified into two classes as: 
a) Nucleoside and nucleotide analogues (NRTI) 
b) Non-nucleoside reverse transcriptase inhibitors (NNRTI) 
1.7.1 Nucleoside Reverse Transcriptase Inhibitors 
Currently, seven drugs belonging to the 2',3'-dideoxynucleosides (ddNs) have been 
approved by the Food and Drug Administration for the treatment of HIV and are 
commercially available. They include, Zidovudine (AlT, Retrovir),15 Stavudine (d4T, 
Zerit),16 Zalcitabine (ddC, Hivid),17 didanosine (ddl, Videx),18 Lamivudine (3TC, 
Epivir),19 Abacavir (ABC, 1592489, Ziagen),2o and Emtricitabine «-) FTC, 
Emtriva™).21 One nucleotide analogue, Tenofovir disoproxil fumarate (PMPA, 
Viread™) has also been approved by the FDA and is currently in clinical use22 (Fig. 
1.4). 
2',3'-Dideoxynucleosides are the most important class of compounds active against 
HIV. They act as DNA-chain terminators and competitive inhibitors of viral reverse 
transcriptase (RT)?3 Elongation is blocked because the chain terminators lack the 3'-
OH functional group essential for incorporation of additional nucleotides. NRTls are 
not highly specific and can inhibit normal cellular polymerases, causing serious side 
effects. They must first be phosphorylated intracellularly to their 5'-triphosphate form 
by cellular kinases before they act as chain terminators in the RNA-directed DNA 
polymerisation reaction catalysed by HIV-1 RT. In their 5'-triphosphate form, these 
dideoxynucleosides compete with the natural substrate (dTTP, dCTP, etc) of RT.24 
d4T shows selective anti-HIV activity comparable to that of AZT in vitro. However, 
d4T is less toxic and less inhibitory to mitochondrial DNA replication than AlT.25 
- 6 -
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0 0 NH2 
"':Jr HO& HO oAN I tJ 
N 
3 AZT d4T ddC 
0 
N5 
H,~ 
(eN" ~X} HO oAN I HO ~~ Ho'tj ~.?--NH, 
rJ 1j 
ddl 3TC ABC 
COOH 
-( 
COOH 
(-) FTC 
PMPA 
Fig. 1.4: Nucleoside analogues currently used to treat HIV/AIDS 
1.7.2 The Structure of HIV-1 RT in Complex with Nucleoside Inhibitors 
Nucleotide analogues bind at the dNTP-binding site (Fig. 1.5), adjacent to the 3' 
terminus of the primer strand that is located in the palm subdomain of the p66 
subunit.12 The catalytic triad of aspartic acids, (Asp11 0, Asp185 and Asp186), which 
are conserved in most polymerases are also located at this site. The nucleotide 
analogue binding site is composed of both protein and nucleic acid. The nucleic acid 
part of the binding site is made up of the 3'-primer terminus, which possesses the 3'-
OH group that is the site for the covalent attachment of the incoming substrate. The 
base of the 3'-primer terminal nucleotide also helps to bind incoming substrate via 
base-stacking interactions. The first base in the template overhang contributes base-
specific H-bond donor and acceptor groups that guide dNTP selection based on 
Watson-Crick base pairing rules. Based on modelling experiments, residues Asp185 
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and Asp186 of the conserved Tyr-Met-Asp-Asp motif and Asp110 are believed to 
bind the triphosphate moiety of the incoming dNTP via one or two chelated Mg2< 
ions 1t 
jpS' 
primer grip 
displacement 
(:'3'-
~229ICP) ~'­W229 (DNAI ~.' ,,~ \ ''/ . CP-94,707 
Fig. 1.5: Superpos~lan of HIV-l RT In complex with an irlhlbttDr and In ternary complex W1th primer 
template DNA and illComing dNTP Displacement of TRP-229 and concomItant displacement 01 the 
primer gnp are indicated w~h arrOWS _ NOO~Clfic contacts between the primer grip and the primer 
strand DNA are In[\oCated with p.3 rallelllnes 
1.7.3 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI) 
In 1987, when the 1' t NRTI (AZT) was approved for the treatment of HIV infection. 
the 1.I1derstanding of the replication cycle of the HIV virus was limited and the 
molecular targets that are known today to be central to HIV replication had not been 
identified n A broad screening of the Janssen compound library in the early nineties 
led to the discovery of TIB02B and a_APA29 as anti-HIV agents, This was followed by 
systematic lead optimization. which Yielded the first-generation NNRTls Tivirapine, a 
TIBO derivative. and Loviride. an a-APA derivative. 14,:lO These compounds were 
effective against wild-type HIV-1 but had lower potency when tested against common 
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NNRTI-resistant mutants. Chemical modifications were introduced in these TIBO and 
a-APA derivatives, resulting in a systematic structure-based molecular modelling 
study which played a key role in understanding the three dimensional structure-
activity relationships in these two chemically distinct series. 14 
The disclosure of TIBO compounds inspired the search for more potent and selective 
RT inhibitors.27 To date, more than 30 structurally diverse NNRTls have been 
identified.31 They include DABO derivatives,32 HEPT derivatives,33 TSAO 
derivatives,34 Thiocarboxanilide derivatives,35 Quinoxaline derivatives36 and PETT 
derivatives37 (Fig. 1.6). The number of compounds within the NNRTls is rapidly 
increasing and by the end of 1998, the following three compounds had been 
approved for clinical use by the food and drug administration: Nevirapine 
(Viramune®),38 Delavirdine (Rescriptor~39 and Efavirenz (Sustiva™)4o (Fig. 1.7). 
DABO 
Thiocarboxanilide 
UC-781 
PETT 
Trovirdine 
y 
0'1'0 
o 
/U)::5/ 
HEPT 
I-EBU (MKC-442) 
1)CI 0 I H ::::-.. r-CI ::::-.. 
H 0 
a-APA 
Loviride 
o 
H 
Quinoxaline 
HBY 097 
S HN-{ 
0'~m"" ~N 
CI ~ 
TIBO 
Me0w' 
1-'5;-0 l..---lo /H~ / 
o=s-o OSi~ 
II \ \ 
o 
TSAO 
Fig. 1.6: Chemical structures of some selected NNRTI inhibitors 
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Nevirapine 
y 
H~ 
r~) 
V 
o 
Delavirdine 
Fig. 1.7: NNRTls approved for the treatment of HIV/AIDS 
I ntrod uction 
/ C1'COo 
H 
Efavirenz 
Soon after the NNRTls were being used in clinical settings, it became apparent that 
this class of inhibitors was vulnerable to HIV's high mutation rate, which resulted in a 
rapid selection of resistant strains. This tempered the initial enthusiasm and even led 
some groups to abandon NNRTI research altogether. 3D 
By early 2000, structural activity studies around the a-APAs had produced 
imidazoylthiourea (ITU) derivatives. An effort to improve the metabolic stability of the 
ITUs led to the serendipitous discovery of DATA compounds. These compounds 
have a triazine ring that replaced the unstable thiourea mOiety of ITU (Fig. 1.8). 
Molecular modelling of DATA compounds suggested that replacing the central 
triazine ring with a pyrimidine ring would improve the activity further. This structural 
modification led to the discovery of etravirine, a diarylpyrimidine (DAPY) derivative, 
that is highly potent and effective against wild-type and drug-resistant HIV-1 
variants.27 
I I ~ CI::::"" CI::::"" H NH ~ 
NH S 
ITU 
R100943 
I I ~ CI ~ CI ~ lyNH 
~N 
N~ 
DATA 
R106168 
Fig. 1.8: Chemical structures of second-generation NNRTls. 
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1.7.4 The NNRTI Binding Pocket 
NNRTls bind at a largely non-conserved site. Detailed structural information of the 
RT enzyme in complex with the inhibitor is useful for effective drug design. The 
NNRTI binding site ('pocket') is located in the p66 domain at about 10A distance from 
the substrate-binding site. The ligands in this pocket are of mainly hydrophobic 
nature with substantial aromatic character with the most prominent ones being Y181, 
Y188, F227, L 100, L234, V179 and K103. The pocket region also contains a few 
hydrophilic residues (Lys101, Lys103, Ser105, Asp192, Glu224 and Glu1138) and 
backbone atoms that may form hydrogen bonds to non-nucleoside compounds, 
which all include hydrogen-bond donor and acceptor groupS.12 
1.7.5 Interaction of NNRTls with their Pocket Site at the HIV-1 RT 
The NNRTls block the HIV-1 reaction through interaction with an allosterically 
located, non-substrate binding site.41 The NNRTI binding in this pocket causes a 
repositioning of the three-stranded beta-sheet in the p66 subunit, which contains the 
catalytic aspartic acid residues 100, 185 and 186. This inhibits HIV-1 RT by locking 
the active catalytic site into an inactive conformation, reminiscent of the conformation 
observed in the inactive p51 subunit.42 Steady state kinetic studies carried out by 
Anderson et 81. have revealed that NNRTI binding to HIV-1 RT does not prevent the 
binding of nucleotide triphosphate substrates to the enzyme, but instead blocks the 
chemical step of NRTI incorporation.43 
When bound into their pocket of HIV-1 RT, the first-generation NNRTls maintain a 
very similar conformational 'butterfly-like' shape. They roughly overlay each other in 
the binding pocket and appear to function as n-electron donors to aromatic side-
chain residues lining the pocket. 44 
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Fig, 1-9: Close-up of the future bonding pocket area in lIIlliganded RT. Amioo aCid residue 100 (shown 
in blue) makes contact with residues Y181 and Y188 (shown in red) which uridergo major structural 
rearrangement prior to OOI1-nucleoside inhibitor bonding L 1 00 also makes contact with K101 and K103 
(purple) in the uncomplexed state " 
In crystal structures of unliganded HIV-1 RT, the non-nucleoside inhibitor-binding site 
(NNIBS) does not exist (Fig. 1.9). During the process of inhibitor binding, significant 
conformational changes occur in the orientatiOll of the side chains of Tyr181 and 
Tyr188 leading to the formation of the hydrophobic pocket accommodating the 
inhibitor. It is evident from a comparison of the various RT structures that the NNIBS 
has a very flexible strucllxe, and that this flexibility apparently allows the enzyme to 
accommodate structurally diverse inhibitors having different shapes and sizes. In 
fact, side-chain residues adapt themselves to each bound inhibitor in a highly specific 
manner, closing about the surface of the drug to make tight van der Waals 
contacts'& 
,., 
Fig. 1.10: Structure of Ne~irapine in the NNRTI binding pocket" 
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A three-dimensional structure of HIV-1 RT complexed with nevirapme (Fig, 1.10) 
demonstrates that it binds to a hydrophobic pocket on the enzyme near to but distinct 
from the pol active site, Nevirapine was shown to interact with two tyrosine residues 
at positions 181 and 188. which had been shown previously. by affinity labelling and 
point mutant studies, to be involved in binding.H The thiocarboxanilides UC-781 bind 
to their pocket in a similar fashion to other NNRTls, i.e, through hydrogen bonding 
with the main-chain oxygen of Lys101 together with hydrophobic interactions with 
Leu100, VaI106, Va1179, Tyr188, Phe227, Leu234 and His235 The thiocarboxanilide 
UC-781 also makes important hydrophobic interactions with Try229,44 The 
dlmethylally group of TIBO (Wing 1 of butterfly) interacts with amino acid residues 
Pro95, Tyr181, Tyr188. Gly190 and Trp229. while the benzodiazepinone group (Wing 
II) interacts with Lysl 01, Lys 103. His235 and Tyr318.~8 
, 
Fig. 1.11 , Simulated annealing omit electron density milps showing the bound inhibitors at the 
NNRTI pocket ofHIV-1 RT ii, PEn-I , b, P En -2'" 
Comparison of PEn inhibitors with nevirapine and TIBO reveals that these inhibitors 
adopt conformations that occupy similar volumes of space within the drug pocket 
despite their diverse structures (Fig. 1.11). When trovirdine and other PEn 
molecules were docked into the composite binding site. the composite binding pocket 
showed space around the phenyl ring in the Wing 2 (ring B) region of the binding site 
The 5-bromopyridyl group binds tightly in this region,.9 with an intramolecular 
hydrogen bond between the ring B pyridyl nitrogen atoms and one of the nitrogen 
atoms of the thiourea group. Ring A is positioned at the "top·' of the NNRTI pocket. 
and thus forms ring stacking interactions with the side chains of both Tyr188 and Tyr 
181 . The sulphur atom makes a number of van der Waals contacts with the 
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backbone of Lysi 0 1. There IS a single hydrogen bond 10 the main chain from one of 
the thiourea nilJogens to the cmbonyl of Lys 101 (Fig 1.12).50 
Fig. 1.12: Stefoo ~Iew shOWII">g PETT· ' and PETT·2 po$~loned on the NNRTI bifldll'lg pocket 01 HI"'· ' 
RT RT $KIe C ~31ros that l orm the NNRTI b< nd ong s.ite are marlced The mhitmo.s are 11"1 310m colours 
Wlt~ PCTT·2 shown 10 a darke r hue TIl e Plote; 1\ for the PETT·1 complex IS fJ10wn 10 //gMt gray. 
wnereas that lo r the PETT·2 comp le .. Is shown In r:J8 r1< gray ne pcl!OI>OM of hyd rogen oon(l$ are 
lTI8I1<.eo In broken }'IIllm" lmes.'" 
(.~ \~ Ji Ii; rc,(~ if , • b 0' ' !...)~) ,.-(. ;: J.' ., . , ,!/', v • \j..l ,I) " " ~ ,!.l \iJ 
• 
- ).. t ........... ); y.. A i , , 
;:0 " . , • ~ 1"' -' (~r) '0 - > '0 ... I \ ' ) { 'i , ~ / i 9-' ~ • I I (fj .) 
" 
" 
., "lD 
.C , 1/'(11 \1/' , <l:,·i/y <1, -, U/ 
Fig. ' .13 Schematic diagrams; showing the Intermolecular interaction. betw~en PETT 
Inhlbllors (in red) ~nd the surrounding re.l !kles of HI"'· ' RT for (al PETT.' ~nd (b) PETT·2. 
RH<lues that contact the NNRTI With a m,n/fllum Inte .... lttlmlC d1Stance 01 3.6 A a~ Shown in g,~. 
whereas OIher II'lSidUf!6 lining the Oi')(j'ng pocI<el ale shown in blue Tho IndMdual d<S4a~ between 
the NNRn and the ~ atomG are shown as aasneo I",es (dlsla:teeS 3 3 A In pill/<. sno 3.6 A In hght 
bJue) Hrdrogen boolOs togeTher WIth tI ~elr al$lanees are shown in blacI< ,., 
Structural studies a rouoo PEn led to Ihe discovery of N.[2-(2.5-
dimetho~yphenylethyl)]·N·[2(5.bromopYflclyl ) l · thiourea (HI-236) (Fig. 1.14). which 
was designed to optimize occupancy of the binding pocket. 51 Docking e.pel iments of 
HI·236 revealed that the Z·methoxy group was situated beneath the ethyl linker and 
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fits favourably into a cavity of the binding pocket, providing additional contact with the 
protein residues. 
HI-236 
Fig. 1.14 Struclure of HI -236 
Structure-activity studies of Ring A revealed that the methoxy substitution is more 
favourable at the meta (to the alkyl side chain) position, compared to the para 
position Fluorine substitution is favourable at the artha and meta positions. whereas 
chlorine was only favourable at the ortho position. Similarly. a hydrophobic group is 
more desirable than a polar group or hydrophilic group at the para posi tion. 52 
The crystal structure of HIV-1 RT in complex with ITU (Rl00943). DATA and DAPY 
derivatives showed that these compounds bind In a unique "horseshoe" or "U" mode 
(Fig. 115) compared to the butterfly-like o_APA.'4 DAPY derivatives can adapt to 
changes in the NNRTI binding pocket The torsional flexibility of the DAPY structure 
permits access to numerous conformational variants, and their compact structure 
permits repositionlr19 and reorientation when mutations in the binding pocket are 
present.27 The ability of etravmne (a DAPY derivative) to bind the RT enzyme in more 
than one conformationally distinct mode explains the exceplional spectrum of activity 
observed for this compound 27 
-Trp2:t J. 
\ ( 
Ty.ll' 
-
" " ~Q 
O', /II • ,(NH B,.lyN 
"' nllc 125 
R165335 
Fig. 1.15' -Horseshoe ' confo rmatiOn of the sBCood-generahon NNRTI (TMC125) 
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1.8 Mutations and Drug Resistance 
The HIV-1 reverse transcriptase enzyme makes numerous errors and unlike 
mammalian polymerase enzyme, it does not have 3'-exonuclease proofreading 
activity and cannot, therefore, proofread and correct the mistakes made during DNA 
synthesis. This results in rapid emergence of drug-resistant mutants. 
1.8.1 NRTI Resistance 
There are two currently known biochemical mechanisms of NRTI drug resistance. 
The first mechanism is mediated by mutations that allow the RT enzyme to 
discriminate against NRTls during DNA synthesis, thereby preventing their addition 
to the growing DNA chain. The second mechanism is mediated by nucleotide 
excision mechanism (NEM) that increase the rate of hydrolytic removal of the chain-
terminating NRTI and enable continued DNA synthesis.53 ,54 In the second 
mechanism, the oxygen anion of a nucleoside diphosphate or triphosphate is used as 
a pyrophosphate nucleophile to attack and cleave the 3'/5'-phosphate bond of the 
primer, producing an unblocked primer and a dinucleoside tri- or tetraphosphate 
containing the dideoxynucleoside monophosphate from the primer terminus linked 
through its phosphate group to the distal phosphate of the free nucleoside di- or 
triphosphate (Fig. 1.16).54 
Nucleoside triphosphate 
Chain Terminated DNA Chain 
~~NH 0 0 0 0 (~NH l . ./ """" l . ./ 
l3fo O-P-O-P-O-P-O-P-°tJ ° 6H 6H 6H 6H 0 HO 
° 
T 
+ OH 
Unblocked 
N3 
Dinucleoside tetraphosphate 
Fig. 1.16: Removal of NRTI from the primer terminus through dinucleoside polyphosphate synthesis 
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Biochemical and structural modelling studies suggest that the bulky azido group of 
AZT interferes with the formation of a dead-end catalytic complex by sterically 
preventing the addition of the next dNTP (Fig. 1 17). This explains why NEMs cause 
the highest levels of phenotypic resistance to AZT 
Fig. 1.17' Stene hloorance when an AZT-termmated primer is bouoo to RT at the P site The figure. 
based on the strocture of the ternary RT-ONA-dNTP complex, shows that the distaoce between the 
azido of AZT and 0185 wc>u1d cause sterk; conflict; the d'staoce between 0185 and the lirst and 
second azido nitrogens is less than the sum of the yan der Waills rad II 
The Ml84V mutation causes the high-level lamlvudine resistance observed and 
emerges rapidly in patients receiving lamivudine monotherapy. This mutation 
(M184V) and other NRTI resistance mutations interfere with the effects of the NEMs 
The mutational antagonism between the NEMs and several of the mutations that act 
by allowing RT to discriminate against NRTls explains the clinical synergism 
observed with dual NRTI combinations such as Zidovudine/Lamivudine, 
StavudinelLamivudine, Zidovudineldidanosine and Stavudine/didanosine.53 
1.8.2 NNRTI Resistance 
NNRTls have been notorious for rapidly triggering the emergence of drug-resistant 
HIV variants. Resistance usually emerges when an NNRTI is administered as a 
monotherapy. NNRTI resistance mutations arise rapidly and most often direclly in 
contact with the NNRTI molecule. They are associated with changes in the binding of 
NNRTI to RT. The most common mutations are Lys103Asn (K103N) and Tyr181Cys 
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(Y181C).38 The Y181C mutation causes a loss of aromaticity, by reducing favourable 
TC-TC interaction, whereas the K103N mutation indirectly affects NNRTI potency by 
stabilizing the closed form of the non-nucleoside inhibitor binding pocket (NNIBP) 
through the formation of a hydrogen bond between the Asn1 03 side-chain amide and 
the Tyr188 phenoxy oxygen, reducing the rate of inhibitor entry.38 The Leu100lle 
mutation causes steric interference between the ,B-branched isoleucine and a bound 
NNRTI. The Gly190Ala mutation causes resistance through steric conflict of the 
methyl side chain and the bound inhibitor.44 
Mutations associated with resistance to nevi rapine involve residues Y181, K103, 
V106, V108, Y188, L 100 and G190, which have van der Waals contact with the 
inhibitor. Mutations of these residues lead to the weakening of the inhibitor binding to 
RT. 55 The most common resistance mutation observed for nevi rapine in vivo is 
Y181 C, which is prevented from emerging by co-administration of AZT. The mutually 
antagonistic effects of different resistance mutations (ie Y181 C or L 1001 versus 
T215Y) and the hypersensitivity that is seen under some conditions (i.e. with P236L 
mutation towards some NNRTls), argues in favour of the combined use of NNRTls 
with NRTls and different NNRTls with one another. 56 
1.9 Combination Therapy 
Combination therapy is a treatment regime that combines two or more drugs, in 
which each drug can work on the same or different drug-target, with either 
independent mechanisms of inhibition or patterns of resistance. The drug entities are 
either co-formulated in the same tablet or capsule (e.g. Combivir 
(Zidovudine/Lamivudine) in HIV-1 treatment) or co-administered in separate tablets 
or capsules (e.g. AZT and Nevirapine). Combination therapy has been used to 
exploit the synergistic and additive activities of individual drugs and is commonly 
used in the treatment of tuberculosis, cancer, leprosy, malaria and HIV. In the case of 
HIV, combination therapy has been coined the term "highly active anti-retroviral 
therapy" (HAART), which is a treatment regime that commonly combines the use of 
two NRTls and one NNRTI or protease inhibitor.57 Combinations of NRTI and 
NNRTls have been found to decrease viral load, increase CD4 count, decrease 
mortality and delay disease progression to AIDS. While achieving synergism in their 
- 18 -
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anti-HIV action, a combination of different drugs reduces the risk of HIV drug-
resistance development and diminishes toxic side-effects through reduction of the 
individual doses.44 
1.9.1 The Double-Drug Strategy 
The double-drug strategy involves the combination of two different classes of 
inhibitors into a single molecular entity. The aim is to enhance activity of the 
individual drugs, and thus prevent resistance as well as improve physicochemical 
characteristics. Such compounds may be divided into two types as: 
(a) Compounds containing cleavable linkers that can unleash two different drugs 
intracellularly and thus act as prodrugs. These compounds can target two active 
sites in the same substrate or different steps of the virus/parasite life cycle. The 
design of these drugs requires that: 
(i) They contain a linker that is stable outside the target cell 
(ii) Once in the cytoplasm, they should regenerate the parent compounds. 
(b) Compounds containing non-cleavable linkers that target two active sites that are 
located in close proximity. 
1.9.1.1 Double-Drugs in Cancer and Malaria 
5'-O-Butanoyl and 3'-O-retinoyl esters of 5-fluoro-2'-deoxyuridine (FDU) (Fig. 1.18) 
have been synthesized to act as anticancer double prodrugs that would serve as a 
depot to release two active drugs that act through different mechanisms. The 
nucleotide derivative of FDU could act as a competitive inhibitor for thymidylate 
synthase whereas retinoic acid and butyric acid were expected to induce cell 
differentiation. The ester derivatives exhibited comparable activity to FDU. 58 
Retinoids have been reported to induce differentiation and arrest proliferation in a 
wide spectrum of cancer cells and are currently used for treatment of promyelocytic 
leukaemia. Butyric acid is an effective inhibitor of cell proliferation and inducer of 
cytodifferentiation. Retinoyloxymethyl butyrate, a mutual prodrug combining butyric 
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acid and all-trans-retinoic acid was evaluated for anticancer activity and was found to 
be more potent than the parent drugs. 59 Furthermore, the differentiation activity 
elicited by the double-drug was greater than that of the combined parent acids. The 
large increase in activity was attributed to two factors: 
(i) The all-trans-retinoic acid fragment imparted lipophilicity and facilitated the 
penetration of butyric acid to the cellular target site. 
(ii) The intracellularly released all-trans-retinoic acid and butyric acid affected 
the cells synergistically. 
o 0 
F F 
HN I HN I ~ A ~ A Me Me 
Me 
HO CH3(CH2l2yO 
o 
[FDU]-[Butanoic acid] [Retinoyl]-[Butanoic acid] 
~ 0 o~ OH 0 
H ~ :?" '-'::: UJ~ ~~ ~H l H OHV» 0y 
[Primaquine]-4,4'-oxy-bis(benzoic acid)-[PLM II] 
o 
I ( 9Y0 mHN~~O~ :?" '-'::: CI ~ I ~ 
[4-aminoquinoline]-[GR Inhibitor] 
Fig. 1.18: Cancer and Malaria double-drugs 
The statine-based inhibitor of Plasmepsin (II) (PLM II) was linked to the antimalarial 
drug Primaquine (PO) using dicarboxylic acid linkers (Fig. 1.18). PLM II is one of the 
aspartic proteases involved in the degradation of haemoglobin during the 
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intraerythrocytic cycle of Plasmodium falciparum. Primaquine is highly active against 
all malaria species infecting humans. Its toxicity levels can be minimised and the 
activity increased by converting it to a peptide prodrug. The PQ-Statine double-drugs 
showed remarkable improvement in the inhibition of both PLM II activity and P. 
falciparum growth in vitro. The double drugs kill the parasites mainly by inhibiting 
PLM II and consequently the digestion of haemoglobin that is essential for the 
survival of the parasite.6o 
Biot et a1. 61 .62 synthesized double-headed antimalarial prodrugs that target two 
essential functions of the malarial parasite, namely glutathione regeneration and 
heme detoxification, with the aim of exploring their synergistic or additive effects. The 
double drugs combined a glutathione reductase (GR) inhibitor to a 4-aminoquinoline 
moiety with a bioreversible linker. However, these double-drugs exhibited poor 
inhibition activity. 
1.9.1.2 Double-drugs in HIV 
(a) NRTl/Protease/Chemokine Receptor Double-Drugs 
A combination of HIV protease inhibitors and AZT into a single molecule has also 
been successfully used to improve poor membrane permeation. The protease 
inhibitors (e.g., KNI-727), unable to penetrate the cell membrane were linked to AZT 
by a cleavable linker and this resulted in a considerable boost in potency in the cell 
assal3 (Fig. 1.19). 
Tamamura et al. 64 employed the double-drug strategy to synthesize a bifunctional 
drug that incorporated a chemokine receptor, CXCR4 inhibitor (T140) and an NRTI 
(AZT) linked by succinate. T140 is a 14-amino acid residue peptide which inhibits 
infection of target cells by T cell-line-tropic strains of HIV through specific binding to 
its chemokine receptor, CXCR4. An equimolar mixture of AZT and T140 caused a 
remarkable increase in anti-HIV activity compared to the single compounds. This 
result led to the synthesis of conjugated compounds which combined each entity into 
a single molecule. The conjugate drugs exhibited a synergistic effect for anti-HIV in 
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vitro. The mechanism of action is based on the hydrolysis of the enzymatically labile 
ester 5'-O-bond between the NRTI and the spacer. 
m=1, n=2 
[AZT]-succinic-[KNI-727] conjugate 
o Me0 l.o/ NH ~o 
o~ I I 
o NH-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH 
[AZT]-succinate-[T140] (l 
(NH HN) 
N HN 
(NH ) HN 0 U '(CH214CONH(CH2)4~O OH 
CH3(CH2hy NH 
o 
Gal-AMD3100 Conjugates 
R = H or 5'-O-(succinate)-AZT 
[AZT]-succinate-[K-carrageenan] 
Fig. 1.19: Structure of NRTI (AZT), Protease (KNI-727), Chemokine Receptor (T140, Gal, AMD3100) 
and K-Carrangeenan Conjugates. 
Daoudi et al.65 synthesized bifunctional compounds combining bicyclam AMD3100 
and a galactosylceramide (GaICer) analogue in a single molecule with the aim of 
inhibiting several steps of the complex virus/cell cascade interactions (virus/cell 
adsorption/fusion processes). The double-drug [Gal]-[AMD3100] conjugate (Fig. 
1.19) exhibited lower potencies than that of AMD3100. AMD3100 is a CXCR4 
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antagonist and interferes with the viral binding to the cellular co-receptors, whereas 
GalCer provides an attachment platform for the virus through its gp120 and/or gp41 
onto the cell. When compared to the activity of GaiSer, the bipharmacophore 
conjugate moderately increased its antiviral activity. 
Similarly, AlT coupled onto K-carrangeenan using a succinate diester spacer was 
synthesized with the aim of enhancing AlT intracellular uptake and testing synergism 
of the prodrug.66 Carrageenans are natural sulphated polysaccharides extracted from 
different species of red seaweed that have a common structural backbone of 0-
galactose residues. The K-form is characterised by a repeating unit of 4-sulfate-~-D­
galactopyranose linked 1 ~3 and 3,6-anhydro-a-D-galactopyranose linked 1 ~4. The 
K-carrangeenan was expected to act not only as a drug-delivery carrier for AlT, but 
also as an anti-HIV agent which would act synergistically with AlT. Carrangeenans 
possess anti-HIV activity and inhibit the binding of the virions to the cell (gp120 
adsorption inhibitors) as well as the cell-to-cell fusion. The [K-carrangeenan]-
succinate diester-[AlT] conjugate inhibited the binding of the virions to the MT-4 cells 
and concomitantly delivered AlT to these cells to further inhibit the RT. 
(b) Reverse Transcriptase Double-Drugs 
(i) NRTI homolheterodimers 
Several homo- and heterodimers targeting the HIV reverse transcriptase enzyme 
have been synthesized by attaching the linker at the 5', 5 or N-3 positions of the 
nucleosides. Ijichi et al. 67 have reported the synthesis of nucleotide heterodimers of 
AlT, ddl and Ribavirin. The dimers were formulated as a mixed phosphate diester 
via the 5'-hydroxyl groups of the nucleoside, with the aim of releasing two 
nucleosides at the active site. Thus, 5'-O-phosphorylation of AlT gave AlT 
cyanoethyl phosphate 1, which condensed with ddl 2 in the presence of p-
toluenesulfonyl chloride to afford heterodimer [AlT]-cyanoethylphosphate-[ddl] 3. 
Deprotection of the cyanoethyl group with 1 N NaOH led to the heterodimer 4 
(Scheme 1.1). Similarly, [ddl-phospho-Ribavirin] 5 (EC50 > 17.5 flM) and [AlT-
phospho-Ribavirin] 6 (EC50 = 0.004 flM) heterodimers (Fig. 1.20) were synthesized 
using the same procedure. The heterodimers 4 and 6 showed enhanced anti-HIV 
activity relative to their monomers. Furthermore, AlT-P-ddl 4 (EC50 = 0.002 flM) was 
ten times less toxic than AlT to human granulocytes macrophage progenitor cells. 
- 23 -
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 1: 
4 
AZT-P-ddl 
Scheme 1.1. Reagents and Conditions: (i) p-TsCI, CH2CI2 (ii) NaOH. 
Introduction 
H~N> ~ & NlefO-~-OpO ,~ 
5 
ddl-P-Ribavirin 
Fig. 1.20: Structures of AZT, ddl, Ribavirin and HEPU heterodimers 
0- 0 
OH 0 N + 
o a 
N3 
6 
AZT -P-Ribavirin 
In a similar fashion, homo- and heterodimers of ddl, AZT and d4T have been 
synthesized by Mohamed et al.68 with the aim of enhancing the antiviral activity of 
their components (Scheme 1.2). They used an ester linkage to link to a glutaric acid 
spacer. The synthetic strategy involved converting d4T 7 into half ester 8 by 
treatment with glutaric anhydride in methylene chloride, followed by an EDC-
promoted esterification of the glutarate with ddl to form the heterodimer 9 in good 
yield (Scheme 1.2). AZT-ddl and ddl-ddl heterodimers bearing an ester linkage were 
also synthesized using this methodology. Other spacers used in this class of 
compounds were the carbonates and carbamates to form AZT and d4T homo- and 
heterodimer carbonates 10 and carbamates 11, respectively (Fig. 1.21). Following 
intracellular hydrolysis of the carbonate or carbamate, the two nucleosides would be 
regenerated in the cytoplasm. The carbonates displayed anti-HIV activity comparable 
to AZT, while the carbamates displayed low anti-HIV activities. No synergistic effects 
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on the inhibition of HIV replication was detected for the carbonates 10a-c and 
carbamates 11a-c. 
0 0 M.'{ I NH Hr}' HOid..AO .. HO~OB 
o 0 
ii 
7 8 
HN~N) :& l,.J-~o~0t1 
9 
Scheme 1.2. Reagents and Conditions: (i) Glutaric anhydride, EhN, CH2CI2; 85%. (ii) ddIlDMAP/EDC, 
HCI, CH2CI2IDMF; 80%. 
10a 
11b 
10c 11c 
Fig. 1.21: Structure of AZT/d4T homo- and heterodimer linked by a carbonate or carbamate spacer 
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(ii) NRTlINNRTI heterodimers 
The combination of a nucleoside and a non-nucleoside RTI into a single molecular 
entity was advocated by Nanni et a/ in 1993.69 This was supported by structural11 , 69 
and biochemical43,7o studies which indicated that linking the compounds with an 
appropriate spacer resulted in improved inhibitory capacity. The first heterodimers 
incorporating a NRTI with an NNRTI were synthesized by the Velazquez group in 
1995.71 They reported the synthesis of a family of anti-HIV heterodimers based on 
combining AZT with either TSAO-T or HEPT via a polymethylene spacer between the 
N-3 of the thymine base of both compounds (Scheme 1.3). TSAO derivatives were 
first synthesized in 1992 and represent a unique structural class of NNRTI as they 
specifically interact at the interface between the p51 and p66 subunits of HIV-1 RT. 
The prototype compound of this family is the thymine derivative designated TSAO-T 
and the most selective compound is its 3-N-methyl substituted derivative TSAO-m3T. 
The synthetic strategy for formation of 13 and 14 involved selective N-3 alkylation of 
AZT with a dibromoalkyl reagent followed by reaction of the N-3-bromoalkyl AZT 
intermediate with TSAO-T or HEPT. The polymethylene spacer was varied from n = 
3-6. Thus, treatment of AZT with 2 equiv of 1,3-dibromopropane in dry acetone:DMF 
(1 :1) and in the presence of K2C03 gave the N-3 substituted derivative 12. 
Subsequent reaction of 12 with TSAO-T or HEPT under basic conditions gave 
heterodimers 13 and 14 in 50-60% yield. 
ii 
TSAO 
13a 
.. 
o 0 
Me~N-(CH2k~Me ~)L,.Ao HO{oy 
- ~oJ ,,~ 
14 N3 
12 ii 
HEPT 
Scheme 1.3. Reagents and Conditions: (i) (CH2)nBr2 (n = 3-9), K2C03, acetone, DMF (1: 1). (ii) K2C03 , 
acetone, DMF (1:1). 
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The most active compound in the series was [TSAO-T]-(CH2h-[AlT] 13a (EC50 = 
0.10 11M) incorporating a short spacer. Heterodimers bearing polymethylene linkers [-
(CH2)n-] with n = 4-6 showed good antiviral activity, while longer spacers with n > 7 
showed diminished activity. The precursors to the dimers were also tested. 
Specifically, AlT derivatives such as 12 proved inactive irrespective of the chain 
length of the methylene spacer. The activity of the TSAO-T-spacer derivatives 13d 
decreased with increasing length of the spacer. Replacement of AlT with d4T 
resulted in improved anti-HIV activity. No marked differences in activity were 
observed when the spacer consisted of 1-butynyl, 1-butenyl or ethoxyethyl moieties. 
The attachment of a propynyl spacer to the C-5 position of the pyrimidine base of 
AlT showed comparable antiviral activity to that of the AlT heterodimer 13a bearing 
a propylene spacer between two N-3 positions, whereas the corresponding d4T 
analogue of 13b led to a 5-fold decrease in anti-HIV potency. 
o 0 
" Me'C~spacer-C! ~Si-~O ~O HO~N 0 /H2N 0 0 
c:/ 
O=S-O OSi~ N3 o \ \ 
spacer 13d 
13b -CHrC= c-
Fig. 1.22 
Spacer rigidity in the C-5 series did not markedly influence the antiviral potency since 
the heterodimer 13c bearing a flexible propyl group as spacer was endowed with 
anti-HIV-1 activity comparable to that of the corresponding propynyl analogue 13b 
(Fig. 1.22). Converting AlT, d4T and thymidine heterodimers to 
phenoxyphosphoramidate72 heterodimers had no improved activity over the 
corresponding non-phosphorylated analogues. Overall, the d4T heterodimers had 
better inhibitory efficacy than AlT. 
Combinations of TSAO-m3T and foscarnet (PFA) (Fig. 1.23) as individual entities at a 
variety of concentrations revealed that these compounds displayed additive antiviral 
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activity.73 These results inspired the synthesis of a single molecule combining a 
TSAO derivative with foscarnet through a labile phosphate ester bond. PFA is an 
effective antiviral agent approved for intravenous treatment of Human 
Cytomegalovirus (HCMV) Retinitis in patients with AIDS.74 It is also effective against 
HIV replication and inhibits HIV-1 RT by blocking the pyrophosphate binding site. 75 
o 
Me0wcH3 
1-'Si-O lw/lo 
o 0 
HO-C-P-OH 
I 
OH /H'~ • Phosphonoformate (PFA) 
o=s-o OSi~ 6 \ \ 
TSAO-m 3T 
Fig. 1.23: Structure of TSAO-m3T and Foscarnet 
o 
Me0 
" l .. / N-(CHvrOH \\5i-~0 ~o T/H~ 0 
~ 
0=5-0 05i~ 
II \ \ 
o 
15 
o 0 
II II 
BnO-C-P-CI 
I 
CI 
16 
i 
-
Me II II 
'C
o 0 0 
I N-(CHvro-~-C-OBn 
7" L OH 5i-~0 ~o /H~ 0 
~ 
0=5-0 05i~ 
II \ \ 
o 
17 
o 0 0 Me'CN-ICH,)rO-~-C-OH 
~'si_~O ~o OH T/H~ 0 
~ 
0=5-0 05i~ 
0\\ 
18 
Scheme 1.4. Reagents and Conditions: (i) (a) 16, Et3N, CH 2CI2 , -20°C (b) H20; 54%. (ii) H2, Pd/C, 
MeOH; 60%. 
Thus, treatment of TSAO derivative 15 with the foscarnet-based phosphorylating 
reagent 16 in the presence of triethylamine led to the formation of the PFA diester 17 
in moderate yield. Catalytic hydrogenolysis of 17 yielded the [TSAO-T]-[PFA] 
conjugate 18 in 60% yield (Scheme 1.4). Unfortunately, conjugate 18 was less active 
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than the parent compound 15, displaying no additive or synergistic anti-HIV activity 
and thus indicating the activity to be due to the TSAO part of the molecule and not 
the PFA part. 
The design, synthesis and anti-HIV-1 evaluation of several non-cleavable 
heterodimers of the general formula [d4T]-NH(CH2)n-NH-[imidazo[1,5-b]pyridazine] 
(n = 6-12) involving a C-5 linkage to d4T was reported by Laduree et al.76 in 1998. 
Imidazo[1,5-b]pyridazine was chosen as the NNRTI due to its exceptional potency. 
The synthetic strategy involved synthesis of the NNRTI linked to a 1,n-diaminoalkyl 
spacer followed by substitution onto d4T via a C-5 chloromethyl group. The synthesis 
of the d4T coupling derivative (Scheme 1.5) involved C-5 hydroxymethylation of 
protected uridine 20 to give 21 in good yield followed by C-2'/3' double-bond 
introduction to afford 22 and selective chlorination of the hydroxymethyl group in the 
presence of the C-5' hydroxyl group of 22 to give 23. 
0 HO O~ 
H~ ~ 
HO OH 
19 
° HO O~ ii H~ 
°XO 
20 
23 
~ 
iii 
o 
HNyOH o~j HO 
22 
Scheme 1.5. Reagents and Conditions: (i) 2,2-DMP, APTS, MeCOMe. (ii) CH20, E~N, 60°C; 93%. 
(iii) TMSCI, 1 ,4-dioxane, 60°C. 
Imidazo[1,5-b]pyridazine 24 was synthesized in seven steps from alanine, and was 
heated with a 1, n-diaminoalkane at 120°C to give monomers 25 a-d via aromatic 
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nucleophilic substitution. Condensation of 25 a-d with 23 in DMF gave heterodimers 
26 a-d in 72-85% yield (Scheme 1.6). The anti-HIV activity of the NNRTI linked to its 
spacer 25 a-d was evaluated independently and the results revealed a decrease in 
activity compared to the unsubstituted NNRTI. The activity of the heterodimers 26a-d 
was comparable to that of d4T and thus mainly due to the nucleoside part of the 
molecule. 
o o 
24 25 a-d 
o 
Scheme 1.6. Reagents and Conditions: (i) H2N-(CH2)n-NH2; a: n=6, b: n=8, c: n=10, d: n=12. (ii) 
d4CIMUrd 23, DIEA, DMF. 
Similarly, the same group reported the synthesis of a NRTIINNRTI heterodimer of the 
formula [NRTI]-Glycyl-Succinyl-[Trovirdine].77 Nucleosides d4U and d4T were used 
as the NRTI and spacer linking was achieved via the C-5' hydroxyl group of NRTI 
with the N-piperazine of trovirdine. A succinyl-glycine moiety was chosen as a 
spontaneously cleavable linker, and introduced via coupling of the NRTls with Boc-
gly-OH using DCC in the presence of DMAP in DMF to give the 5'-esters 27. 
Deprotection of Boc using 4M HClidioxane afforded the amine hydrochlorides 28 
which were condensed with trovirdine analogue derivatives 29 using BOP/HOBt in 
the presence of triethylamine in DMF to afford the heterodimers 30 a-c in 35-45% 
yield. The heterodimers were unfortunately devoid of antiviral activity at non-toxic 
concentrations (Scheme 1.7). 
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7 27 
30a: d4T R = Me 
30b: d4U R = H 
Scheme 1.7. Reagents and Conditions: (i) HOOC-CH2-NHBoc, DCC, DMAP, DMF; 78%. (ii) 4M 
HCllDioxane; 87%. (iii) succinic anhydride, CH 2CI 2; 64%. (iv) Et3N, HOBt, BOP, DMF; 35-45%. 
The synthesis by of an analogous system using C-5/NRTI as the attachment 
poinea,79 (Scheme 1.8) was accomplished employing a Sonogashira reaction. Pd(O) 
mediated Sonogashira coupling at C-5 of 31 with a C-3 propynyloxy spacer protected 
as its THP ether produced 32. Deprotection of THP using CF3COOH in CH2CI2 
followed by condensation of the resultant alcohol with Boc-Gly-OH using DCC in the 
presence of DMAP and subsequent deprotection of the Boc group using 4M HCI in 
dioxane afforded the amine hydrochloride 33. Condensation of amine 33 with 
trovirdine derivative 29 followed by deprotection of the acetate group with cyanide ion 
gave the heterodimer 35 in 35-45% yield for the last step. The heterodimers 
displayed inferior anti-HIV activity (compound 35 displayed an IC50 > 20 ~M) 
compared to the parent compounds. The lack of activity was attributed to the wrong 
positioning of the linker to either NRTI or NNRTI with respect to their active sites in 
the enzyme. 
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o 
H~I kog 
31 32 
Scheme 1.8: Reagents and Conditions: (i) alkyne, (PPh3)4Pd, Cui, Et3N, DMF; 67%. (ii) CF3COOH, 
CH2CI2, CH30H (iii) HOOC-CH2-NHBoc, DCC, DMAP, DMF (iv) 4M HCl/Dioxane (v) 29, EhN, HOBt, 
BOP, DMF; 48%. (vi) NaCN, MeOH; 38%. 
Pedersen et al. 80 has recently reported the synthesis and antiviral activities of double-
prodrugs against HIV based on the mixed S-acyl-2-thioethyl (SATE) prodrug 
approach. The SATE prodrugs were first introduced in 1993 by Imbach et al as a 
carboxyesterase-Iabile protecting group for the ddU nucleotide.81 The double pro-
drug in question incorporated d4T as a 5'-phosphate and as a SATE ester linking 
through the phosphate to N-3 of MKC-442 (a HEPT derivative) via a cleavable p-
hydroxybenzoyl linker. The synthesis involved protecting the N-3 position of MKC-
442 with a p-benzyloxybenzoyl group to give 36 in 86% yield. The amidite 37 was 
successfully reacted with the debenzylated analogue of 36 using OlEA as a base and 
tetrazole as an activating agent, which was followed by oxidation with tert-
butylhydroperoxide to give 38 as a mixture of two diastereomers in 38% overall yield 
for the 3 steps (Scheme 1.9). The double-prod rug 38 had good activities against HIV-
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1 (EC50 = 0.03 ~lM) and Y181 C mutant (EC50 = 2.7 ~M). The authors conclude that 
compound 38 acts as a prodrug and that the active drug contains the d4T moiety. 
o 
Me0 l .. / NH Hotto 
7 
v 
iii. iv 
38 
37 
Scheme 1.9. Reagents and Conditions: p-Benzyloxybenzoic acid chloride, OlEA, pyridine; 86%. (ii) 
H2, Pd/C (iii) 37, 1 H-tetrazole, CH3CN (iv) tert-butylhydroperoxide; 38% (3 steps). (v) (S-pivaloyl-2-
thioethyl)-N,N-bis(diisopropylamino)phosphine, OIA, 1 H-tetrazole, CH3CN; 94%. 
In conclusion, most approaches have pursued the easier synthetic option of 
connecting the tether via the C-5' OH or N-3 of the nucleoside base. For the C-5 
heterodimers, linker attachment has been achieved via a Pd(O) Sonogashira coupling 
(compound 35) or hydroxymethylation of uridine (compound 26a-d). Most of the 
heterodimers were designed as prodrugs linked with a cleavable tether, with the aim 
of regenerating the parent drugs once in the cell cytoplasm. 
1.10 Objective of the Study 
The use of combinations of different drugs is designed to prevent resistant HIV 
strains by effectively suppressing viral replication, thus denying HIV the opportunity 
to produce new mutations. This principle holds provided there is minimised cross-
resistance between the drugs. NNRTls act by slowing down the chemical step 
catalyzed by RT, and this retardation allows the two-step binding of NRTI to come to 
equilibrium leading to tighter binding of the nucleotide. The research in this thesis 
aimed to: 
(i) Synthesize and evaluate the anti-HIV activity of heterodimers of the 
general formula [d4T]-spacer-[HI-236] involving a biologically non-
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cleavable spacer, in the search for evidence of synergism between the two 
drugs and hence sites. 
(ii) Evaluate a structure-activity relationship by using different types of linkers. 
(iii) Synthesize and evaluate the anti-HIV activity of HI-236 linked to a spacer. 
HI-236 was selected due to its potency against wild-type and NNRTI resistant HIV-1 
strains (carrying the NNRTI resistant mutations K103N, V106A and Y181C). 
Furthermore, the relative simplicity of its structure, ease of its synthesis and options 
for spacer attachment also made HI-236 an attractive NNRTI choice. D4T is currently 
used to treat HIV, and was chosen due to its higher inhibitory effect and lower toxicity 
compared to AZT. 
1.11 Strategies for the Synthesis of d4T 
1.11.1 Synthesis of d4T from 2' -deoxythymidine 
Horwitz et 81. 82 reported the first synthesis of d4T 7 in 1964 as a potentially novel 
anti-cancer drug. The strategy involved conversion of 3',5'-anhydrothymidine 40 to 
d4T by a base-mediated elimination reaction. Thus, 2'-deoxythymidine 39 was readily 
converted into 1-(3' ,5'-anhydro-2-deoxy-J3-D-threo-pentofuranosyl)-thymine 40 by 
converting it first into its 3',5'-di-O-mesyl derivative, and then by heating the crude 
product under reflux with an excess of aq. sodium hydroxide. Oxetane formation from 
the dimesylate of 39 proceeded via intermediacy of the pyrimidine base with the ring 
closing step as shown. Elimination of oxetane 40 was achieved by treatment with t-
BuOK in DMSO (Scheme 1.10). 
0 0 0 0 
~-1y M.'t M.'t I NH I NH i, ii ~o iii H°tJ~O .. S~~H ---- .. ~ ~ " 
HO 
39 40 7 
Scheme 1.10. Reagents and Conditions: (i) MeS02CI, C6H5N (ii) aq. NaOH, reflux (iii) t-BuOK, DMSO; 
57%. 
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Prolonged exposure of d4T to strong base at high temperature led to decomposition 
to give thymine as an undesired product thereby decreasing the overall yield. 
In an attempt to overcome the decomposition of d4T just mentioned, Mansuri et a/. 83 
precipitated the 5'-alkoxide potassium salt of d4T by adding solvents such as toluene 
and acetone during work-up. Skonezny et a/,84 in a US patent, disclosed an improved 
process for producing d4T from the oxetane intermediate 40 by eliminating with 
potassium hydroxide in isopropanol. 
In a modified procedure of Horwitz, Reese et a/. (Scheme 1.11) converted 2'-
deoxythymidine 39 directly in one step into anhydro derivative 41 in 68% yield via a 
3'-sulfite ester leaving group. The key elimination reaction to form d4T in 76% yield 
was achieved by reacting anhydro compound 41 with NaH in N,N-dimethylacetamide 
at 100 °C.85 
0 0 0 
Me Me 
"I ii 1 NH ~ ~ 
HO 39 41 7 
Scheme 1.11. Reagents and Conditions: (i) (PhO)zSO, 1-methylimidazole, DMA; 65%. (ii) NaH, DMA, 
100°C; 81%. 
Lipshutz et a/. 86 developed a method based on transient cyclonucleoside formation 
across the C-5'-oxygen of the sugar and C-6 of the pyrimidine base (Scheme 1.12) 
as a protection of the C-5' hydroxyl group, thereby permitting introduction of 
unsaturation into the sugar moiety prior to unravelling via p-elimination to the target 
nucleoside. The cyclonucleoside 42 was prepared by an electrophilic addition 
reaction of deoxythymidine with N-bromosuccinimide and catalytic trifluoroacetic acid 
(TFA) in DMF. In a 'one pot' procedure, the alcohol was then treated with 
trifluoromethanesulfonic anhydride in pyridinefTHF followed by DBU to introduce the 
2',3'-double bond via elimination of the triflate, followed by reductive elimination of the 
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bromine and alkoxy groups in the base with zinc dust in acetic acid to furnish d4T in 
good overall yield. 
0 0 0 
f: Me M.'t NH I NH \10 ii H°rt° ~ ~ 
HO 39 HO 42 7 
Scheme 1.12. Reagents and Conditions: (i) NBS, DMF, cat. TFA; 62%. (ii) (a) Tf20/pyr, THF (b) DBU 
(c) Zn/HOAc; 82% (3 steps). 
1.11.2 Synthesis of d4T from 5-methyluridine 
Luzzio et al. 87 demonstrated an efficient synthetic route to nucleoside olefins in the 
uridine and thymidine series, utilizing a Garegg-Samuelsson88 
iodine/triphenylphophine/imidazole-promoted deoxygenation of the 2',3'-hydroxyl 
groups as the key step (Scheme 1.13). The mechanism of the reaction involves 
reaction of imidazole with triphenylphosphine diiodide to form an 
imidazolephosphonium salt I. Complex I then reacts with the vicinol diol to form bis-
oxyphosphonium salt II. Nucleophilic substitution of one of the oxyphosphonium 
groups of II to form III by iodide followed by iodide-mediated elimination furnishes 
alkene IV (Fig. 1.24). 
OH H 
I I 
RL-C-C-R2 
I I 
H OH 
+ 
2 I 
-imidazole 
Fig. 1.24: Mechanism of Garegg-Samuelsson elimination 
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In order to avoid anhydronucleoside formation during olefination, the synthesis of 46 
required a selective C-5' hydroxyl protection. Thus, protection of the 2',3'-hydroxyl of 
5-methyluridine 43 with 1, 1-dimethoxycyclopentane and p-toluenesulfonic acid 
provided the cyclopentylidene ketal 44 in excellent yield. Protection of the C-5' 
hydroxyl group of 44 as its N3-5'-O-dibenzyl or p-methoxybenzyl ether 45 was 
accomplished in 93% yield by treatment with NaH/BnBr (or PMBCI) in 1,2-
dimethoxyethane. Deprotection of the cyclopentylidene group was accomplished by 
employing 30% aq. TFA to furnish dibenzyl diol 46a, which was subjected to the 
olefination conditions to give the desired olefin 47 in good yield. However, the 
procedure is sensitive to the C-5' hydroxyl protecting group. Since olefination of the 
5'-silylated derivative 46b, obtained directly from 5-methyluridine without the need to 
protectldeprotect the C-2' and C-3' hydroxyl groups, was unsuccessful. 
0 0 
ii 
~ ~ 
HO OH 0
0
0 
43 
44 45 
0 0 Mete Mete I NH I NPMB Hotto vi PMBotto v .. OIl( 
7 47 
o 
MeteNR 
R10 ~o ~ 
HO OH 
46a: R = R1 =PMB 
46b: R = H, R1 = TBDMS 
Scheme 1.13. Reagents and Conditions: (i) p-toluenesulfonic acid, 1, 1-dimethoxycyclopentane; 95%. 
(ii) 4-methoxybenzyl bromide, NaH, DME; 75%. (iii) aq. dichloroacetic acid (66%); 96%. (iv) TBDMSCI, 
imidazole, DMF (v) 12 , PPh3 , imidazole, toluene/CH3CN (2:1); 82%. (vi) CAN, CH3CN/H20; 68%. 
By comparison, Mansuri et al. 89 explored three other methods for the conversion of 
the vicinol diol functionality of nucleosides to olefinic analogues. The methods 
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investigated included the Corey-Winter90 reaction, olefin formation from 2',3'-0-
methoxymethylidene cyclic ortho ester 49 and reductive elimination of 2' ,3'-
haloacetates 52. In the Corey-Winter procedure (Scheme 1.14), 5-methyluridine 43 
was protected as its 5'-0-trityl ether and then converted to 1,3-dioxolane-2-thione 
(cyclic thionocarbonate) 48, which fragmented with triethyl phosphite to furnish the 
protected olefin. However, the overall yield of protected olefin from uridine was only 
30%. Deprotection of the trityl group under acidic conditions resulted in cleavage of 
the glycosidic bond, leading to an overall yield of 12% of the desired olefin 7. The 
mechanism of the Corey-Winter step involves attack by the thiophilic phosphorus at 
sulphur, followed by a chelotropic elimination of CO2 with expulsion of 
triphenylphosphine sulphide (Fig. 1.25). 
ROt) 
O~O 
~:P(OEth 
A 
ROt] 
+ s= P(OEth + cO2 
B 
Fig. 1.25: The mechanism of Corey-Winter deoxygenation 
0 0 
H I H I 
i, ii iii, iv 
~ • 
HO OH 0yO 
43 48 
s 
0 
"CNH Hotto 
7 
Scheme 1.14. Reagents and Conditions: (i) Ph3CCI, pyridine (ii) 1,1 '-thiocarbonyldiimidazole, THF; 
67% (2 steps). (iii) triethyl phosphite, 160°C; 45%. (iv) cat. p-TsOH, CHClsfMeOH (5:1); 40%. 
In the second approach (Scheme 1.15), 2-methoxy-1,3-dioxolane 49 was subjected 
to an acid-catalysed fragmentation to give the olefin 50 in 2 steps and 22% overall 
yield. In this case, anomeric cleavage of the olefin also occurred to form N1-acetyl 
uracil 51. Addition of a base (triethylamine or NaHC03) to neutralise the acid did not 
improve the yield. The mechanism for this elimination involves protonation of the 
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methoxy group to form I followed by expulsion of methoxyl group under anchimeric 
assistance to form II, and fragmentation with loss of C02 to form the olefin (Fig. 1.26). 
0 0 0 
H I H I 'CNH 0 ii 
'CNH • • Acotto + ~O 
I 
Ac 
HO OH 0yO 50 51 
43 OMe 49 
Scheme 1.15. Reagents and Conditions: (i) trimethyl orthoformate, pyridinium p-toluenesulfonate, 
THF, rt; 68%. (ii) p-TsOH, acetic anhydride, 140°C; 40%. 
~0t) PG~ ~~. PG0t] H+ -H+ 0 + CO2 + H+ ~ - -
0yO 0:y~ 0t(Q@ III 
" 
OMe w~" H 
I II 
Fig. 1.26: The mechanism of reductive elimination of orthoesters 
The third method (Scheme 1.16) involved reacting uridine or thymine with Mattock's 
bromide (2-acetoxyisobutyryl bromide)91 to give a mixture of acetates 52, which were 
reduced with activated zinc-copper couple to give the desired olefinic product in 38% 
overall yield. A major limitation of this method was the formation of large amounts of 
thymine by-product during the reductive syn-elimination of bromoacetate. 
0 0 
° M.'C HN I HN I ii, ii I NH 
• • Htl° 
HO OH AcO Br 0 CH3 7 
43 R = Ac or AciBu AciBu = lLf:cH, 
52 Ac 
Scheme 1.16. Reagents and Conditions: (i) 2-acetoxyisobutyryl bromide, CH3CN; 67%. (ii) Zn/Cu, 
DMF, rt (iii) NH3 , MeOH; 55%. 
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Chen et al. (Scheme 1.17) from the Bristol-Myers Squibb group, minimized extensive 
nucleoside bond cleavage by inverting the stereochemistry to proceed via a trans 
haloacetate. This was achieved by base-mediated conversion of the trimesylate of 43 
into epoxide 54 via intermediate 53, which opened with acetyl bromide to afford a 
regioisomeric mixture of trans bromoacetates 55a-b. p-Elimination with Zn/Cu couple 
as before afforded 5'-mesyl d4T 56 under mild reductive elimination conditions, 
without significant nucleoside bond cleavage92 as a result of superior trans 
stereoelectronic alignment in the elimination step. 
o o 
H I 
i 
- M~~ -
HO OH MS<Y' 54 
43 53 ! ii
0 0 o o Her iv, v Her HoB MS~ iii .. .. H I H I + 
7 56 Bf 55a 55b Br 
Scheme 1.17. Reagents and Conditions: (i) (1) MsCI, NMM, acetone (2) 1N NaOH/H20; 82%. (ii) (1) 
AcBr, MeOH (2) AcBr, CH2CI2; 92%. (iii) Zn/Cu, MeOH; 88%. (iv) PhC02Na, DMF; 91 %. (v) BuNH2; 
90%. 
Alternatively, the use of a sulfonyl group at the 3'-position of 5-methyluridine instead 
of an acetyl group in the syn bromomesylate 59 completely avoided the undesired 
cleavage of the base (Scheme 1.18). D4T was prepared employing this methodology 
in 75% overall yield starting from the readily available ribonucleoside 5-
methyluridine.93 The key step in the synthesis was the zinc-induced reductive 
elimination of bromomesylate 59, which afforded d4T without nucleoside bond 
cleavage. Sodium benzoate acted as a base to form anhydro ring 58 as well as a 
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nucleophile to displace the 5'-mesyl group, preparing the way for the final facile 
deprotection with butylamine. 
o o o 
H I H I 
ii 
HO OH MsO OMs MsO 
43 57 58 
0 0 
Me 
I NH 
v 
H I 
iv 
• • 
7 60 MsO Br 
59 
Scheme 1.18. Reagents and Conditions: (i) MsCI, NMM, acetone; 97%. (ii) PhC02Na, CH3CONH2; 
90%. (iii) AcBr, MeOH, EtOAc; 98%. (iv) Zn, EtOAc/MeOH, cat. AcOH; 97%. (v) BuNH2 , 70°C; 90%. 
D4T has also been synthesized by ring-closing metathesis94 (Scheme 1.19, Fig. 
1.27). This methodology necessitated the simultaneous creation of two vinyl groups 
to afford 62, which in turn led to a new route to 2',3'-didehydro-2',3'-
dideoxynucleosides. Treatment of 5-methyluracil derivative 62 with Grubbs' reagent 
in DCM resulted in efficient ring closure to form the protected d4T 63.95 
R (, 
Fig. 1.27: Mechanism of olefin metathesis 
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o 
H I 
HO OH 
43 
o 
H I 
HO OH 
61 
o Me0 l . ...-NH Hotto 
7 
Introduction 
ii 
62 
iv 
.. 
Scheme 1.19. Reagents and Conditions: (i) TrCl, pyridine (ii) (a) Nal04, EtOH/H20 (b) Ph3PCH3Br, t-
BuOK, toluene (iii) AcOH; 80% (iv) Grubbs' reagents, CH2CI2. 
Apart from the Bristol-Myers-Squibb synthesis, most of the syntheses are only 
amenable to producing research quantities of d4T and not for production purposes, 
because of the involvement of protecting groups. 
1.12 Synthesis of PETT 
Phenethylthiazolylthiourea (PETT) compounds were first synthesized in 1995 by Bell 
et a/. 96 as potent inhibitors of HIV-1, resulting in a structure-activity relationship profile 
amongst various substituents in their structure. The PETT derivatives were 
synthesized according to two general methods. In the first route, thiourea analogue 
66 was prepared by condensation of the amine 64 with the thiocarbonyl reagent 65 
derived from 2-aminothiazole and thiocarbonyldiimidazole (Scheme 1.20). 
F F 
~N~ s s~ + N~jl~~ 
\ I H 
~H H S () MU 
64 65 66 
Scheme 1.20: Synthesis of PETT compounds from thiocarbonylimidazole thiazole. 
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The second method (Scheme 1.21) to the thiourea analogue 69 involved reacting 
phenethyl isothiocyanate 67 with a heterocyclic amine (2-aminothiazole) 68. 
~N=C=S + 
67 68 
DMF 
1000 C 
~ S S~ ~jl~~ 
H H 
69 
Scheme 1.21: Synthesis of PETT compounds from phenethyl isothiocyanate. 
HI-236 72 was synthesized according to the first method by condensation of amine 
71 with thiocarbonyl reagent 70 derived from 1,1 '-thiocarbonyldiimidazole and 2-
amino-5-bromo pyridine (Scheme 1.22).97 
87% 
Br V-N~ BrY'll S ~~~~N 
W 
70 
OMe 
+ H~ 
OMe 
71 
OMe J 
ii 
40% 
Brv-~~ 
H HOMe 
72 
Scheme 1.22. Reagents and Conditions: (i) 1,1'-thiocarbonyldiimidazole, acetonitrile, rt, 12-15h. (ii) 
DMF, 100 cC, 16h. 
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CHAPTER 2 
Synthesis of Thiourea Derivatives for this Thesis 
2.1 Synthesis of Thiourea derivatives 
Various thiourea derivatives (Fig. 2.1) were prepared either to probe the origin of HIV 
activity in the bifunctional compounds or as models and/or intermediates in the 
synthesis. Thus, two NNRTls linked to a spacer (77 and 78) were synthesized and 
evaluated for possible anti-HIV activity. Thiourea derivatives 74-76 were model 
compounds synthesized to optimize conditions for the final condensation step. 
Compound 73 was synthesized as a substrate for alkylation in the synthesis of target 
compound 95 (Chapter 4). Compound 79 was an intermediate in the synthesis of 73. 
The NNRTls synthesized are shown in Fig. 2.1. This Chapter describes their 
synthesis. 
76 
S 
.~~NH I o H ~ Y" ~ ~ I I ~ ocQ 
Br 
77 78 
Fig. 2.1: Structure of NNRTI and NNRTllinked to a spacer 
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The retrosynthetic analysis of 73 (Fig. 2.2) revealed amine 80 derived from reduction 
of Henry derivative 83 to be a key intermediate. Converting 80 to 73 could be 
envisaged to proceed via two routes depending on the timing of introduction of the 
thiourea moiety. The first route (a) involved condensation of amine 80 with thiourea 
reagent 89 to give 79. The second route (b) involved extra steps as a result of 
protection of amine 80 with a Boc group. The resultant Boc-protected amine was 
considered to be an attractive intermediate to purify. Catalytic hydrogenolysis of 82 
would furnish 81 and this substrate was considered to be a key intermediate in the 
synthesis of the target molecules via alkylation. 
OH OBn ¢r:H H :;/ Ni(NUN a I b S I ==> ~ ~ Br 
OMe 73 <r:~uH :/ I s I ~ ~ Br OMe 79 ==> 
OBn ¢r:NHBOO 
OMe 82 
~ioe OH 
~NHBOO 
OMe 81 
Hydrogenolysis 
> 
Fig. 2.2: Retrosynthetic analysis of thiourea derivatives 
OBn ¢r:NH' 
OMe 80 
U R""clioe 
OBn 
~NO' y 83 
OMe 
The starting amine 80 required in the synthesis of phenylethylbromopyridylthiourea 
(PETT) derivative 73 is not commercially available and was thus synthesized in 6 
steps from aldehyde 84a which is expensive. Thus, for optimisation purposes in the 
synthesis of 80, the regioisomer and less expensive aldehyde 84b was used 
(Scheme 2.1). However, for clarity, this series won't be described, since it served its 
purpose as a model sequence with no complications on transposing to the desired 
series. 
Thus, for the actual synthesis, the phenolic hydroxyl group of aldehyde 84a was first 
protected as its benzyl ether to give 85 in good yield. Its 1 H NMR spectrum displayed 
diagnostic peaks at 6H 7.41 (5H, m) for the aromatic protons and a singlet at 6H 5.15 
for the benzylic methylene group, while the 13C NMR spectrum displayed 
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corresponding signals at be 136.3, 128.7, 128.2 and 127.3 for the aromatic carbons 
and be 71.4 for the benzylic carbon. The melting point (44-45 DC) of a recrystallised 
sample was in agreement with the literature value98 47-48 DC, and this sample 
returned an acceptable combustion microanalysis. 
In the next step, the benzylated aldehyde 85 was condensed with nitromethane in a 
Henry reaction99 at 70 DC using ammonium acetate as promoter to give nitrostyrene 
derivative 83 in 75% yield and as a bright yellow solid after recrystallization from 
EtOH. Condensation of the aldehyde with nitromethane at reflux resulted in the 
desired product together with by-product 86 which was formed as a result of 
subsequent Michael addition onto 83. Thus, the temperature of the reaction was 
carefully monitored. 
OH OBn OBn ¢f=' ~CHO qCHO ii ¢JNO' N02 -:?" • • + I 
R ~ ~ 
R2 OMe OMe OMe 
84a: R1 = H, R2 = OMe 85 83 86 
84b: R1 = OMe, R2 = H 
Scheme 2.1. Reagents and Conditions: (i) BnBr, K2C03, EtOH, reflux, 16 h; 95%. (ii) CH3N02, 
NH40Ac, 70 DC, 14 h; 75%. 
Mechanistically, the ammonium acetate provides both a proton source to activate the 
carbonyl oxygen as well as a base to abstract the acidic protons on nitromethane. 
The nitromethane anion formed then attacks the electrophilic carbonyl carbon 
generating intermediate 88. An E2 elimination of water subsequently results in the 
formation of ,B-nitrostyrene 83 (Fig. 2.3). At higher temperatures, the nitrostyrene 83 
acts as a Michael acceptor and undergoes a conjugate addition with a second 
nitromethane anion to form by-product 86 which was isolated when the reaction was 
conducted over a prolonged period at reflux (::::0 78 DC). 
The spectroscopic and analytical data for 83 was in agreement with the assigned 
structure. The 1H NMR spectrum of 83 displayed two doublets at 6H 8.12 and 6H 7.79 
for the nitroethenyl group with a large coupling constant J1,2 of 13.4 Hz, while its 13C 
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NMR spectrum displayed diagnostic signals at be 136.1 for C-1 and be 135.4 for C-2. 
The Mp of this compound was in agreement with the literature value. 99 The absence 
of aldehydic signals for both the 1H (at bH 10.51) and 13C (at be 189.4) NMR spectra 
of 83 confirmed the assigned structure. The large coupling constant between H-1 and 
H-2 indicated that these protons are trans to each other and thus an E-
stereochemistry. If the protons were cis, the coupling constant Jcis would have been 
between 10-12 Hz. The E-geometry is consistent with an E2 elimination. 
-
87 88 
Fig. 2.3: Mechanism of formation of nitrostyrene 
Reduction of nitrostyrene 83 by lithium aluminium hydride (LAH) in THF at reflux 
yielded the amine 80 in good yield (Scheme 2.2). The reaction could be followed by 
tic towards the formation of the polar amine. Conventional extractive work-up could 
not be pursued in view of 80's water solubility. Thus, work-up involved adding 
saturated aq. Na2C03 solution dropwise at 0 DC. The precipitate formed was filtered 
and the filter-cake washed with large volumes of methanol. Following complete 
evaporation of all solvent, the 1 H NMR spectrum of the crude amine 80 revealed the 
presence of a broad singlet resonating at bH 3.25 for the amine protons and two 
triplets at bH 2.73 and bH 2.63 representing the two sets of methylene protons. The 
13C NMR spectrum revealed the presence of ethyl carbons at be 42.1 for C-1, and be 
34.6 for C-2 consistent with formation of a j3-phenethylamine. As expected, the amine 
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was very polar towards tic, running with an Rf = 0.3 with an EtOAc/MeOH (9: 1) 
system. Thus it wasn't purified but used in the next step. However, tic indicated it to 
be predominantly a single compound, which was corroborated by the 1H NMR 
spectrum. 
OBn 
~N02 
OMe 
83 
.. 
OBn 
NH2 
s· 
OMe 
80 
Scheme 2.2. Reagents and Conditions: (i) LiAIH4, THF, reflux, 4 h; 80%. 
With amine 80 in hand, attention focused on exploring the two possible routes to 73. 
The thiourea reagent 89 required for condensation with the amine was synthesized 
by condensation of 2-amino-5-bromopyridine with 1, 1'-thiocarbonyldiimidazole in 
CH3CN at room temperature for 12h (Scheme 2.3). Filtration of the precipitate that 
formed gave 89 in good yield, which was recrystallized from methanol/CH3CN. This 
treatment resulted in substitution of the imidazole group by methoxy to form 90, as 
indicated by the 1H NMR spectrum which revealed the presence of a methoxy singlet 
resonating at iSH 3.99 and a broad singlet at iSH 11.56 for the NH proton. The 
presence of a thiocarbonyl was confirmed by the 13C NMR spectrum, which revealed 
a diagnostic signal at iSe 188.7. 
Br 
"ClNH2 
90 
Scheme 2.3. Reagents and Conditions: (i) 1,1 '-Thiocarbonyldiimidazole, CH3CN, rt, 12 h; 87%. 
In view of the lability of 89 towards nucleophilic substitution, it was decided to use the 
precipitate of 89 without further processing. Thus, amine 80 was condensed with 
precipitated thiourea derivative 89 in DMF at 100°C to give the protected derivative 
79 in 37% yield over two steps after column chromatography (Scheme 2.4). The 1H 
NMR spectrum of 79 revealed the presence of two broad singlets resonating at iSH 
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11.18 and bH 8.80 for the two NH protons, while its 13C NMR spectrum displayed a 
diagnostic signal at be 179.0 for the thiocarbonyl carbon. 
OBn OBn OH ¢JNH' ~n ¢J~U • sis' X~ I s I 6' 3' ~ ~ ~ Br 
4' Br 
OMe OMe 
79 
OMe 
73 
80 
Scheme 2.4. Reagents and Conditions: (i) 89, DMF, 100 DC, 16 h; 37%. (ii) H2 , Pd/C, rt. 
An attempt to deprotect the benzyl group of 79 was unsuccessful and did not result in 
the desired product 73, but instead led to recovered starting material. In this case, 
the thiourea scaffold in the molecule probably coordinates with the palladium 
catalyst, thus inhibiting the deprotection as anticipated in the planning. 
Hydrogenolysis of amine 80 using palladium-on-carbon catalyst did not yield the 
desired product either, presumably due to poisoning of the catalyst by the amine 
group. It was therefore envisaged that protection of the amine as a Boc would 
provide a better route to the desired thioureas 73-76. It was felt that this protecting 
group would serve appropriately in subsequent steps including the Sonogashira 
coupling reaction. The Boc group is also relatively stable under basic conditions 
since the carbonyl group is relatively hindered and its electrophilicity diminished due 
to mesomeric stabilisation of oxygen and nitrogen. The strong resistance of the Boc 
group under basic conditions would allow chemoselective deprotection of the benzoyl 
group later in the synthesis, without disturbance of the double and triple bond 
functional groups. To this end, amine 80 was protected as its Boc-carbamate, by 
reacting with di-tert-butyldicarbonate (1.2 equiv.) and Et3N in acetonitrile at room 
temperature to give 84a in 76% yield (2 steps with LAH reduction) after purification 
by column chromatography (Scheme 2.5). The use of a catalytic amount of DMAP 
led to incomplete reaction thus necessitating the addition of more di-tert-
butyldicarbonate up to 1.5 equiv. This resulted in formation of the desired carbamate 
in 36% overall yield for the two steps, together with di-boc by-product 84b in 28% 
yield. In the absence of DMAP, the nucleophilic amine attacks di-tert-
butyldicarbonate directly to form the Boc-protected amine 84a (Fig. 2.4), which is not 
nucleophilic enough to undergo further substitution. 
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OBn OBn Boc OBn Boc 
~NH2 
~ ~~H + ~~BOC 
76% 
OMe OMe OMe 
80 84a 84b 
Scheme 2.5. Reagents and Conditions: (i) (BOC)20, Et3N, DMAP, CH3CN, rt, overnight. 
OBn ~O, 0 1_ ~NH2 r~,)lcr"( 
OMe 
80 
~OBn l: ---" I ~ 
OMe 
84a 
Fig. 2.4: Mechanism of formation of 84b in the absence of DMAP 
(NMe2 (NMe2 
0 ~ J6):: Fast :yo"~loy --- t;'~~ + --- -o~ 
o 0) II III 
OBn ( NMe2 
~NH' OB" Boo 0 ~~H ~I Fast 
- -
OM. Va-f OMe 
80 84a 
Fig. 2.5: Mechanism of formation of 84a and 84b in the presence of DMAP 
+ CO2 
OBn Boc 
~~BOO 
OMe 
84b 
In the presence of DMAP, the latter reacts with di-tert-butyldicarbonate to form 
intermediate I which acts as a Boc transfer agent (Fig. 2.5). The butoxide anion III 
formed acts as a base. Since the carbamate NH hydrogen of mono-Boc derivative 
84a is relatively acidic, deprotonation occurs resulting in a fast second substitution to 
furnish 84b. Thus in this case, it was better to leave out the DMAP. 
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The 1H NMR spectrum of 84a revealed the presence of a methyl singlet at DH 1.42, 
and a downfield shift in the methylene protons adjacent to nitrogen to DH 3.37. By 
comparison the 1 H NMR spectrum for compound 84b had these protons resonating 
downfield at DH 3.89 consistent with the electron-withdrawing effect of the second Boc 
group. The 13C NMR spectrum of 84a revealed the presence of a carbamate carbonyl 
carbon at Dc 155.9 and a methyl carbon at Dc 27.8. The carbonyl carbon for 
compound 84b resonated at Dc 153.7. 
Table 2.1: 
OBn H OBn Boc 
I ~lBOC ~Boc 
84a OMe OMe 84b 
Nucleus Signal (CDCI3, ppm) 
84a 84b 
H-1 3.37 (2H, q, J 6.4 Hz) 3.86 (2H, t, J 7.4 Hz) 
H-2 2.83 (2H, t, J 6.4 Hz) 2.95 (2H, t, J 7.4 Hz) 
C=O 155.9 153.7 
OC(CH3h 77.0 81.8 
C-1 40.8 46.4 
The other significant difference between these two compounds was the difference in 
the quarternary carbon resonating at Dc 77.0 and Dc 81.8 for 84a and 84b, 
respectively. Some of the important signals are shown in Table 2.1. The presence of 
a carbonyl group was also confirmed by the IR spectrum of these carbamates. 
Compound 84a displayed a strong carbonyl signal at 1707 cm-1, while 84b displayed 
two strong peaks at 1776 and 1736 cm-1, for the C=O asymmetric and symmetric 
stretches respectively. 
Hydrogenolytic debenzylation of 84a-b in the presence of 10% palladium-on-carbon 
in ethanol at room temperature led to phenols 81a-b in good yield. The 1H NMR 
spectrum of these compounds revealed the absence of a benzylic methylene singlet 
at DH 5.03 and DH 5.04 for Dc 81a and Dc 81b respectively, as well as aromatic 
protons at DH 7.45-7.29. The debenzylation was also confirmed by its 13C NMR 
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spectrum, which showed only six aromatic carbons and no benzylic methylene 
carbons at be 70.9 and be 70.8 for 81a and 81 b, respectively. The IR spectrum of 
81a-b displayed a diagnostic broad peak between 3398-3295 cm-1 for the hydroxyl 
stretch. 
OBn 
~NRBOC 
OMe 
84a R = H 
84b R = Boc 
OH 
~NRBOC 
OMe 
81a R = H 
81b R = Boc 
ii 
OH 
~NH2 
OMe 
91 
Scheme 2.6. Reagents and Conditions: (i) H2, Pd/C, EtOH, rt, 5 h; 66%. (ii) CF3COOH/CH2CI2 (1 :2), 0 
DC, 30 min; 31 %. 
Deprotection of the Boc group on 81 a or 81 b was accomplished with trifluoroacetic 
acid in methylene chloride (1 :2) at 0 °C to provide the desired amine 91 (Scheme 
2.6). The mechanism involves protonation of the carbonyl oxygen to form I (Fig. 2.6). 
Elimination of a stable tert-butyl cation III via SN1 gives carbamic acid II which 
undergoes decarboxylation to give the desired amine. The reaction is driven by the 
relative stability of the tert-butyl cation III. 
H+ 
-
OH H 
~~j< Y I H 
OMe 
Fig. 2.6: Mechanism of deprotection of Boc 
-
+ 
III IV 
For elaboration into the HI-236 end of the molecule, amine 91 was condensed with 
thiourea reagent 89 to give 73 in 44% yield (Scheme 2.7) after column 
chromatography. The 1 H NMR spectrum of 73 displayed resonances for the thiourea 
NH protons at bH 11.12 and bH 10.59 whereas, its 13C NMR spectrum showed the 
presence of a thiocarbonyl carbon at be 179.0 which was downfield to that of a urea. 
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Compounds 74-76 were synthesized in a similar manner described for 73 and the 
structures were assigned on the basis of spectroscopic analysis. 
OH OMe 
~NH2 B'~;~ 
OMe 91 OH 73 
Scheme 2.7. Reagents and Conditions: (i) 89, DMF, 100 ec, 1 h; 44% 
A further advantage of producing Boc-derivative 81 was that it could be used to 
access key intermediate 93 required in Sonogashira coupling as well as models 77 
and 78 via alkylation of phenolic carbamate 81 a with 3-butyn-1-01 activated as its 
tosylate 92. The alkylation reaction turned out to be unexpectedly troublesome. 
Heating carbamate 81a with 3.0 equiv. K2C03 and 3.0 equiv. butynyl tosylate in 
acetonitrile at reflux for 5 days gave the desired product 93 in only 31 % yield, along 
with a 60% recovery of starting material (Scheme 2.8). The use of a large excess of 
K2C03 and tosylate did not improve the yield, although the reaction didn't produce 
any other by-products according to tic, and variation of solvent and base brought no 
significant improvement to the result either. The use of NaH as a base in either THF 
or DME led to decomposition of starting material. The poor yield and the 
incompleteness of the reaction prompted an investigation of the factors influencing 
this reaction. After a number of reactions using different equivalents of K2C03, it was 
discovered that the rate of the alkylation reaction was dependent on the amount of 
potassium carbonate used. The slow conversion of the substrate to product was 
attributed to the fast rate of elimination of the tosylate to form but-1-en-3-yne (Fig. 
2.7) in view of the acidity of the allylic hydrogens. This rationale was confirmed by 
minimising the amount of base, to 1.5 equiv. base and using a large excess of 
tosylate (6 equiv.). Thus, alkylation of 81a under these conditions (1.5 equiv K2C03 
and 6 equiv. tosylate) yielded the alkylated carbamate 93 after 5 days in 70% yield. 
Alkylation of 81 b with butynyl tosylate 92 did not yield any product, probably due to 
steric hindrance as a result of the two bulky tert-butyl groups on nitrogen. 
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OH 
~NHBOC 
OCH3 
81a 
Synthesis of Thiourea Derivatives 
4 H ~" 1" 0-2" /' o 
NHBoc 
5' 
Scheme 2.8. Reagents and Conditions: (i) 92, K2C03, CH3CN, reflux, 5 d; 70%. 
~~,,? '-':: Qvsn H H '-' I - H -
/ ~ 
B: But-1-en-3-yne 
92 
Fig. 2.7: Mechanism of elimination of the tosylate 
The 1 H NMR spectrum for compound 93 displayed a signal for the alkyne proton (H-
4") at bH 2.03 which appeared as a triplet with a small coupling constant of J 2.7 Hz, 
due to allylic coupling with the H-2" signals. Additional signals in the spectrum at bH 
2.66 for H-2" and a triplet at bH 4.05 for H-1" confirmed that alkylation had taken 
place. The 13C NMR spectrum displayed diagnostic signals at be 80.7 and be 69.8 for 
the alkyne carbons. The presence of an alkyne was further confirmed by the IR 
spectrum, which displayed a weak signal at 3309 cm-1 for the =C-H stretch as well as 
a weak signal at 2413 cm-1 for the alkyne C=C stretch. 
OH R 
~lBOC 
OCH3 
81a R = H 
81b R = Boc 
1" 
2" 3~O R ? .. I ~~BOC 
OCH3 
94a R = H 
94b R = Boc 
Scheme 2.9. Reagents and Conditions: (i) Propargyl bromide, K2C03, CH3CN, reflux. 
For introduction of the shorter C-3 propynyl tether, 81a was treated with equimolar 
quantities of K2C03 and propargyl bromide resulting in low yields (31 %) of the 
alkylated derivative 94a and recovered starting material. The optimised conditions 
from before, in which an excess of propargyl bromide (6 equiv.) and 1.5 equiv. K2C03 
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led to the desired carbamate 94a in 75% yield after 20 h. In contrast to the 
incomplete reaction observed in the alkylation of 81 a using equimolar concentration 
of propargyl bromide and K2C03 , the use of bis-Boc 81 b significantly enhanced the 
conversion to the target alkyne 94b in 70% yield (Scheme 2.9) in 1 h (Table 2.2). 
Table 2.2. Optimization of alkylation of 81 
Propargyl bromide K2C03 Time Yields 
81a 6 equiv 1.5 equiv 5 days 71 % (94a) 
81a 3 equiv 3 equiv 20 h 31% (94a) 
81b 3 equiv 3 equiv 1 h 70% (94b) 
The spectroscopic data of 94a-b was consistent with the assigned structures and the 
presence of the alkyne group was evident in both the 1H and 13C NMR spectra. Thus, 
the 1 H NMR spectrum of 94b displayed a diagnostic signal at DH 2.47 and DH 4.65 for 
the alkyne proton and H-1 ", respectively. The 13C NMR spectrum provided further 
confirmation with new signals at Dc 79.0 and Dc 75.2 for the alkyne carbons and Dc 
56.7 for C-1". 
Compound 77 was then produced in the following way. Deprotection of the Boc 
group in 93 using trifluoroacetic acid in dichloromethane (1: 1 0), liberation of the 
amine with diisopropylethylamine, total evaporation of all the solvent followed by 
condensation of the resultant oil with thiocarbonyl derivative 89 in DMF at 100 DC 
afforded the coupled product 77 in unoptimised 25% yield (for the two steps) 
following column chromatography (Scheme 2.10). The 1 H NMR spectrum of 
compound 77 displayed a combination of aromatic ring hydrogens corresponding to 
the two rings as well as two broad singlets at DH 11.13 and DH 8.44 for NH-3 and NH-
2, respectively. In addition, the 13C NMR spectrum displayed a diagnostic signal at Dc 
179.2 corresponding to the thiocarbonyl carbon. The presence of the thiocarbonyl 
group was further confirmed by the IR spectrum, which displayed a weak signal at 
1137 cm-1 for a C=S stretch. 
- 55 -
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 2 
H O~ 
~NHBO' 
OCH3 
93 
Synthesis of Thiourea Derivatives 
S 
~~NH ~O PI H'0 ~ OM~ 
Br 
77 
Scheme 2.10. Reagents and Conditions: (i) CF3COOH, CH 2CI2 , 0 DC, 1 h and then OlEA, rt, 10 min 
followed by 89, OMF, 100 DC, 1 h; 25%. 
The synthesis of 78 bearing a propyne spacer was performed in an identical manner 
to 77. Deprotection of the Boc groups of 94a-b under the same conditions as used 
for 93 followed by total evaporation of solvent and reaction with thiourea reagent 89 
afforded 78 in low yield (17%) along with a complex mixture of products, presumably 
as a result of decomposition of the alkyne under acidic conditions (Scheme 2.11). 
The triflate salt I as well as the diisopropylethylamine salt III are fairly acidic and 
probably promoted dealkylation as depicted in Scheme 2.12. 
The structure of 78 was confirmed by both 1 Hand 13C NMR spectroscopy, which 
revealed a similar set of resonances to 77. Thus the expected downfield shift for N-3 
to bH 11.13 was observed in the 1 H NMR spectrum as a result of intramolecular 
hydrogen bonding of these protons with N-1 of the pyridine ring. The 13C NMR 
spectrum of this compound displayed a diagnostic thiocarbonyl signal at be 179.1. 
The presence of a thiocarbonyl group was further confirmed by the IR spectrum 
which displayed a weak signal at 1137 cm-1. 
~O R 
P ~lBO' 
OCH3 
94a R = H 
94b R = Boc 
S 
~~~J\NH ~ 0 H ¢ :?' 1N ~ I I 
~ OMe ~ 
Br 
78 
Scheme 2.11. Reagents and Conditions: (i) CF3COOH/CH 2CI2 (1:10),0 DC, 1 h and then 89, OMF, 
100 DC, 16 h; 17%. 
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~¢J0 l 
'/ Boc 
I 
~ 
OCH3 
94a R = H 
94b R = Boe 
Nu 
H =c--.l 
Scheme 2.12 
91 
Synthesis of Thiourea Derivatives 
OlEA 
+ 
~~ e 
~ + CF3C02 IV 
III 
Thioureas bearing a tether were synthesized according to the procedure described 
for the synthesis of HI-236 and were obtained in low yields. Optimisation of 
conditions for their synthesis needs to be done. These compounds are currently 
being tested for anti-HIV activity. 
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CHAPTER 3 
Synthesis of d4U-Alkyne-HI-236 
3.1 Strategy for the Synthesis of [d4U]-Spacer-[HI-236] 
The bifunctional molecules 95-99 targeted in this thesis are shown in Fig. 3.1. The C-
5 position on the pyrimidine ring of the base was selected as the attachment point of 
the tether due to its anticipated low interference with base-pairing in DNA.100 In fact, 
tethering at the C-5 position with a flexible chain of about 10A has been reported 101 
to permit the triphosphate to be generated and thus be incorporated into nucleic 
acids. It was decided to lengthen the spacer using ethylene glycol units in view of 
their anticipated water solubility. 
Br 
ifo ~ ~~oLr:~ ~ - ~~/NH A I IT HOB 99 s 
Fig. 3.1: Structure of bifunctional target molecules 
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Structural studies49.51.52 around HI-236 by Uckun and co-workers in the original work 
on the drug revealed that the C-1 oxygen substituent of HI-236 is located at the 
entrance of the NNRTI pocket. This position was, therefore, chosen as the 
attachment point to the linker (tether). Attachment of the linker to the C-5 position of 
the nucleoside was thought to be accessible via a palladium cross-coupling 
Sonogashira 102 reaction of a terminal alkyne with a 5-iodo nucleoside. C-5 tethered 
heterodimers have also been developed extensively by the Laduree78.79 group in 
which a Sonogashira coupling strategy has also been demonstrated. Full awareness 
of their work only occurred once the work in this thesis was in progress. Furthermore, 
C-5 substituted pyrimidine nucleosides constitute a class of biologically significant 
molecules and the C-5 alkenyl and alkynyl substituted ones have shown various 
antiviral activities. For example, (E)-5(2-bromovinyl)-2'-deoxyuridine (BVOU) shown 
in Fig 3.2 is a highly potent and selective anti-Herpes agent, which inhibits Herpes 
Simplex Virus type 1 (HSV-1) and is currently in clinical use.103 Other C-5 substituted 
nucleosides in clinical use include 5-iodo-2'-deoxyuridine (IOU) and 5-trifluoromethyl-
2'-deoxyuridine (TFT) which are both administered as eye drops or ophthalmic cream 
in the treatment of herpes virus. 104 
o 
~7' H0\:j 
HO 
Idoxuridine (IOU) 
HSV-1, HSV-2 and VZV 
o 
~7CF' H0\:j 
HO 
Trifluridine (TFT) 
HSV-1, HSV-2 and VZV 
Fig. 3.2: C-5 substituted nucleosides in clinical use 
3.1.1 Retrosynthesis of [d41]-alkyne-[HI-236] 
o 
~~B' H°tf 
HO 
Brivudin (BVOU) 
HSV-1 and VZV 
Two possible strategies were envisioned for the synthesis of the alkynyl target 
molecules 96-99, with appropriate retrosynthetic analysis depicted in Fig. 3.3. 
1. The first strategy (a) would involve a divergent approach via palladium cross-
coupling reaction of an alkyne of type A with iodo-d4U 100 followed by 
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deprotection of the benzoyl and Boc groups and then condensation of the 
resultant amine with thiourea derivative 89 to furnish the target compounds 
96-99. It was anticipated that the use of sodium methoxide as a nucleophile 
for deprotection of the benzoyl group, as well as trifluoroacetic acid for 
deprotection of the Boc group might present a potential problem regarding 
nucleoside bond cleavage. Attention would therefore focus on optimising 
conditions for these two key reactions. 
Condensation 
Sonogashira " \ 5 
Coupling Alkylation ~ 
o ~ (CH:Z}nlOPEGln-01&~ ~ ¢N~ ~~ I I ~) "b ~ OCH3 h-
R~ 96-99 B. 
b U Sonogashira 
Coupling 
~NHPG a if 0 .0. (CH:Z}nlOPEGln-O ~ ==>~ ~ I ~ I ~ OCH3 ROB 
o 
U 
Sonogashira 
Coupling 
~j1y1 
ROO~) 
't) t\
NHPG 
(CH:Z}nlOPEGln-O ~ 
~ I 
A ~ OCH3 
U COO,. ","00 
100 R = Bz 
101 R = H 
Fig. 3.3: Retrosynthetic analysis of heterodimers bearing an alkyne spacer 
OH 
¢l:NHB~ 
OMe 81 
2. The second strategy (b) was more convergent and involved Sonogashira 
coupling of an alkyne of type B with iodo-d4U 100 followed by deprotection of 
the benzoyl group to furnish the target compounds directly. Attention would 
focus on the reactivity and potential interference of the thiocarbonyl group 
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under Sonogashira coupling conditions. It was anticipated that the presence of 
a bromopyridine ring might compete with the iodopyrimidine in the cross-
coupling step, although literature precedence suggested that it is possible to 
regioselectively couple an iodonucleoside in the presence of an aryl 
bromide.105 The use of Cui as a co-catalyst has been found to inhibit coupling 
of aryl bromides but enhance the coupling of aryl iodides. 106 
The key 5-iodo nucleoside 100 would be synthesized according to the Bristol-Myers-
Squibb93 procedure outlined in Scheme 1.17. 
3.1.2 Literature Overview on Sonogashira Coupling 
Sonogashira coupling of 5-iodouridine with terminal alkynes has been extensively 
studied.107 The mechanism of this reaction starts with oxidative insertion of Pd(O) into 
the aryl-halide bond. Cui activates the alkyne by forming a copper acetylide, which 
undergoes transmetallation with the palladium complex to form the alkynyl-Pd-R 
intermediate. Reductive elimination of Pd(O) leads to the coupled product (Fig. 3.4). 
Et3N 
H R ~ Cu R 
Cui Ar 
Ar I L-Pd 
Pd(O) I I 
~ L-Pd-X L I Ar-X 
Oxidative L 
Insertion 
Transmetallation 
Fig. 3.4: Mechanism of Sonogashira coupling 
Pd(O) ) ~ R Ar R 
Reductive 
Elimination 
Regarding literature precedent for our approach, Crisp and Flynn have demonstrated 
that the C-5 alkynyl derivatives 104 could be obtained in high yield (70-90%) by 
cross-coupling of acetylated uridine triflate 102 with a range of terminal alkynes 103 
(Scheme 3.1) using tetrakis(triphenylphosphine)paliadium(O) as a catalyst. Slight 
elevation of reaction temperature increased the rate of coupling. In this case, 
furanopyrimidine by-products 105 were isolated in low yield (7%) or in trace 
amounts. 108 
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102 
R1 = R2 = OAe 
R1 = OAe R2 = H 
R1 = OH R2 = H 
103 
Pd(PPh3)4, 10% 
Cul,20% 
Et3N, 1.2 equiv. 
DMF 
R3 = Me3Si, Ph, 4-MeOCsH4' 3,5-(CF3hCsH4, 
3,5-Fr CsH4, 4-CF3CSH4, 4-FCsH4' CsFs 
Scheme 3.1 
104 
Major 
70-97% 
Synthesis of d4U-alkyne-HI-236 
+ 
105 
Minor 
<7% 
Robins et al applied the Sonogashira reaction to couple protected 2'-deoxythymidine 
derivatives 106 with several alkynes 107 in triethylamine at 50°C in the presence of 
bis(triphenylphosphine)palladium (II) chloride and copper (I) iodide (Scheme 3.2). 
106a R = OAe 
106b R = Tol 
Scheme 3.2 
107 
Pd(PPh3hCI2, 10% 
Cul,20% 
Et3N. 
C2Hs, C3H7, C4Hg (n), CSH11 (n), 
C(CH3b. CsHs, Si(CH3b. H, 
CH20THP, CH20H, CH2CH20THP, 
CH2CH20Tol, CH2CH20Ts. 
+ 
108 109 
In this case, the extent of cyclization was dependent on the reactants. Thus, coupling 
of 106a with (trimethylsilyl)acetylene gave the target product 108 in 80% yield, 
whereas the use of 1-hexyne, 4-(p-toluyloxy)butyne, 4-tetrahydropyranyloxy)butyne 
or 4-(trityloxy)butyne under the same conditions gave the cyclized furanopyrimidin-2-
one compound 109 as the major product. Conversely, coupling reactions with the 
same range of alkynes but using the nucleoside protected as its p-toluyl ester 
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proceeded smoothly with minimal formation of deiodinated and furanoprimidin-2-one 
by-products. 109 
Hobbs 110 (Scheme 3.3) attempted to use the conditions optimised by Robins et al to 
couple propargylamine 111 with unprotected 5-iodouridine 110 but failed owing to the 
nucleoside's insolubility in triethylamine. Successful coupling was achieved to form 
the coupled products 112 in good yields (70-90%) by using DMF as a solvent and 
tetrakis(triphenylphosphine)palladium as a catalyst instead of the Pd(lI) used by 
Robins. He concluded that the successful coupling was a result of using Pd(O) 
instead of Pd(II). A review of these conditions by Robins revealed that the use of 
DMF significantly improved the rate of coupling and not the Pd(0).111 
0 o R 
~&' ~~ AI H R HO~ 111 HO~ R • Pd(PPh3hCI2, 10% (a) CH2NHCOCF3 
Cul,20% (b) (CH2bNHCOCF3 
Et3N, 2 equiv. (c) (CH2)1ONHCOCF3 
HO OH DMF HO OH (d) CH2NH2 
110 112 (e) (CH2bNH2 
Scheme 3.3 
Sonogashira coupling of protected propargylamine 111a with 2'-deoxynucleoside 113 
by the Robins group in the presence of triethylamine as a base furnished the target 
nucleoside 114 together with triethylammonium salts that were difficult to separate. 
To improve the purification of these nucleosides, Garg et al. 112 developed a 
heterogeneous protocol that employed a palladium-on-carbon catalyst and a resin-
bound tertiary amine (Amberlite IRA-67) as a base. These conditions furnished the 
coupled product 114 in good yield (Scheme 3.4). The study involved a cross-coupling 
reaction of nucleoside 113 in the presence of Amberlite IRA-67 and Pd(O) (10 mol%) 
which resulted in the coupled compound 114 in 79% yield after filtration of the 
reaction media and purification by column chromatography. The authors then 
substituted Pd(O) with a heterogeneous transition-metal catalyst (Pd/C) to further 
simplify the purification process. 
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~~I 
HOO~) 
tJ 
HO 
113 
Scheme 3.4 
111a 
5% Pd/C, 10% 
Amberlite IRA-57 
CuI, DMF, 50 cC. 
(72% yield) 
Synthesis of d4U-alkyne-HI-236 
114 
C-5 alkynylated d4T analogues 117 and 119 have been synthesized via the smooth 
and efficient coupling of alkynes 116 and 118 with 5'-O-acetyl-5-iodo d4U 115 in 
DMF under co-catalysis of Pd and Cui (Scheme 3.5). Reaction with unprotected 
alkynes 118 gave the coupled compounds 119 after 22-24 h in low yields (35-45%), 
whereas the protected alkynes 116 gave the target compounds in good yields (70-
76%).113 
o (CH2)n 0 ~~ '-OTHP PdIO) 10%1\ ';;- ~7' AC0't)0 0 .. CuI 20% . H0't) 
Et3N,DMF 
3h 
Pd(O) 10% 
CuI 20% 
• Et3N,DMF 
22-24 h 
117a; 76% 
117b; 70% 
HC C-(CH2)n-OTHP 115 HC C-(CH2)n-OH 
Scheme 3.5 
11Ga n = 1 
11Gb n = 2 
118a n = 2 
118b n = 3 
118cn=4 
119a; 45% 
119b; 43% 
119c; 35% 
In summary, the use of Cui as a co-catalyst has been shown to give better results. A 
mole ratio of 2: 1 copper to palladium has been shown to offer the best coupling 
conditions for alkynes, as the production of side products (cyclic furanopyrimidine) is 
minimized. It is noteworthy that performing the reaction in the presence of Cui has 
also been reported to increase the conversion rate to by-products. Solvent has been 
reported to be an important determinant for successful coupling of terminal alkynes 
with iodonucleosides. 111 The use of DMF as a solvent has been shown to reduce the 
percentage of cyclic by-product formed. A considerable percentage of this cyclized 
by-product was isolated when longer reaction times were employed or when an 
electron-withdrawing group on the nucleoside was present. Optimal conditions have 
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been found to be 2.0-2.5 equiv of terminal alkyne, 10% Pd(PPh3)4, 20% Cui and 1.2 
equiv Et3N in DMF. Pd (0) has been reported to give better results than Pd (11).107 
3.2 Strategy (a): Synthesis of Target Compounds 96-99 
3.2.1 Synthesis of [d4U]-butyne-[HI-236] 
3.2.1.1 Synthesis of iodo-d4U 
Having successfully synthesized alkynes 93 and 94 (Schemes 2.8 and 2.9, Chapter 
2), attention focused on the synthesis of iodo-d4U derivative 100 (Scheme 3.6). The 
5'-O-benzoyl d4U derivative 124 was synthesized in four steps according to the 
Bristol-Myers Squibb procedure outlined in Scheme 1.18 in Chapter 1.93 Reaction of 
uridine with methanesulfonyl chloride (3 eq.) in pyridine furnished trimesylate 121 in 
good yield. The product was isolated by adding the reaction mixture into ice-cold 
water, filtration of the precipitate formed and washing the filter cake with water. 
Following extensive drying on the pump, the 1H NMR spectrum of 121 revealed the 
presence of three mesylate methyl singlets resonating at bH 3.22, bH 3.33 and bH 3.35 
while its 13C NMR spectrum displayed resonances at be 37.9, 37.9 and 36.9 for the 
methyl groups. 
The next step involved chemoselective transformation of the C-5' centre as well as 
preparation of C-2' for bromide substitution. Thus, the 2,2'-anhydrouridine 122 was 
synthesized by treatment of 121 with sodium benzoate in acetamide at 115°C. After 
1 h, the product was poured into ice-cold water, stirred at 0 °C for 15 min and the 
solid filtered to give the target compound in 75% yield. The 1H NMR spectrum of 122 
displayed the absence of an NH singlet at bH 11.51 in 121 as well as the presence of 
additional resonances in the downfield region for the aromatic protons of the benzoyl 
group. Its 13C NMR spectrum displayed the appearance of a carbonyl carbon at be 
170.6 and aromatic carbons, confirming the presence of a benzoyl group, which 
could be assigned to the C-5' position in view of the relative deshielding of the 
diastereotopic H-5' protons. There was also a significant downfield shift in the C-2' 
carbon from be 76.0 in 121 to be 86.0, thus confirming that displacement of the 
- 65-
Un
ive
rsi
ty 
of 
Ca
p
 To
wn
Chapter 3: Synthesis of d4U-alkyne-HI-236 
mesylate and formation of the anhydro ring had taken place at this carbon. C-2' over 
C-3' attack by the pyrimidine base is observed in view of the 5-exo-tet cyclization 
being faster than the 6-exo-tet process as well as the C-3' substitution forming a 
bridged compound. 
o 
HO OH 
120 
i 
-
v 
-
o 
MsO OMs 
121 
o 
BZ~ 
124 
ii 
-
iv 
-
o 
122 
MsO I ... 
III 
o 
MsO Br 
123 
Scheme 3.6. Reagents and Conditions: (i) MsCI, pyridine, 0 ec, 5 h; 71 %. (ii) NaOBz, CH3CONH2, 
115 ec, 1 h; 75%. (iii) CH3COBr, EtOAc/MeOH (10:1), reflux, 1 h; 97%. (iv) Zn, EtOAc/MeOH, rt; 89%. 
(v) 12, CAN, CH3CN, 60 ec, 1 h; 80%. 
Nucleophilic attack by bromide ion at the 2'-position using acetyl bromide in 
MeOH/EtOAc (1 :10) gave cis-bromomesylate 123 in high yield (97%). Introduction of 
the bromine atom was evident in the 1H NMR spectrum which displayed an upfield 
shift in the H-2' protons from DH 5.69 in 122 to DH 4.67 in 123. Similarly, the 13C NMR 
spectrum of 123 displayed an upfield shift of the C-2' resonance from DC 86.0 in 122 
to DC 47.5 consistent with substitution by bromine. The mechanism of this reaction 
involves SN2 displacement by bromide at C-2' with a protonated pyrimidine ring as a 
leaving group. The net result is inversion of configuration to afford the syn 
stereochemistry in 123. 
Reductive elimination of bromomesylate 123 employing zinc metal in ethyl acetate 
and methanol containing catalytic acetic acid afforded the 5'-O-benzoate ester of d4U 
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124 in 89% yield with no detectable cleavage of the nucleoside. The downfield shift 
of the C-2' and C-3' carbons in the 13C NMR spectrum of 124 from bc 75.6 and be 
47.5 in 123 to be 133.6 and be 127.2 respectively, confirmed the introduction of the 
double bond via elimination of bromine and mesylate groups. Elimination of the 
mesylate was further confirmed by the absence of the mesylate methyl carbon at be 
38.8. Although syn elimination is energetically more demanding than anti, 
undoubtedly the potent leaving ability of the sulfonyl group assisted the elimination. 
Halogen-substituted nucleosides have been shown to exhibit interesting 
chemotherapeutic, biochemical and biophysical properties.103 They have also been 
utilized as intermediates for coupling with terminal alkynes to give 5-alkynyl 
nucleosides with antiviral activity.107,114 The first 5-iodination of uridine was described 
by Prusoff et al using an iodine/nitric acid system. 115 Dale et a/116 subsequently 
reported iodination of 5-mercuriuridine derivatives using elemental iodine in aqueous 
alcohol. N-Iodosuccinimide as well as iodine monochloride have also been utilized for 
iodination of pyrimidine nucleosides. The CAN-mediated C-5 halogenation of uracil 
derivatives was first reported by Asakura, et al in 1990, in which molecular iodine as 
well as Nal and Lil were used as the iodine source. 114 Ultimately in this work, 
iodination of 124 to its 5-iodo d4U 100 was effected using elemental iodine and CAN 
at 60°C in 80% yield. This reaction was found to be dependent on time and 
temperature. Thus, higher temperatures and long reaction times led to isolation of a 
by-product as a result of migration of the benzoyl group from the C-5'-hydroxyl to the 
pyrimidine nitrogen. Iodination was confirmed by the 1H NMR spectrum which 
revealed the absence of a doublet at bH 5.33 for H-5 and a downfield shift in H-6 from 
bH 7.34 in 124 to bH 7.86. H-6 also appeared as a singlet in the 1H NMR spectrum of 
100. The 13C NMR spectrum of 100 revealed that C-5 had shifted upfield from be 
102.7 in 124 to be 68.9, indicating iodination at C-5. 
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3.2.1.2 Sonogashira Coupling, Deprotection and final Condensation 
Sonogashira coupling of 5-iodo-5'-O-benzoyl d4U 100 with alkyne 93 yielded the 
desired coupled product 125 in 94% yield within 3 h at room temperature (Scheme 
3.7). The 1H NMR spectrum data for 125 revealed signals for both the alkynyl and 
d4U moieties in the ratio of 1: 1. A successful coupling was further confirmed by the 
absence of an alkyne proton at around DH 2.04. The 13C NMR spectrum of 125 
displayed diagnostic resonances at Dc 141.6 (C-6), 150.5 (C-1""), 100.7 (C-2"'), 91.3 
(C-1"'), 90.7 (C-1'), 72.4 (C-5) and 40.6 (C-2"'") thus confirming the presence of both 
the nucleoside and alkyne. The structure was further confirmed by 2D NMR. The 
HMBC spectrum revealed a correlation between the methylene protons at DH 2.68 (H-
3"') with the carbons at Dc 100.7 (C-2"'), 91.3 (C-1"'), 72.3 (C-5) and 66.6 (C-4"'). 
With 125 in hand, only benzoyl deprotection, Boc removal and thiourea elaboration 
remained for the synthesis of the target. It was feared that the basic conditions of 
deprotecting the benzoyl group would cleave the nucleoside. Gratifyingly, the benzoyl 
group on 125 was deprotected using sodium methoxide (cat.) in methanol at 0 °C to 
furnish 126 in 70% isolated yield. The reaction was monitored by tic and after all the 
starting material was converted to product, the base was diluted by adding water and 
the aqueous phase extracted with large volumes of ethyl acetate. The crude product 
was purified by column chromatography using 80% ethyl acetate in hexane. 
Debenzoylation was confirmed by the upfield shift in the diasteretopic protons at H-5' 
from DH 4.64 and DH 4.50 in 125 to DH 3.88 (dd, J 2.7, 12.4 Hz) and DH 3.78 (dd, J 3.0, 
12.4 Hz), respectively. The presence of a broad hydroxyl singlet resonating at DH 
1.96, as well as the absence of aromatic protons for the benzoyl group also 
confirmed the loss of the benzoyl group. Similarly, its 13C NMR spectrum displayed 
an upfield shift in the C-5' carbon from Dc 65.1 in 125 to Dc 62.9. The absence of a 
carbonyl carbon resonating at Dc 166.2 as well as carbons for the aromatic group 
further confirmed debenzoylation had taken place. Other signals were intact 
indicating that no other transformation had taken place. 
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, ,."rNHBOC , ~NHBOC 
~JY'; ~~°ti~CH';; ~yOUOCH' 
BZOId - BZO
Id 
- HOld 
o 0 125 0 126 
l' 
- - -
100 
+ 
Scheme 3.7. Reagents and Conditions: (i) Alkyne 93, (PPh3)4Pd, Cui, E~N, DMF, THF, rt, 4 h; 94%. 
(ii) NaOMe, MeOH, 0 cC, 20 min; 50%. (iii) CF3COOH, CH2Cb, 0 cC, 30 min then 89, DMF, 100 cC, 1 
h; 41%. 
The key condensation reaction required extensive optimization and the isolation 
conditions proved critical to ensure a reproducible result. Thus, deprotection of the 
Boc group on 126 using trifluoroacetic acid in methylene chloride at 0 °C furnished 
the crude amine as a triflate salt. The reaction could be monitored by tic to form a 
very polar primary amine spot (Rf = 0.4 in 10% MeOH in CH2CI2). Since the product 
couldn't be extracted from water into an organic solvent, work-up involved adding 
HOnig's base to liberate the amine, and condensing directly with thiocarbonyl 
derivative 89 in DMF at 100°C. This resulted in the formation of product 96 but with 
accompanying nucleoside bond cleavage to generate compound 96a. TLC analysis 
of the amine intermediate employing different solvent systems (10% MeOH in EtOAc, 
5% MeOH in CH2CI2, 10% MeOH in CH2CI2, 100% THF, 50% hexane in THF, 2% 
MeOH in THF and 10% MeOH in THF) revealed one product, thus showing that the 
degradation of the product did not take place during Boc deprotection. The cleavage 
appeared to take place during the final condensation reaction, presumably promoted 
by the ammonium salt from the HOnig's base treatment «iprhEtN+H CF3CO£). 
Addition of K2C03 and MeOH to neutralise the acid (CF3COOH) prior to heating in 
the condensation with 89 resulted in nucleoside bond cleavage, presumably as a 
result of attack by the hydroxide ion generated during neutralisation. To circumvent 
this problem, the work-up was changed to first adding diisopropylethylamine to 
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liberate the amine, evaporation of the solvent on the rotary evaporator without 
extensive heating to remove excess trifluoroacetic acid followed by addition of K2C03 
and MeOH to make the reaction mixture basic. Filtration of the potassium-triflate and 
excess carbonate followed by removal of all volatiles furnished a crude amine 
presentable for condensation with thiocarbonyl derivative 89 in DMF at 100 °C for 1 h 
to furnish the target compound 96 in 41 % overall yield. Despite efforts to make the 
reaction mixture basic, impurities as a result of the nucleoside cleaving were isolated. 
Some breakdown also seemed to occur on the acidic silica-gel. The impurity co-
eluted with the target compound and was not easy to remove by column 
chromatography. However, repetitive preparative thin layer chromatography followed 
by recrystallization from methylene chloride/hexane furnished a pure sample of 96 
which was subjected to anti-HIV activity testing. The 1H NMR spectrum of a mixture 
of 96 and 96a is shown in Fig. 3.5. It is clear from the spectrum that certain signals 
double up indicating common fragments. Furthermore, the sugar resonances are 
diminished and only gave single signals in both 1H and 13C spectra indicating that this 
grouping was only present in one of the compounds (96). Some signals appeared 
together such as the low-field thiourea protons NH-1 and NH-2 for 96 and 96a, given 
that these protons are far away from the cleavage point to the sugar. Resonances for 
positions closer to the latter did, however, appear as two. Notably, the pyrimidine NH 
of 96 appeared as a singlet, with the pyrimidine ring of 96a probably being enolised. 
A very good marker for the two compounds was the aromatic methoxy group 
appearing as two singlets as shown in Fig. 3.5a, resonating at OH 3.62 and OH 3.61 for 
96 and 96a, respectively. Resonances for the aglycon part integrated for one proton 
each, whereas those of the phenyl ABC splitting pattern as well as the pyridine ABX 
splitting pattern integrated for two protons each. Similarly, in the 13C NMR spectrum, 
the presence of 96a was confirmed by the presence of additional signals for the 
uracil, linker and the HI-236 part. Specifically, the spectrum displayed two sets of 
resonances for the following carbons: C-4 (oc 162.7, 161.7), C-5 (oc 73.9, 73.7), C-2" 
(oc 98.4, 97.3), C-1" (89.8, 89.6) and one set of resonances for the sugar part. 
Important resonances in the 13C spectrum are shown in Fig. 3.5b and Table 3.1 
(Page 83). 
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Fig. 3.5: (a) 1H and (b) a section of 13C NMR spectra showing a mixture of 96 and 96a. 
C-5' 
I 
96 
A plausible explanation for the cleavage relates to the leaving ability of the pyrimidine 
base being favoured by both allylic and resonance (oxygen) stabilising effects of the 
resultant oxocarbenium ion as shown in Scheme 3.8. The cleavage could well have 
been favoured by acidic residues in the medium or even on the silica-gel 
chromatography. The latter perception is supported by the observation that multiple 
chromatography resulted in extremely low yields of product with by-product 
formation. 
Scheme. 3.8: Plausible mechanism of degradation of 97 
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3.2.2 Synthesis of [d4U]-propyne-[HI-236] 
Similarly, synthesis of 97 bearing a propyne spacer was pursued according to the 
procedure described above (Scheme 3.7) for the synthesis of 96, the only difference 
being that the diboc-derivative 94b was used. The structures of 127 and 128 were 
confirmed by spectroscopic analysis and high resolution mass spectroscopy. 
Compound 127 displayed resonances in its 1H and 13C NMR spectra for molecular 
entities of both 100 and 94. 
100 
+ + 
97a 
Scheme 3.9. Reagents and Conditions: (i) Alkyne 94b, (PPh3)4Pd, Cui, EhN, DMF, THF, rt,4 h; 94%. 
(ii) NaOMe, MeOH, 0 °C, 20 min; 74%. (iii) CF3COOH, CH2CI2, 0 °C, 30 min then 89, DMF, 100°C, 1 
h; 40%. 
Deprotection of the benzoyl group of 127 furnished 128 in good yield after column 
chromatography purification, with the Boc groups intact and the absence of the 
benzoyl group in both the 1H and 13C spectra. Deprotection of the Boc groups of 128, 
according to the procedure described for 126, followed by condensation of the 
resultant amine with thiourea derivative 89 in DMF at 100°C furnished a product 
which unfortunately decomposed to mainly the cleaved product following multiple 
chromatographic purification. A similar mechanism of degradation of 97 is presumed 
to operate as outlined in Scheme 3.8, involving acid-catalysed elimination. Isolation 
of the aglycon derivative 97a provided evidence for its elimination. In view of this 
complication, pursuit of this target was discontinued. Future work might involve 
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hydrogenation of the triple and double bond before condensation in order to minimise 
the cleavage problem described. 
3.2.3 Synthesis of [d4U]-monoPEG-propyne-[HI-236] 
With a plausible yet low-yielding route developed of the prototype, attention was 
turned towards synthesizing heterodimers with longer spacers for structure-activity 
purposes. A polyethylene (PEG) unit was chosen as the repeating unit in view of its 
synthetic accessibility as well as its promotion of water solubility. It was envisaged 
that an equivalent NBoc-derivative with a modified spacer would be prepared for 
Sonogashira coupling as in strategy (a) described previously. The PEG linkers were 
incorporated via two nucleophilic substitution reactions, and were targeted as mono 
and di. The overall synthetic scheme for the initial phase of the synthesis is shown in 
Scheme 3.10. Following the method described by Marshall et al.,117 1,2-ethanediol 
129 was mono-protected as its monobenzyl ether 130 in 53% yield with BnBr and 
NaH in THF. The product was easily isolated by distillation. Although only a moderate 
yield, the mono-benzylation could be carried out on a large scale. The presence of a 
benzyl group in the product was confirmed by the 1H NMR spectrum, which revealed 
aromatic protons integrating for 5 protons resonating at 8H 7.34 as well as methylene 
protons resonating at 8H 4.56. The 13C NMR spectrum displayed a methylene carbon 
at 8c 73.3. 
Treatment of alcohol 130 with carbon tetrabromide in methylene chloride smoothly 
yielded the bromide 131 in 95% yield. Work-up involved evaporating the solvent and 
purifying the crude product directly by column chromatography. Mechanistically, 
reaction of triphenylphosphine with carbon tetrabromide generates a 
bromophosphonium ion in situ which then reacts with the alcohol to give an 
alkoxyphosphonium ion (Fig. 3.6). The phosphonium ion intermediate then 
undergoes nucleophilic attack by bromide ion, displacing triphenylphosphine oxide. 
The driving force for the cleavage of the C-O bond is the formation of the strong 
phosphine oxide bond (P=O). 
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/'.... ,OH 
HO' '-/ 
129 
6' H 
l' 3' 5~ ~O~ 
NHBoc 
2" 
OMe 
ii 
130 
vi 
OIl 
~OBn 
_/'-.... /Br BnlT .....--
iii ~NHBO' 
131 
OMe 
132 
~OTS ~OH 
CrNHBO' v ~NH&' 
.. 
OMe OMe 
135a 134 133 
Scheme 3.10. Reagents and Conditions: (i) BnBr, NaH, THF, reflux, 20 h; 53%. (ii) PPh3, CBr4, 
CH2CI2, 0 °C, 30 min; 95%. (iii) 81a, K2C03, CH3CN, reflux, 20 h; 87%. (iv) H2, Pd/C, EtOH, rt, 18 h; 
87%. (v) TsCI, EhN, DMAP, CH2CI2, 0 °C-rt, 20 h; 76%. (vi) Propargyl bromide, K2C03, reflux, 20 h; 
74%. 
s~ e ~ .. --~ .. CBr3 + Br-PPh3 HO~OBn 
~@ 
Br ..... ~ 
"-./ ~OBn 
131 
Fig. 3.6: Mechanism of formation of bromide 131. 
The 1H NMR spectrum of compound 131 revealed the absence of the hydroxyl proton 
at bH 2.52, while its 13C NMR spectrum revealed an upfield shift of the carbon at C-1 
from be 61.8 in alcohol 130 to be 30.4, thus confirming substitution by bromine had 
taken place. 
The next step in the reaction sequence was the nucleophilic substitution of the 
bromide by 81a to give 132. In contrast to the difficulty encountered in alkylating 
phenol 81a with tosylate 92, alkylation of phenol 81a with bromide 131 in the 
presence of K2C03 as a base in acetonitrile afforded the desired compound 132 
smoothly in 87% isolated yield. The 1H NMR spectrum of alkylated carbamate 
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revealed a downfield shift of the protons a to bromine at 8H 3.50 for the bromide 131 
to 8H 4.11 as well as the presence of signals for the phenolic moiety, thus confirming 
that the alkylation had taken place. 
Catalytic hydrogenolysis of 132 using palladium-on-carbon catalyst in ethanol 
furnished 133 in 87% yield. The appearance of a hydroxyl proton as a broad singlet 
resonating at 8H 1.25 and the absence of the characteristic benzylic methylene 
singlet at 8H 4.63 for 132 provided evidence that debenzylation had taken place. 
Three possible reactions were considered for the conversion of alcohol 133 to alkyne 
135a. The first involved direct alkylation with propargyl bromide to furnish alkyne 
135a in a single step. The second strategy relied on Mitsunobu coupling of propargyl 
alcohol with 133 and the last strategy was conversion of the hydroxyl group to a good 
leaving group, in this case a tosylate, followed by substitution with propargyloxide 
anion. The second method was attempted first and resulted in the desired target in 
only 41 % yield. Of the other two methods, it turned out to be more efficient to 
substitute with propargyloxy anion, rather than alkylate with propargyl bromide, 
probably due to the softness of propargyloxide anion. Thus, to this end, the hydroxyl 
group on 133 was converted to the tosylate 134 in 76% yield by reacting it with p-
toluenesulfonyl chloride in the presence of triethylamine and a catalytic amount of 
DMAP in methylene chloride. The 1 H NMR spectrum of 134 displayed aromatic 
protons with an AS coupling (JAB 8.2 Hz) resonating at 8H 7.75 and 8H 7.28 as well as 
a methyl singlet at 8H 2.39. The presence of additional aromatic signals in the 13C 
NMR spectrum further confirmed the presence of a tosylate group. 
Alkylation of tosylate 134 was accomplished in the presence of NaH and a large 
excess of propargyl alcohol in THF at reflux. Aqueous work-up followed by 
purification by column chromatography furnished the alkyne 135a in 74% yield. An 
upfield shift of the H-2' signal in the 1H NMR spectrum from 8H 4.30 in tosylate 134 to 
8H 3.88 in 135a confirmed the displacement of the tosylate. The 13C NMR spectrum 
of compound 135a displayed signals for the alkyne carbons at 8c 74.7 for C-5' and 8c 
79.6 for C-6'. 
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Sonogashira coupling of iodo-d4U 100 with alkyne 135a yielded the coupled product 
136 in 92% yield (Scheme 3.11). The 1H NMR spectrum of 136 displayed the 
absence of the alkyne proton at DH 2.45 in 135a. Some of the resonances for 136 
derived from 100 and 135a included a broad singlet at DH 8.21 (1 H, H-6), a multiplet 
with allylic coupling at DH 6.97 (1 H, H-1'), a singlet at DH 4.40 (2H, H-3"'), a singlet at 
DH 3.73 (3H, OCH3) and a multiplet at DH 3.34 (2H, H-2""). The 13C NMR spectrum 
displayed diagnostic signals for the alkyne carbons at Dc 99.8 for C-1'" and 89.9 for 
C-2"', and the anomeric carbon of the sugar (C-1') at DC 90.7. 
2'''' 
o ~-' NHBoc _ 3- _./"-... 6"':.,.0 I'" 2'" ~2 II ""'" 7 7 I ~ 5"" 
OMe 
136 
100 
5 
2'" U 
1'" W"NH 
o 0_2''' H¢'" ~ ~ '7 3'" ":: 3"-H....if 6"'~ 1 4", I ~4-" ~ I 5'" 5-" 
HO 0 OMe Br tj 98 
iii 
--
~NHBOC Vo ':: 3" ~O 7 H.... '?' I 4 ~ Jz 61 HO 0 OMe ~,. 137 
2' 3' 
Scheme 3.11. Reagents and Conditions: (i) Alkyne 135a, (PPh3)4Pd, Cui, EhN, DMF, THF, rt, 4 h; 
92%. (ii) NaOMe, MeOH, 0 ac, 30 min; 69%" (iii) CF3COOH, CH2CI2, 0 ac, 30 min then 89, DMF, 100 
eC,1 h; 40%. 
Deprotection of the benzoyl group proceeded well with sodium methoxide in 
methanol to give the deprotected compound 137 in 69% yield. The 1H NMR 
resonance for 137 exhibited an expected upfield shift for the diastereotopic H-5' 
protons to DH 3.90 and DH 3.79 as a result of a loss in the deshielding effect of the 
carbonyl group. Similarly, the 13C NMR spectrum displayed the absence of a 
carbonyl carbon at Dc 166.2 and an upfield shift of C-5' from Dc 65.0 in 136 to Dc 62.7 
in 137. The deprotection was further confirmed by the presence of a broad band in 
the IR spectrum at 3535 cm-1 for the hydroxyl group. 
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Using the optimised one-pot procedure (Pages 69-70), the Boc group on 137 was 
deprotected employing trifluoroacetic acid in methylene chloride, and the resultant 
amine after processing condensed with thiourea derivative 89 in DMF at 100 °C to 
furnish a mixture of products containing 98 in 40% combined yield after 
chromatography. The 1H NMR spectrum of the mixture, shown in Fig. 3.7a, revealed 
two sets of signals for the sugar vinyl protons (H-2', H-3'), the two allylic methylene 
singlets (H-3") at DH 4.39 and DH 4.36 and two methoxy singlets at DH 3.71 and DH 
3.69. Further purification by column chromatography and preparative tic led to 
separation of the two compounds. The 1H NMR spectra of the mixture of 98 with the 
unidentified by-product is shown in Fig. 3.7a. Importantly, though Fig. 3.7b shows a 
pure sample of 98, with the vinyl signals of d4U integrating correctly as one proton 
relative to the downfield protons of the thiourea. Also, the 13C NMR spectrum of 98 
rendered one set of resonances with every carbon assignable. It is not clear what the 
structure of the second compound is. Work is currently underway to resolve its 
structure, and 98 is currently being tested for possible anti-HIV activity. 
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Synthesis of d4U-alkyne-H 1-236 
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Fig. 3.7: 1H NMR Spectrum of 98. (a) shows a mixture of the two compounds while (b) represent the 
purified compound 98. 
3.2.4 Synthesis of [d4U]-diPEG-propyne-[HI-236] 
The synthesis of di-PEG alkyne 135b was similarly accomplished according to the 
procedure described for 135a. Thus, diethylene glycol was selectively benzylated 
using benzyl bromide and NaH in THF. Treatment of the protected glycol with carbon 
tetrabromide, followed by alkylation of the resultant bromide with phenol 81a in the 
presence of NaH in DME gave the corresponding alkylated compound. Catalytic 
hydrogenolysis gave the corresponding alcohol, which was converted to its tosylate 
in good yield. Alkylation of this tosylate with propargyloxy anion yielded 135b in high 
yield (91 %) (Scheme 3.12). The structures of these compounds were unequivocally 
confirmed by both 1H and 13C NMR spectra, IR, elemental analysis and/or HRMS. 
~O~OTS 
~N~~ 
OMe OMe 
134b 135b 
Scheme 3.12. Reagents and Conditions: (i) Propargyl bromide, NaH, THF, reflux, 20 h; 91%. 
The synthesis of 99 (Scheme 3.13) was accomplished using the procedure described 
for 98. Specifically, palladium cross-coupling of alkyne 135b with 100 afforded the 
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coupled compound 138 in 82% yield after column chromatography. The 1H and 13C 
NMR spectra of 138, shown in Fig 3.8, revealed resonances derived from both 138b 
and 100. Some important resonances in the 1H NMR spectrum include 6.88 (H-1'), 
7.64 (H-6), 4.21 (H-3111), 3.71 (OCH3) and 2.76 (H-111111). Similarly, its 13C NMR 
spectrum displayed corresponding resonances at 142.3 (C-6), 90.7 (C-1'), 58.9 (C-
3111),55.6 (OCH3) and 31.0 (C-1"111). 
~-2' .a 
NH 
ppm (1'1) 
I Iii i I Iii I I j , I I I •••• I i I • i I I 
650 600 550 5 (X) 
ppm ("f1) 
f 1 i 
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C-4 .... 
I 1 I 
80 
C-3' 
H-1' 
• I ' 
70 
C-2' 
V 
H-2 ..... H-1 ..... 
I I ' 
60 
i I • 
50 
i I I 
40 
T 5"" I 9"" _I 
ii' 
30 
~._OCH3 ~o ,,'" ~O~' ~3""H Ii.... 4- ,.. I '.~:" ,. ~, 'I 138 '-,.. y0,!< r 00 0 ~ \:j C-S' C-3'" 
o ", ;C-1' C-4' ~ J OCH
3 
~ 
C-2 ..... 
i I • 
C-1 ..... 
j ~ J1 \l 
, , , , , , I , 
50 
ppm (1"1) 
Fig. 3.8: 1H and 13C NMR spectra of 138. 
The benzoyl group on 138 was deprotected using the standard established 
conditions of NaOMe in MeOH. After aqueous work-up, 139 was isolated in 86% 
yield after purification by column chromatography. The structure of compound 139 
was unequivocally assigned on the basis of its spectroscopic data, using a 
combination of both 10 and 20 1H and 13C NMR as well as IR techniques and high-
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resolution mass spectrometry. The 1H and 13C NMR spectra of 139 revealed the 
absence of resonances for the benzoyl group. The 1 H NMR spectrum revealed that 
H-5' protons had shifted upfield from DH 4.65 and DH 4.47 in 138 to DH 3.87 and DH 
3.66, indicating debenzoylation. The appearance of a broad singlet at DH 2.41, 
corresponding to the hydroxyl group, supported the absence of a benzoate ester. 
Further evidence was given in the 13C NMR spectrum which displayed an upfield shift 
in the C-5' resonance from Dc 65.0 in 138 to Dc 62.8 as well as the absence of a 
carbonyl carbon at Dc 166.2. Furthermore, the IR spectrum of 139 revealed a broad 
band at 3400-3200 cm-1 characteristic of an alcohol, and no carbonyl stretching 
frequency. 
o 
"'&' tSNHBOC 
BZ0'tj0A I ~~~: I ~ 
o OMe 
135b 
100 
s 
, ["~NH H....v~ ~OUH~ ~ I OM~ 
HO~ 99 ;' 
Y~ <T'P' ~~ Q: N/" U 0 A I OMe HO 99a Br 
iii 
-
2~"' 
o ,-
''''4- 1&"., NHBoc 3.'~ 2·' o 1"· ~ 3"" 2 I 4"" ::::,... OMe 
138 
£ NHBOC ~2" 3" /".. 10 1'" 2'" 1'~ if ~ ~ r H.... ~ 2 1 4 , I 6'" ::::,... I 5'" OMe O  139 H0tj, 
Scheme 3.13. Reagents and Conditions: (i) Alkyne 135b, (PPh3)4Pd, Cui, EhN, DMF, THF, rt, 4 h; 
82%. (ii) NaOMe, MeOH, 0 ec, 30 min; 86%. (iii) CF3COOH, CH2CI2, 0 ec, 30 min then 89, DMF, 100 
eC,1 h; 40%. 
The focus then shifted to the troublesome deprotection of the Boc group and 
subsequent coupling of the resultant amine to furnish the target compound 99. Once 
again, 139 was deprotected with trifluoroacetic acid in methylene chloride and 
processed according to the optimised conditions described for compound 126. This 
resulted in isolation of a mixture of closely-running compounds (on tic) in an 
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estimated combined yield of about 60%, after column chromatography. Compound 
99 was isolated as a mixture of two closely-running compounds which were 
separated by further chromatography and recrystallization. Pure 99 is currently being 
tested for its anti-HIV activity. The 1H NMR spectra shown in Fig. 3.9 depicts the 
various stages of the purification. Once again, as with 96, a number of NMR markers 
for distinguishing the two components in the mixture were identified. These included 
thiourea NH at around bH 11.10 and bH 8.86, the H-3" allylic methylene at bH 4.33 and 
the aromatic methoxy at bH 3.75. The impurity 99a is likely to be the cleavage 
product. 
(a) 
99a 
NH 99 
~ ,( NH 
11.0 
ppm (f1) 
10.0 
99 
99a NH 
NH 
9.0 
l .. : 
6.0 
II. 
Br 
(b) ,. oMeQ'-~ ~ 4-
,. 5" ,. !r.' . , 
ifo .,. ~O~~.-? 3 N", r ~ ~ r ~ r 3 5, ,- ~./NH ~, r IT HO~,o,1 S 
'U' 
, z 
99 
NH , 99a NH J 
7.0 
I ' 
I I T ----------,----,-- 1 
" 0 ppn-o (f1) 
70 
99: 99a 
== 2 : 1 
Recrystallized 
== 85% 99 
5.0 40 
H-3" 
H-3" ! I 
~I ~ill 
3,0 
\1' 
3.0 
Fig. 3.9: 1H NMR spectrum showing 99 and 99a (a) mixture of 99 and 99a (b) 99 with trace impurities 
of 99a. 
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S S Br 
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3' 2 3' 2 3' ? 
Table 3.1. Some 13c NMR chemical shifts for 96,98 and 99. 
Position 96 98 99 
4 162.7 161.9 161.4 
6 144.8 144.6 144.9 
l' 89.4 90.3 90.3 
5' 61.8 62.8 62.8 
1" 89.8 95.5 89.4 
3" 20.1 59.3 59.2 
1'" 150.3 151.2 151.8 
6'" 113.4 112.9 111.7 
1"" 29.1 30.0 30.1 
2'''' 44.6 46.0 45.8 
4" 11 ' 141.2 141.1 141.1 
5'"" 113.4 113.5 112.7 
6"1" 145.7 146.7 146.6 
C=S 179.1 179.1 179.1 
Three bifunctional compounds were synthesized employing this strategy. The final 
condensation step proved troublesome and more work needs to be done to optimise 
conditions for this step. Decomposition of these compounds seemed to also occur 
during purification by chromatography. 
3.3 Strategy (b): Condensation followed by Sonogashira 
Given the problems of contamination with impurities that were difficult to remove in 
the final condensation step just described, it was decided to synthesize the target 
compounds using strategy (b). It was hoped that this would result in a much cleaner 
reaction with fewer polar impurities that could be easily removed by column 
chromatography. Initially, it was decided to pursue a convergent Sonogashira 
coupling with unprotected nucleoside 101 in order to gain direct access to the final 
target. To this end, the coupling strategy began with some preliminary studies on 
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nucleoside 101 and but-3-yn-1-01 protected as its THP ether. Attempted coupling of 
these two produced the desired coupled product 140 in only 38% yield after column 
chromatography (Scheme 3.14). 
o 
~jlyl 
HO~ i 
-
Yo 0'00 ~ 4-HOO~ I l,o,J 140 
U s 
101 L5~NH o 0 H ~ ~ ~~ ~IOM¢ HOt~r B, U 96 iii ~ -------I--X _~ 
Scheme 3.14. Reagents and Conditions: (i) HC=CCH2CH20THP (2 equiv.), (PPh3)4Pd (10%), Cui 
(50%), E~N (2 equiv.), DMF, THF, rt. (ii) alkyne 77 or 78 (0.5 equiv.), (PPh3)4Pd (10%), Cui (50%), 
Et3N (2 equiv.), DMF, THF, rt. 
Moreover, an attempt to couple alkynes 77 or 78 (Chapter 2) with 101 was not 
successful. The most plausible explanation for these discouraging results was that 
homo-coupling of the alkyne seemed to compete with cross-coupling as judged by tic 
which revealed a non-polar spot whose 1H NMR spectrum revealed the absence of 
the alkyne proton. Attention was therefore directed to using 5'-O-benzoyl protected 
nucleoside 100. Gratifyingly, Sonogashira coupling of iodo d4U 100 with alkyne 77 
yielded the coupled product 141 in 54% yield (Scheme 3.15) based on 77. The lower 
yield was attributed to the use of an excess amount of 100 instead of using an 
excess of the alkyne 77. Owing to selectivity observed during this coupling, it is likely 
that it would be possible to obtain higher yields employing the optimised conditions (2 
equiv. alkyne) for this coupling. Owing to limited amount of compound 141 obtained, 
it was not possible to get a good 13C NMR spectrum. However, its 1H NMR spectrum 
revealed resonances for both the nucleoside 100 and alkyne 77, thus confirming that 
the coupling had taken place. Specifically, resonances were observed at OH 7.67 (1H, 
s, H-6), OH 6.92 (1H, m, H-1'), OH 3.77 (3H, s, OCH3), OH 2.68 (2H, t, J 6.2 Hz, H-1"III) 
and of importance was the doublet at OH 8.11 with a small coupling constant (J 3.2 
Hz) assigned to H-6""" on the pyridine ring. Thus, in view of time constraints and a 
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lack of material, the debenzoylation reaction was not optimised. However, this 
convergent route appears to hold great promise for future work. 
o o 2'" 
H--. I 1'4 
100 
s 
3"' H n
"'· ~NH 
4"' 0 1'· 
P I 0 
141 
::::,... oc~ 
Br 
Scheme 3.15. Reagents and Conditions: (i) Alkyne 77 (0.5 equiv.), (PPh3)4Pd (10%), Cui (50%), Et3N 
(2 equiv.), DMF, THF, rt, 4 h; 54%. 
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3.4 Biological Results and Discussion 
The inhibitory activity of the test compounds was explored against HIV-1 (IIIB) 
replication in MT-2 cell cultures. The prototype bifunctional [d4U]-butyne-[HI-236] 96 
was evaluated by comparison to HI-236 and d4T for inhibition of HIV-1 multiplication 
in cells of lymphocytic lineage (MT-2). Preliminary studies of the target compound 
revealed that it inhibited the cells with an EC50 value of 200 nM. This is the lowest 
value of any bifunctional NNRTI-spacer-NRTI compound reported to date and 
indicated our prototype to be the most promising candidate for this type of inhibitor. 
The EC50 value lies between that of d4T (~2 JlM) and that of HI-236 (~5 nM), holding 
promise that we are on an interesting track of pursuit. The notion of synergism hasn't 
been proven, but importantly, nor has it been excluded. This is in contrast to an 
earlier study involving linkage of the spacer to trovirdine by Laduree and co-workers77 
which led to dimers which did not display any anti-HIV activity, and which could thus 
exclude synergism. Importantly, the work strongly suggests that the connection point 
to HI-236 is a good choice. 
3.5 Future Work 
The synthetic work accomplished in this thesis has established a healthy platform for 
future study. Understandably, many questions now present themselves as: 
1) The synthesis of the alkynyl spacer compounds still needs to be optimized 
regarding the final step. Options include changing the Boc protecting group 
and/or further investigation of the reaction conditions. The choice of alkynyl 
spacer is also a key issue. 
2) A small library of compounds needs to be prepared. With the EC50 result 
obtained, emphasis shifts towards focusing on incremental changes to the 
spacer length, i.e from 3 carbons to five carbons. 
3) The question of much longer spacers and their influence on the entropy of 
activation needs to be addressed. 
4) Computational studies (eg QSAR studies) need to be implemented to develop 
a better understanding of the compounds interacting with HIV-1 RT and to 
thus be able to develop a predictive model to work with. 
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Nucleoside analogues have to be phosphorylated intracellularly to their 5'-
triphosphate form using nucleoside kinases before the chemical step of 
polymerization. Some of them (eg d4T) are known to be poor substrates for these 
kinases and have thus prompted the development of prodrugs that bypass initial 
kinase dependency by intracellular delivery of the monophosphorylated analogue. 
AZT and d4T prod rugs exhibit higher potency against HIV compared to the parent 
nucleoside in vitro. Future work would involve converting [d4T]-spacer-[HI-236] 
bifunctional molecules into phosphoramidate prod rugs and compare their activity to 
the non-phosphorylated parent drugs. 
- 86-
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 4: Towards the Synthesis of [d4U]-Butane-[HI-236] 
MAXi;;; u ad": ilM sallI : , nUl .• a. 
CHAPTER 4 
aMtmhtttrtntmtz" 7'2'= t ""7 
Towards the Synthesis of [d4U]-butane-[HI-236] 
4.1 Retrosynthetic Analysis of [d4U]-butane-[HI-236] 
The question of flexibility in the linker and its effect on activity focused on converting 
the directional triple bond to a less rigid polymethylene grouping. It was understood 
that a chemoselective route needed to be devised in order to preserve the double 
bond of the nucleoside based on d4T. This precluded the convergent strategy (b) 
described previously in which both double and triple bonds are generated in the 
same product. 
The synthetic plan for the synthesis of double-drug 95 containing a C4-alkyl tether is 
shown in Fig. 3.1 and is centered on the construction of the key intermediate A which 
was perceived to be available by dideoxygenation of a uridine derivative. It was thus 
clear that the synthesis of A would require a good reductive elimination strategy to 
generate the double bond at the 2',3'-position. lodouridine E was considered to be a 
versatile intermediate as it would allow the introduction of the tether at the C-5 
position by making use of palladium cross-coupling chemistry to form intermediate D. 
Two possible synthetic strategies, both using A but differing in the level of 
convergency, were envisaged: 
(i) The first strategy would involve a convergent route (a) in which synthons A 
and 73 would be coupled via a phenolic O-alkylation reaction involving 
Mitsunobu conditions or via the sulfonate ester of A. Of concern was the 
competing nucleophilicity of the thiourea towards alkylation. 
(ii) The second strategy also involved A but via a more "linear" route (b), 
involving alkylation of phenolic carbamate 81a, followed by condensation 
with thiocarbonyl derivative 89. It was noted that this strategy would require 
deprotection of the Boc group followed by condensation of the resultant 
amine, a step that had already proved to be problematic. 
In spite of the latter, of the two strategies, (ii) was considered to be the better option 
because of the anticipated interference from the thiourea sulphur in the alkylation 
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step in strategy (i). Thus, the initial strategy for the synthesis of key intermediate A 
was to investigate a good protecting-group strategy for the following key reactions in 
order as: (i) Sonogashira coupling of E with a protected alkyne, (ii) hydrogenation of 
the triple bond on 0 and (iii) 2' ,3'-dideoxygenation of vicinol diol to form the olefin. 
The primary hydroxyl group on uridine could be protected selectively as a silyl ether, 
while the vicinol diol would be protected as a ketal. 
S 
~H Ho~~T5~c6 
'\::J 95 B~ Condensation 
~kYlation ",~O 0, ~NHPG 
~I U 
HO 0 B ~ OCH3 
+ 
U Condensation 
OH ¢r'NHBOC 
OCH3 
81a 
o 
tt..rOH ~I PGOB A 
~Reduction and Reductive Elimination 
'\::J ~ Alkylation 
~o ~r°M> 
PGtJ c 
tt..ifO 4- OPG tt..(r0 I 
I Sonogashira ~ Coupling ~ I 
PGO~ :> PGO~ 
HO OH HO OH 
D E 
Fig. 4.1: Retrosynthetic analysis of [d4UJ-butane-[HI-236] 
4.2 Synthesis of key intermediate A 
Preparation for the Sonogashira coupling began with iodination of uridine using the 
procedure of Wah 118 using molecular iodine and AgN03 at 0 °C in methanol to give 
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110 in 83% isolated yield reproducibly (Scheme 4.1). The main advantage of using 
silver salts is that following heterolytic cleavage of iodine, precipitation of Agi 
removes the residual iodide ions from the reaction rapidly. In this reaction, AgN03 
acts as a Lewis-acid catalyst and coordinates with iodine generating an electrophilic 
iodo species, which is attacked by the alkene I to give intermediate II (Fig. 4.2). 
Isolation of the product was facile, involving Agi filtration, and crystallization of the 
residue following methanol removal. 
o 
HN~ I 1-1--· AgN03 ~.. 0tf 
o 
I 
R 
-
HN jfo 0-A9N03 oA~ -
I 
R 
II 
Fig. 4.2: Mechanism of iodination of uridine 
o H..Jlv
1 
I 
oAj + Agl(S) + HN03 
I 
R 
110 
Formation of 110 was corroborated by its 1H NMR spectrum which revealed the 
collapse of H-6 at bH 8.45 from a doublet to a singlet. Similarly, the 13C NMR 
spectrum revealed an upfield shift in C-5 to be 69.9, thus confirming that C-5 
substitution by iodine had taken place. 
5-lodouridine 110 was then chemoselectively protected at the 2' and 3' positions as 
an acetonide 142 in high yield using the standard method introduced by Levene and 
Stiller119 in the 1930's of acetone and conc. H2S04 with CUS04 as an added 
dehydrating agent. The method takes advantage of the cis disposition of the two 
hydroxyl groups resulting in desired differentiation of the various hydroxyl groups. 
Following reaction, the acidic medium was quenched with KOH in MeOH, the salts 
filtered, the solvent evaporated and the residue recrystallized from methanol to give 
142 in high yield. The 1H NMR spectrum of 142 displayed two diastereotopic methyl 
singlets at bH 1.50 and bH 1.36, while the 13C NMR spectrum confirmed the formation 
of the ketal by displaying a quaternary ketal carbon resonance at be 114.5 as well as 
two methyl carbons at be 27.2 and be 25.3. 
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o o o 
H-.. I H-.. I 
ii 
HO OH 
19 
HO OH 
110 
Ox 
142 
Scheme 4.1. Reagents and Conditions; (i) 12, AgN03, MeOH, 0 °C, 30 min; 83%. (ii) Acetone, CUS04, 
H2S04 , O°C-rt, 22 h; 95%. 
In preparation for the pivotal Sonogashira coupling, initially it was considered 
necessary to protect the 5'-hydroxyl group of 142, which was carried out using 
triisopropylsilyl chloride and imidazole as a base in DMF at room temperature to give 
triisopropylsilyl ether 143a in 77% yield (Scheme 4.2). By comparison, protection of 
the 5'-hydroxyl group as its tert-butyldiphenylsilyl ether 143b was only achieved in 
40% yield. Interestingly, the by-product of the latter reaction, obtained in 60% yield, 
was the deprotected ketal 144. The deprotection reaction presumably used the 
imidazole hydrochloride as acid catalyst, and allowed release of steric strain between 
the bulky silyl group and pyrimidine base by rupturing the 5,5-bicyclic ring system 
that brings them into closer proximity compared to the sugar ring by itself. 
The 1H NMR spectrum for compound 143a showed two doublets for the 
diastereotopic isopropyl methyl groups integrating for 18 protons at DH 1.09, as well 
as a methine multiplet at DH 1.18. Similarly, the 13C NMR spectrum displayed 
corresponding carbon resonance at Dc 18.0 and Dc 12.0. Spectroscopic data for 143b 
showed aromatic protons at DH 7.41-7.71 integrating for 10 protons as well as a t-
butyl methyl singlet resonating at DH 1.12 integrating for 9 protons. Its 13C NMR 
spectrum displayed additional signals in the aromatic region, a t-butyl methyl signal 
at Dc 27.1 and a quaternary carbon signal at Dc 19.3 for the t-butyl group. 
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o 
~ I 
°XO 
143a R = TIPS; 77% 
143b R = TBDPS; 40% 
+ 
o 
~ I 
HO OH 
144 R = TBDPS 
Scheme 4.2. Reagents and Conditions: (i) TIPSCI, imidazole, DMF, rt, 12 h. 
The deprotection of the ketal group during the silylation reaction to form 143b 
prompted a reappraisal of the chemoselective protection of the hydroxyl groups of 
110. Treatment of 110 with TBDPSCI (1.5 equiv.) in the presence of imidazole (1.5 
equiv.) yielded the desired nucleoside 144 in 49% yield, together with a by-product 
145 (30% yield), which had two silyl ether groups. To minimise formation of the by-
product, the amount of silyl chloride used was minimised to 1.0 equiv, however this 
resulted in incomplete reaction. The starting nucleoside 110 is soluble in water, and 
TLC was carried out on the aqueous phase revealing the presence of unreacted 
starting material. Treatment with 1.2 equivalents of silyl chloride significantly 
improved the yield of mono-TBDPS 144 to 77% with the di-TBDPS being formed in 
only 3% yield (Scheme 4.3). The 1H and 13C NMR spectroscopic data of 144 
indicated the anticipated additional signals in the aromatic and highfield regions, 
confirming the presence of a silyl group. 
o o o 
~ I ~ I ~ I 
+ 
HO OH HO OH HO OTBDPS 
110 144; 77% 145; 3% 
Scheme 4.3. Reagents and Conditions: (i) TBDPSCI (1.2 equiv.), imidazole, DMF, rt, 12 h. 
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With 5-iodouridine derivatives (143a, 143b and 144) in hand, Sonogashira coupling 
with protected alkynol was attempted. The benzyl (Bn), p-methoxybenzyl (PMB) and 
tetrahydropyran (THP) protecting groups were selected to protect the hydroxyl group 
on 3-butyn-1-ol and to provide a range of comparisons in the Sonogashira coupling. 
The benzyl and PMB groups were selected in anticipation of their stability towards 
acid hydrolysis of the acetonide needed to introduce the 2'/3' double-bond. The 
tetrahydropyranyl ether was selected in view of its anticipated stability towards 
hydrogenation post-coupling. The hydroxyl group protections were achieved following 
standard literature procedures, and the structures of the protected 3-butyn-1-01 
derivatives 146, 147 and 148 were confirmed by comparison of their 1H and 13C NMR 
spectra to those reported in the literature. 12o,121,122 
Sonogashira coupling of 143a with 3-butyn-1-ol protected as its benzyl ether 146 
gave 149, in 53% yield after column chromatography (Scheme 4.4). The by-products 
identified included cyclized furanopyrimidine 150 (7%) as well as deiodinated product 
151 (21 %). 
The spectroscopic data for compound 149 was consistent with the assigned structure 
and the presence of the alkyne group was evident in the 13C NMR spectrum. The 1 H 
NMR spectrum for 149 revealed two triplets at DH 2.68 (H-3") and DH 3.62 (H-4"), a 
singlet at DH 4.53 for the benzylic methylene protons and a multiplet at DH 7.30 for the 
aromatic protons. Similarly, the 13C NMR spectrum displayed additional signals at Dc 
100.5 (C-1"), 91.4 (C-2"), 68.1 (C-4") and 20.9 (C-3") compared to 143a. Also 
present were signals for the aromatic carbons as well as signals for the benzylic 
methylene carbon at Dc 72.9. A downfield shift of C-5 from Dc 68.4 in 143a to Dc 72.2 
further supported that the coupling had occurred. The structure was further confirmed 
by 2D NMR spectroscopy. The HMBC spectrum revealed a 3J correlation between 
the singlet at DH 7.68 (H-6) and the alkynyl carbon at DC 100.5 (C-1 "). 
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0 3" 4" OBn 0 
iv O~OBn TIPSO~-) 143a ~ + 2 1~ + 
TlPS~ "hu f' '" ~ 53% 
°Xo °xo 
149; 53% 150; 7% 151; 21% 
Scheme 4.4. Reagents and Conditions: (i) (PPh3)4Pd, Cui, alkyne 146, Et3N, DMF, THF, rt, 16 h. 
By-product 150, although only obtained in low yield, proved to have an interesting 
furanopyrimidine structure shown in Scheme 4.4, via a Cui-catalyzed 5-endo-dig 
cyclization between the C-4 pyrimidine oxygen and acetylenic bond (Fig 4.3). In this 
case, Cui activates the triple bond by forming a complex II. This is followed by 
intramolecular addition of oxygen across the activated triple bond with subsequent 
proton transfer and release of Cui to give the furanopyrimidine product 150. 
R1 R1 yR' ~R' ~.~CUI N~ HN I Cui oA I Cui N I -Cui AI oA 
- -
oA ~ proton 0 
I I I transi:lr I 
R R R R 
II III 150 
Fig 4.3: Plausible Cui-catalyzed mechanism for cyclization of furanopyrimidine 
Furanopyrimidine derivatives are interestingly fluorescent and have been reported to 
display important potency and exclusive selectivity against varicella zoster virus 
(VZR).123 Support for structure 150 was provided by the appearance of an additional 
triplet with an allylic coupling (J 1.8 Hz) at bH 6.13 for H-5 (see numbering in Scheme 
4.4). The 13C NMR spectrum of 150 displayed a downfield signal at be 171.9, which 
was assigned to C-7a. Furthermore, 3 J HMBC correlations were identified between 
the proton at bH 6.13 (H-5) and the carbons at be 171.9 (C-7a), 156.7 (C-6), 135.6 (C-
4), 107.3 (C-4a) and De 29.2 (C-1") confirming that cyclization had occurred. Another 
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important correlation was between the proton at DH 8.34 (H-4) and the carbon at Dc 
100.1 (C-5). 
Literature precedence suggested that formation of the furanopyrimidine was 
dependent on the protecting groups on the nucleoside.108,109 In this case, the 
isolation of 151 suggested that the presence of the ketal pushes the bulky phenyl 
rings of the silyl ether into close proximity with the nucleoside base, thus leading to 
steric hindrance which inhibits the transmetallation step of the reaction. This 
suggested that a nucleoside unprotected at the 2' ,3'-position would be a better 
substrate for this coupling. 
To this end, a series of Sonogashira reactions were performed on 144 using a 
number of different protected 3-butyn-1-0Is (Scheme 4.5). Thus, compound 144 was 
subjected to a cross-coupling reaction with 4-methoxybenzylbut-3-yne to form 152 in 
48% yield following column chromatography. The 1H NMR spectrum of 152 was 
similar to that of 149 except for the absence of ketal signals, and its 13C NMR 
spectrum revealed signals at Dc 100.3 and Dc 91.9 for C-1" and C-2", respectively. 
Another significant signal was the downfield shift in C-5 to Dc 72.5. 
Similarly, the use of a 3-butyn-1-01 protected as its benzyl ether gave the coupled 
product 153 in 76% yield. No cyclic furanopyrimidine by-product was formed in these 
reactions. The absence of furanopyrimidine supports the steric-strain rationale 
discussed before suggesting that in ketal 149, the C-5' silyloxy and C-1' base groups 
are relatively close together compared to 152. Thus for 149, furanopyrimidine 
formation of 150 reduces the steric bulk of the C-5 substituted base. Spectroscopic 
data for compound 153 confirmed that the coupling had taken place. 
Sonogashira coupling of the 3-butyn-1-01 protected as a tetrahydropyran ether with 5-
iodouridine 144 proved to give the most pleasing result furnishing the coupled 
product 154 in 97% yield. Generally, alkynols protected as THP ethers gave excellent 
yields during palladium cross-coupling reactions. The 13C NMR spectrum of 154 
displayed diagnostic signals at Dc 99.4 and Dc 90.5 for the alkynyl carbons at C-1'" 
and C-2"', respectively. 
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0 OPMB 
~ 
TBDPS~ 1 152 
HO OH 
0 0 OBn 
~ I 
51 
ii 
153 
HO OH 
144 0 OTHP 2'· 1"4 
iii 154 
Scheme 4.5. Reagents and Conditions: (i) HC=CCH2CH 20PMB 147 (1.5 equiv.), (PPh3)4Pd (10%), 
Cui (50%), E~N (2 equiv.), DMF, THF, rt; 48%. (ii) HC=CCH2CH20Bn 146 (1.5 equiv.), (PPh3)4Pd 
(10%), Cui (50%), E~N (2 equiv.), DMF, THF, rt; 76%. (iii) HC=CCH2CH20THP 148 (3 equiv.), 
(PPh3)4Pd (10%), Cui (50%), Et3N (2 equiv.), DMF, THF, rt; 97%. 
Having optimised conditions for Sonogashira coupling, the next step in the reaction 
sequence was hydrogenation of the alkyne functionality which was carried out using 
a palladium-on-carbon catalyst. Catalytic hydrogenation/hydrogenolysis of 149, 152 
and 153 would be followed by reprotection of the primary hydroxyl group with a PMB 
group to prepare for introduction of the C-2'/3' double bond. The PMB group was 
chosen in view of its selective removal with CAN. The coupled product 149 was thus 
reduced with hydrogen in the presence of 10% palladium-on-carbon to give alcohol 
155. Filtration of the catalyst followed by purification of the crude product by column 
chromatography afforded 155 in 71% yield (Scheme 4.6). The 1H NMR spectrum of 
155 revealed additional methylene signals at DH 2.30 for H-1" and 1.05 for H-2", while 
its 13C NMR spectrum displayed an upfield shift of the signals at C-1" and C-2" from 
Dc 100.5 and Dc 91.4 in 149 to Dc 32.1 and Dc 26.7, respectively. There was also a 
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significant downfield shift in the C-5 carbon to Dc 115.2, which further confirmed a 
loss in the shielding effect caused by the alkyne. 
o OBn o 0 
~ 4 ~~OH PM~~OH 
--- TIPSO o~) --- TIPSO o~) ~ 155 t? 156 149 
°XO °xO 
1m 
o 
PMR r " 3"-....... 2" 4" OH 4 I HO oJz 
P 4' l' 3 2 157 
HO OH 
Scheme 4.6. Reagents and Conditions: (i) H2, Pd/C, EtOH, rt, 2 d; 71%. (ii) PMBCI, NaH, DMSO, 
THF, rt, 21 h; 75%. (iii) 2M Hel, MeOH, rt, 24 h; 87%. 
Protection of the primary hydroxyl group of 155 via its alkoxide ion as its p-
methoxybenzyl ether resulted in imide 156 in good yield due to N-alkylation. This was 
concluded on the basis that resonance in the C-4" hydroxyl proton could be seen at 
DH 2.28 indicating that C-4" alkylation had not taken place. Furthermore the NH imide 
proton had disappeared. Compound 156 also showed two sets of aromatic protons 
(4H) of an AB system resonating at DH 7.41 (2H, d, J 8.6 Hz) and DH 6.78 (2H, d, J 8.6 
Hz), diastereotopic benzylic methylene protons with a large geminal coupling at DH 
5.04 (d, J 13.5 Hz) and DH 4.96 (d, J 13.5 Hz), and a methoxy singlet at DH 3.73 for 
the p-methoxybenzyl group. Similarly, the 13C NMR spectrum had signals showing 
the presence of an aromatic ring, a methoxy signal at Dc 55.0 and a methylene 
carbon at Dc 43.8. 
Acid hydrolysis of acetonide 156 using 2M HCI led to concomitant cleavage of the 
TIPS group and subsequent formation of triol 157. Reducing the strength of the acid 
such as using acetic acid in water (7:3) failed to generate the expected diol. This 
negative result was attributed to relief of steric strain imposed by the bulky 
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triisopropyl group. The 1H NMR spectrum of 157* revealed the absence of the 
triisopropylsilyl ether methyl signals at bH 1.04 and the appearance of four broad 
singlets resonating at bH 4.20, bH 3.46, 3.28 and bH 2.09 for the hydroxyl groups. The 
choice of TIPS as a protecting group for the 5'-OH group was based on the fact that it 
was easier to cleave at the end of the synthesis. However, its instability under acidic 
conditions prompted us to shift to using TBDPS as a protecting group. 
In view of positive results in the 2',3'-unprotected series, it was decided to focus on 
the 152-154 series containing the C-5' TBDPS group and with free C-2'/3'-hydroxyl 
groups. Thus, hydrogenation of the triple bond in 152 and 153 led to hydrogenolysis 
of the PMB and benzyl protecting groups, respectively to form 158 (Scheme 4.7). 
The 1H NMR spectrum of 158 showed additional signals in the upfield region for the 
methylene protons, while its 13C NMR spectrum revealed the absence of alkyne 
signals at be 99.4 and be 90.5, thus confirming that reduction had taken place. 
o 2 3 4 OBn 
~ '4 
4 
o 0 
H, 1 2 3 4 OH ~ 1 2 3 4' OPMB 
2 61 
HO OH 
~ - 0 
HO OH HO OH 
-
153 158 159 
Scheme 4.7. Reagents and Conditions: (i) H2, Pd/C, EtOH, rt, 1 day; 83%. (ii) PMBCI, NaH, THF, rt, 
16 h; 27%. 
* This compound was not fully characterised and its 1H NMR data is as follows: 8H (300 MHz, CDCI3); 
7.53 (1H, s, H-6), 7.38 (2H, d, J = 8.7 Hz, H-2"', H-6"'), 6.79 (2H, d, J = 8.7 Hz, H-3''', H-5"'), 5.73 
(1H, d, J = 3.9 Hz, H-1'), 504 (1H, d, J = 13.7 Hz, ArCH20), 4.98 (1H, d, J = 13.7 Hz, ArCH20), 4.31 
(2H, m, H-2', H-3'), 4.20 (1 H, brs, OH), 4.09 (3H, m, H-4', H-4"), 3.94 (1 H, brd, J = 11.3 Hz, H-5'), 
3.79 (1 H, brd, J = 11.3 Hz, H-5'), 3.75 (3H, s, OCH 3 ), 3.46 (1 H, brs, OH), 3.28 (1 H, brs, OH), 2.33 
(2H, t, J = 7.1 Hz, H-1 "), 2.09 (1 H, brs, OH), 1.58 (4H, m, H-2", H-3"). 
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Yo 2- 3- 4'" OBn I-l... 4 14 12 61 TBDPS~~,. ~ 
'3H2' 
HO OH 
o 0 
o - 0 
HO OH HO OH 
153 1~ 1~ 
Scheme 4.7. Reagents and Conditions: (i) H2, Pd/C, EtOH, rt, 1 day; 83%. (ii) PMBCI, NaH, THF, rt, 
16 h; 27%. 
An attempt to reprotect the primary hydroxyl group of 158 with p-methoxybenzyl 
(PMB) chloride under basic conditions via the alkoxide led to the desired compound 
in only 27% yield. The low yield was attributed to the cleavage of the TBDPS group 
which was isolated as a by-product (TBDPSOH) of this reaction. Silyl ethers are 
known to undergo base-promoted migration reactions from one functional group to 
the other and the cleavage could have arisen in an attempt to shift to the less 
hindered side-chain primary hydroxyl group. 
The focus then shifted to hydrogenation of the triple bond of coupled THP ether 154 
(Scheme 4.8) to give diol 160. Filtration of the catalyst followed by column 
chromatography gave 160 in 83% yield. In this case, a catalytic amount (0.1 eq.) of 
triethylamine was added to the reaction mixture to avoid deprotection of the THP 
group. 
o 2'· 1-~ 
OTHP o 
H( OTHP 
i 
-
HO OH 
160 
Scheme 4.8. Reagents and Conditions: (i) H2 , Pd/C, EtOH, 2 days; 95%. 
It is noteworthy that the rate of hydrogenation was dependent on the amount of 
triethylamine used. Excluding triethylamine led to deprotection of THP ether while the 
use of 1 mol equivalent of EhN slowed the reaction up to 48 h. The 13C NMR 
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spectrum of 160 showed an upfield shift of the carbons resonating at 8c 99.4 (C-1"') 
and 8c 90.5 (C-2"') to 8c 25.7 and 8c 25.4 for the methylene carbons, but importantly, 
retention of signals for both the THP and TBDPS groups. 
(a) Xanthate formation 
R 
~ 
OH 
NaH 
• 
R 
~ -Oe ( 
s=c=s 
vf 
(b) Barton deoxygenation mechanism 
R-Q-C-SMe + Bu"aSn' 
II 
S 
R-Q-C-SMe 
I 
S-Sn"Bu3 
, I I 
--+- R' H-SnBu"3 
(c) Mechanistic overview of double reductive deoxygenation 
PGO~ OB 
S S 
r O O-..f 
MeS SMe 
PG°'to-S 
MeS H S 
'jr0 O-..f 
SSn-Bu"3 SMe 
PGO~ o B 
------, .. ~ 
. S 
O-..f 
SMe 
+ n-BuSnSCOSMe 
PGO'toJ Lj Fast PG°'tos Y SSnBu 
P-:( 
oil( 
SMe 
Fig. 4.4: Radical deoxygenation of bis-xanthate 
With intermediate 160 in hand, the scene was now set for the crucial introduction of 
the C2'/3' double-bond. Several sets of conditions have been reported in the literature 
including: (i) the Barton-McCombie deoxygenation 124, (ii) reductive elimination of 
bromoacetates91 ,92 and bromomesylates93, (iii) the Garreg-Samuelsson 
12/PPh~imidazole promoted deoxygenation88, (iv) olefin metathesis95 and (v) the 
Corey-Winter procedure.9o The Barton procedure involves deoxygenation of a 
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xanthate ester under tin hydride radical conditions, the various aspects of which are 
depicted in Fig. 4.4. 
In the Barton procedure, a methyl xanthate is prepared by treatment of the relevant 
alcohol with NaOH or NaH and CS2 to give a xanthate anion RO-CS-SNa, followed 
by treatment of this with methyl iodide (Fig. 4.4). In our case, reaction of diol160 with 
carbon disulphide and sodium hydride followed by iodomethane gave five products 
as seen on TLC. Separation of the compounds by column chromatography allowed 
isolation of N-methyl-tris-xanthate 161a, tris-xanthate 161b, N-methyl-bis-xanthate 
161c and bis-xanthate 161d in 22%, 7%, 29% and 15% yield, respectively (Scheme 
4.9). 
o 
~ OTHP 
i 
-
HO OH 
160 
o 
H3CS2CO OCS2CH3 
161a R1 = Me, R2 = OCS2CH3; 22 % 
161b R1 = H, R2 = OCS2CH3; 7% 
161c R1 = Me R2 = H; 29% 
161d R1 = H R2 = H; 15% 
Scheme 4.9. Reagents and Conditions: (ii) CS2, NaH, EiJN, THF, Mel, rt, 24 h. 
The occurrence of N-methylation in 161a and 161c, as well as deprotection of the 
THP ether and subsequent formation of O-xanthate was evident in both the 1H and 
13C NMR spectra of these compounds. The deprotection of the THP group was 
evident in both the 1H and 13C NMR spectrum, which revealed the absence of signals 
for the tetrahydropyran ring. Similarly, the presence of three thiocarbonyl carbons in 
the 13C NMR spectrum of 161a and 161b corroborated that THP deprotection had 
occurred, which was followed by formation of the O-xanthate. The 1H NMR spectrum 
of 161a revealed the presence of three S-methyl singlets at DH 2.60, 2.58 and 2.54. 
There was also a significant shift in the H-2', H-3' and H-4'" protons from DH 4.31, 
4.49 and 3.80 in 160 to DH 6.25, 6.47 and 4.43, respectively. Similarly, its 13C NMR 
spectrum, assigned with the aid of an HSaC and HMBC correlation, exhibited 
diagnostic signals at Dc 215.8, 214.7 and 214.6 which were assigned to the 
thiocarbonyl carbons. C-2', C-3' and C-4'" displayed a downfield shift from Dc 70.4, 
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74.2 and 62.2 in 160 to Dc 78.8, 78.0 and 73.6, respectively. A similar trend was 
observed in the 1H and 13C NMR spectra of compounds 161b-d. Compounds 161a 
and 161c displayed an N-methyl singlet in the 1H NMR at DH 3.30 and 3.31, 
respectively. Similarly, the 13C NMR displayed corresponding signals at Dc 28.0. The 
most important signals for the compounds are shown in Table 4.1. The presence of a 
hydroxyl group in 161c-d was also confirmed by their IR spectra, which displayed 
broad stretches between v 3300-3500 cm-1. 
Table 4.1: Some Important 1H NMR chemical shifts for 160 and 161a-d 
160 161a 161b 161c 161d 
H-2' 4.31 6.25 6.26 6.24 6.23 
H-3' 4.49 6.47 6.47 6.46 6.46 
H-4111 3.80 4.43 4.44 3.49 3.49 
3.19 
C-2' 70.4 78.8 78.9 79.0 78.8 
C-3' 74.2 78.0 77.9 77.9 78.0 
C-4111 62.2 73.6 73.6 62.2 62.2 
THP ethers are labile under acidic conditions, but it is unusual to have deprotection 
of THP taking place under basic conditions. The mechanism for this transformation is 
unknown. 
The formation of various side-products prompted the redesign of the synthesis to 
include protection of the NH group with a benzoyl group. Thus the synthesis returned 
to intermediate 143b and several sets of conditions were investigated for its N-
benzoylation (Scheme 4.10). Eventually, N-benzoyl nucleoside 162 was synthesized 
in 90% yield by treatment of isopropylidene derivative 143b with sodium hydride in 
freshly distilled 1,2-dimethoxyethane (DME) followed by addition of freshly distilled 
benzoyl chloride. The results from the optimization reaction of N-benzoylation of 
143b are shown in Table 3.2. Treatment of 143b with n-butyllithium in THF at -78°C 
followed by benzoyl chloride, and then NH4CI afforded no detectable amount of 
product and only resulted in decomposition of the starting material as judged by TLC. 
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Reaction of 143b and sodium hydride (NaH) in tetrahydrofuran (THF) followed by 
addition of BzCI at 0 °C led to a 15% conversion whereas warming the solution in a 
DMFITHF (1/3) solvent mixture to room temperature led to a 50% conversion. The 
best method involved stirring 143b and sodium hydride in DME at room temperature 
for 30 min to form the anion, cooling the mixture to -78°C and thereafter adding the 
benzoyl chloride dropwise. 
o 
ii 
• • 
HO OH 
163 
Scheme 4.10. Reagents and Conditions: (i) (a) Base / solvent; (b) BzCI. (ii) HCIIEtOAc, rt, 45 min; 
73%. 
Table 4.2. Optimization of the N-benzoylation Reaction 
Base Solvents aT,oC time dYield, % 
n-Butyllithium THF -78 1h decomp 
(PrhNEti DMAP CH2CI2 b24 1d 40 
(PrhNEti DMAP CH2Cb b24 2d 58 
NaH THF 0 15 
NaH DMFITHF b24 12h 50 
NaH DMFITHF bao 12h 60 
NaH DME b24 24h 54 
NaH DME Crt~ -78~rt 2h 90 
a Refers to reaction temp. b BzCI was added dropwise to the anion at 0 ac before warming the reaction 
mixture to the indicated temperature. C BzCI added at -78 ac. d Column chromatography yields 
The 1H NMR spectrum for the desired benzoate 162 displayed signals at DH 7.88, 
7.62 and DH 7.43 for the new aromatic ring protons. The 13C NMR spectrum displayed 
an additional diagnostic peak at Dc 167.4 for the new carbonyl carbon as well as 
additional signals in the aromatic region. 
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Acid hydrolysis of the isopropylidene derivative 162 was found to be a difficult task 
due to the sensitivity of the TBOPS group and several sets of conditions were 
explored. Initial attempts with 2M HCI in MeOH, 2M HCI in THF and 2M HCI in water 
all led to the cleavage of the TBOPS group. Varying reaction conditions (reaction 
time, temperature and concentration) during hydrolysis of the nucleoside with 80% 
acetic acid in water was also unsuccessful. Ultimately, treatment of the acetonide 
with saturated HCI acid in ethyl acetate (~ 7.5 N), a method introduced in 1993 by 
Gardner et a/125 , afforded the target diol163 as a significantly more polar compound 
in 73% yield after column chromatography. The absence of methyl resonances was 
noted in both the 1H (BH 1.53 and BH 1.30) and 13C (Be 27.1 and Be 25.2) spectra. 
o 
TBopsf' .. 
HO OH 
163 
o OTHP 
B ~ 
HO OH 
164 
o 
BZ,~OTHP 
· TBOPSo't( 
HO OH 
165 
Scheme 4.11. Reagents and Conditions: (i) (PPh3)4Pd (10 %), Cui (50%), alkyne (2 equiv.), Et3N (2 
equiv.), DMF, THF, 60 °C, 4 h; 93%. (ii) H2, Pd/C, EtOH, rt, 2 days; 84%. 
Sonogashira coupling of nucleoside 163 with 4-(2-tetrahydropyranyloxy)-1-butyne as 
before gave the coupled product 164 in 93% yield after column chromatography 
(Scheme 4.11). The 13C NMR spectrum of 164 displayed resonances at Be 101.2 and 
93.0 for the alkyne carbon. Reduction of the triple bond using 10% Pd/C in a solution 
of ethanol in THF led to diol 165 (84% yield). Reaction of 165 with carbon disulfide 
and sodium hydride (4 equiv.) in the presence of a catalytic amount of EiJN followed 
by subsequent quenching of the reaction with methyl iodide led to xanthate 166 in 
low yield as well as a by-product 167 (15%) (Scheme 4.12), which had the C-2', C-3' 
hydroxyl groups methylated as methyl ethers. This product arose out of incomplete 
xanthate formation before methylation with methyl iodide. The use of long reaction 
times and higher temperatures failed to provide an adequate solution to this problem 
and thus this approach was abandoned. The mechanism for the deprotection of the 
THP group was again unknown. 
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The 1 H NMR spectrum of the product revealed the presence of two compounds in a 
ratio of 1:1, which were not possible to separate by column chromatography. 
However, detailed 1 Hand 13C NMR spectral analysis revealed the mixture to be a 
combination of 166 and 167. The 1 H NMR spectrum showed two methoxy singlets at 
bH 3.35 and three S-methyl singlets at bH 2.59, 2.57 and 2.49, while its 13C NMR 
spectrum displayed corresponding carbons at be 19.7, 19.5 and 19.5. The presence 
of a thiocarbonyl was also confirmed by the carbons at be 214.9, 214.8 and 214.6. 
o 0 0 
BZ,~OTHP BZ,~OeS2Me BZ,~OTHP 
mDPS0f( ~ mDPSO~ + TBDPs1j 
HO OH H3es2co OCS2CH3 MeO OMe 
165 166 167 
Scheme 4.12. Reagents and Conditions: (i) CS2 , NaH, EhN, THF, Mel, rt, 22 h; 15%. 
Other deoxygenation methodologies were considered and eventually it was decided 
to explore the Corey-Winter90 methodology involving fragmentation of a cyclic 
thionocarbonate by triethyl phosphite to form the olefin. It was anticipated that the 
conditions of the thionocarbonylation reaction would leave the two protecting groups 
intact and thus provide the selectivity required to complete the synthesis. The 
mechanism is outlined in Fig 1.21 (Section 1.12.2, Chapter 1). 
To this end, diol 160 was first converted to its 2',3'-thionocarbonate 168 employing 
1,1 '-thiocarbonyldiimidazole in refluxing 1,2-dichloroethane. Evaporation of the 
solvent followed by purification of the crude product using column chromatography 
afforded 168 in 70% yield (Scheme 4.13). It was necessary to closely monitor the 
progress of this reaction, since prolonged reaction times led to erratic isolated yields, 
through formation of an un-identified by-product. 
Compound 168 revealed a downfield shift in its 1H NMR spectrum for the protons at 
bH 4.31 (H-2') and bH 4.49 (H-3') in 160 to bH 5.62 and 5.48, respectively, which 
supported the formation of the thionocarbonate. This was further confirmed by the 
13C NMR spectrum which displayed a diagnostic signal at be 189.4 for the 
thiocarbonyl carbon. The deshielding effect of the thiocarbonyl resulted in a downfield 
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shift of the C-2' and C-3' carbons to eSc 88.0 and eSc 85.0, respectively from eSc 70.4 
and eSc 74.2 in 160. 
° ° ° HN~OTHP HN~OTHP 
TBDPS~/ ; • TBDPS~/ ;; 
)--( 160 )--( 168 
r OTHP H I .'BDPS"i~1 
U 169 
HO OH 0yO 
S 
Scheme 4.13. Reagents and Conditions: (i) 1,1 '-Thiocarbonyldiimidazole, DCE, reflux, 1 h; 70%. (ii) 
(EtOhP, 160°C, 4 h; 40%. 
Thermolysis of thionocarbonate 168 employing triethyl phosphite at 150°C led to 
formation of 169 in 40% isolated yield. In this case, starting material was recovered 
and an unidentified by-product was isolated. Subjecting the thionocarbonate to 170 
°c for 4 h led to decomposition of the starting material. Several sets of conditions 
were explored and the best involved heating 168 at 160°C for 4 h to form 169 in 40% 
yield as just mentioned. 
The 1H NMR spectrum of 169 revealed a shift in H-1', H-2' and H-3' from eSH 5.56, 
5.62 and 5.48 in 168 to eSH 7.04, 5.85 and eSH 6.37, respectively, while its 13C NMR 
spectrum displayed a shift in C-2' and C-3' from eSc 88.0 and eSc 85.5 in 168 to eSc 
126.3 and eSc 134.8, respectively, all of which was consistent with formation of the 
alkene. 
The THP group on 169 was chemoselectively deprotected employing magnesium 
bromide in ether to furnish 170 in 83% yield (Scheme 4.14) with the mechanism of 
the reaction shown in Fig. 4.5. The use of p-toluenesulfonic acid in methanol resulted 
in undesired deprotection of both the THP and TBDPS groups to give 171. 
The 1 H NMR spectrum for compound 170 revealed the absence of the THP signals in 
the upfield region of the spectrum. This was further confirmed by its 13C NMR 
spectrum which displayed the correct number of resonances for the carbons in 170, 
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revealing the loss of the THP carbons. With key intermediate 170 in hand, attention 
focused on the two possible strategies for the end-game. 
o 
H~OTHP 
TBDPSoi:r ---1 U 169 
MgBr2, ether 
rt, 12h 
83% 
TsOH, MeOH 
o ac, 30min 
o 
r OH H I TBDPs°-r:1 U 170 
o 
r OH H I HoB 171 
Scheme 4.14: Selective deprotection of THP in the presence of a silyl ether 
H~~' ~OMgB". ~OH ~) U-l) II H~) __ _ 
o I I 0 I II ~ 0 I 170 
R R R 
@ H+ +j) -
Fig. 4.5: Possible mechanism of THP deprotection 
4.3 End-game via Strategy (a) 
As previously discussed, strategy (a) was chosen for completing the synthesis in 
view of concern in the convergent strategy around thiocarbonyl alkylation. The major 
challenge anticipated from previous work was the introduction of the thiourea unit in 
the final step. Thus, the primary hydroxyl group on 170 was transformed to its 
mesylate 172 in 47% yield, by reacting it with methanesulfonyl chloride and 
triethylamine and a catalytic amount of DMAP in methylene chloride at 0 °C to room 
temperature (Scheme 4.15). Nucleophilic reaction of phenol81a with mesylate 172 in 
THF using NaH as a base resulted in formation of 173 in an unoptimised 38% yield. 
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o 
H~OH 
mDPs11 
170 
o NHBoc 
o ~ 
H I I 
173 
Towards the Synthesis of [d4U]-Butane-[HI-236] 
o 
H~OMS 
TBDPS~ 
172 
OH 
~Nteoc y 81a ii 
OMe 
Scheme 4.15. Reagents and Conditions: (i) MsCI, EhN, DMAP, CH2CI2 , rt, 1 h; 47%. (ii) 81a, NaH, 
THF, rt, 12h; 38%. 
Owing to insufficient material obtained for compound 173 (17 mg) coupled with the 
problems encountered during deprotection of the Boc group followed by 
condensation of the resultant amine in the synthesis of target compounds 96-99 the 
material was not committed to the last step. However, this sequence has laid the 
foundation for a scale-up followed by deprotection and condensation of 174 to the 
target. 
In conclusion, Sonogashira coupling of 5'-O-protected iodouridine was performed in 
high yields employing the alkyne protected as a THP ether. Dideoxygenation of the 
2',3'-diol was accomplished using Corey-Winter methodology. Converting the diol to a 
bis-xanthate led to deprotection of THP in an unusual mechanism. 
The most challenging aspect of the d4U-butane-H 1-236 synthesis was the 
dideoxygenation of the 2',3'-diol to form the alkene. The key to the success of this 
synthesis lies in the selection of protecting groups that would withstand several key 
reactions. Protection of the 5'-hydroxyl group with a benzoyl group was not attempted 
and this could probably have provided the selectivity required. 
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CHAPTERS 
Conclusion 
Three bifunctional compounds with the general formula [d4U]-spacer-[HI-236] were 
synthesized via a linear strategy and evaluated for their biological activity. The 
bifunctional compounds were linked at the C-5 position of the nucleoside base via a 
Sonogashira reaction. Conditions for this reaction were optimized and high yields 
were obtained for this step. The last key step led to the cleavage of the target 
molecules and future work is required to optimize conditions for this step without the 
nucleoside cleavage taking place. A convergent strategy involving Sonogashira 
coupling of a tethered HI-236 fragment directly with iodo-d4U has afforded promising 
preliminary results and is worth following up. 
Preliminary biological results on compound 96 showed that it displayed anti-HIV 
activity (ECso = 200 nM). This proves that linking the two compounds by a spacer 
does enhance the activity. The point of attachment of the NRTI as well as the NNRTI 
is correct allowing the two compounds to interact with their target site. Future work 
would involve molecular modeling studies to provide insight into the mode of 
interaction of these substrates with their respective active sites. 
Thiourea derivatives bearing a linker at the 2-position were synthesized with the aim 
of evaluating their anti-HIV activity. These compounds are currently being tested and 
will provide an insight into the synergism or additive activity of the bifunctional drugs. 
Studies towards the synthesis of a bifunctional target with a flexible linker resulted in 
the synthesis of the key intermediate 170. Optimum conditions were obtained for one 
of the key reactions, the Sonogashira coupling reaction. Future work would involve 
scaling-up the synthesis of 170 and completing the synthesis. 
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CHAPTER 6 
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Experimental Section 
General Procedures 
All reactions were performed in oven-dried glassware under an inert atmosphere of 
dry nitrogen. All starting materials were purchased from Sigma-Aldrich. South Africa 
except the solvents. acids and common salts. The following reaction solvents were 
distilled from the indicated drying agents: methylene chloride (P205). 1.2-
dichloroethane (P205). N,N-dimethylaniline (CaH2). diethyl ether (P205). 
tetra hyd rofu ran (sodium. benzophenone), toluene (sodium), methanol (Mg), 
acetonitrile (CaH2). triethylamine (CaH2). dimethoxyethane (Na, benzophenone). 
1 H NMR spectra were recorded on a Varian Mercury Spectrometer at 300 MHz or on 
a Varian Unity Spectrometer at 400 MHz. 13C NMR spectra were recorded at 75 MHz 
on a Varian Mercury Spectrometer or at 100 MHz on a Varian Unity Spectrometer. 
The spectra were recorded in COCh. Acetone-d6, MeOO or OMSO-d6 with 
tetramethylsilane as the internal standard. Chemical shifts are reported in ppm (<5); 
multiplicities are indicated by s (singlet), d (doublet), t (triplet). q (quartet), m 
(multiplet) and br (broad). Coupling constants, J, are reported in Hertz. High 
resolution mass spectra were recorded on a VG70 SEQ micromass spectrometer, 
Mass Spectrometry Service, School of Chemistry, University of Witwatersrand. 
Infrared (IR) absorptions were measured on a Perkin Elmer Spectrum One FT-IR 
spectrometer. Peaks are reported in cm-1 with indicated relative intensities: s (strong); 
m (medium); w (weak). Melting points were determined using a Reichert-Jung 
Thermovar hot-stage microscope and are uncorrected. Elemental analysis for C, H 
and N were carried out using a Fisons EA 110 CHN Elemental Analyser. Optical 
rotations were obtained using a Perkin Elmer 343 polarimeter at 20 DC. The 
concentration c refers to g/100 mL. 
The reaction progress was monitored by TLC using Merck silica-gel 60 F254. 
Visualisation was accomplished with UV light or spraying with anisaldehyde and/or 
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cerium ammonium sulphate spray reagents and then heating at 150 DC. Column 
chromatography was performed with Merck silica-gel 60 (70-230 mesh). 
2-Benzyloxy-5-methoxybenzaldehyde (85a) 
2· 
: (Y:q0 2 CHO 11 ::::..... 
5 
OCH3 
A solution of 2-hydroxy-5-methoxybenzaldehyde 84a (4.35 mL, 34.8 mmol), benzyl 
bromide (6.22 mL, 52.2 mmol) and anhydrous K2C03 (14.4 g, 104.4 mmol) in EtOH 
(35 mL) was stirred at reflux for 16 h. The K2C03 was filtered through a pad of Celite, 
washed with large volumes of EtOAc and the solvent removed under reduced 
pressure. The residual mass was dissolved in ether (100 mL). The EhO solution was 
washed twice with 50 mL portions of saturated NaCI solution, aqueous sodium 
hydroxide (5%) and water. The Et20 solution was dried over MgS04, evaporated 
under reduced pressure and the crude product recrystallised from EtOH to give 
colourless crystals (8.04 g, 95%). mp: 44-45 DC, [lit.98 47-48 DC]; IR (CHCI3): Vmax 
3692 (w), 3017 (m), 2872 (m), 2838 (w), 1683 (s), 1493 (s) cm-1 ; 1H NMR (300 MHz, 
CDCb): () 10.51 (1H, s, CHO), 7.41 (5H, m, ArH), 7.34 (1H, d, J = 3.3 Hz, H-6), 7.10 
(1 H, dd, J = 3.3, 9.1 Hz, H-4), 7.01 (1 H, d, J = 9.1 Hz, H-3), 5.15 (2H, s, CH20), 3.80 
(3H, s, OCH3); 13C NMR (75 MHz, CDCb): () 189.4 (CHO), 155.8 (C-2), 153.9 (C-5), 
136.3 (C-1'), 128.7 (C-3', C-5'), 128.2 (C-4'), 127.3 (C-2', C-6'), 125.6 (C-1), 123.4 (C-
6), 115.2 (C-3), 110.4 (C-4) , 71.4 (ArCH20), 55.8 (OCH3); EI HRMS: mlz found 
242.09699 (M+). C15H1403 (M+) requires 242.09429; Found C, 74.35; H, 5.81. 
C15H1403 requires C, 74.36; H, 5.82. 
2-Benzyloxy-4-methoxybenzaldehyde (85b) 
Benzyl bromide (7.04 mL, 59.2 mmol) was added dropwise to a suspension of 2-
hydroxy-4-methoxybenzaldehyde 84b (6.00 g, 39.4 mmol) and anhydrous K2C03 
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(16.4 g, 118.3 mmol) in EtOH (35 mL). The mixture was stirred at reflux for 16 h. The 
K2C03 was removed by filtration and the filtrate concentrated under reduced 
pressure. The crude product was dissolved in Et20 (100 mL). The Et20 solution was 
washed twice with 50 mL portions of saturated NaCI solution, aqueous sodium 
hydroxide (5%) and water. The Et20 solution was dried over MgS04, evaporated 
under reduced pressure and the crude product recrystallised from EtOH to give 
colourless crystals (6.09 g, 64%). mp: 55-56°C [lit. 98 65-66 °C); IR (CHCh): Vmax 
3691 (w), 2865 (w), 2843 (w), 2772 (w), 1676 (s), 1603 (s) cm-1; 1H NMR (400 MHz, 
COCh): & 10.39 (1H, d, J = 0.8 Hz, CHO), 7.84 (1H, d, J = 9.0 Hz, H-6), 7.37 (5H, m, 
ArH), 6.56 (1 H, ddd, J = 0.8, 2.8, 9.0 Hz, H-5), 6.52 (1 H, d, J = 2.8 Hz, H-3), 5.16 
(2H, s, ArCH20), 3.84 (3H, s, OCH3); 13C NMR (100 MHz, COCI3): & 188.2 (CHO), 
166.1 (C-2), 162.8 (C-4), 136.0 (C-1'), 130.5 (C-6), 128.7 (C-2', C-6'), 128.3 (C-4'), 
127.3 (C-3', C-5'), 119.4 (C-1), 106.2 (C-5), 99.3 (C-3), 70.5 (ArCH20), 55.6 (OCH3); 
EI HRMS found mlz 242.09578 (M+). C15H1403 requires (M+) 242.09429; Found C, 
74.23; H, 5.81. C15H1403 requires C, 74.36; H, 5.82. 
2-(2-Benzyloxy-5-methoxyphenyl)-1-nitroethene (83a) 
A solution of 2-benzyloxy-5-methoxybenzaldehyde 85a (5.00 g, 20.6 mmol), 
nitromethane (130 mL) and ammonium acetate (1.59 g, 20.6 mmol) were heated at 
70°C for 14 h. The cooled solution was diluted with CH2CI2 (70 mL) and washed with 
saturated NaCI solution (2 x 250 mL) and water (250 mL), dried over MgS04 and 
evaporated to dryness under reduced pressure. The crude product was recrystallised 
from absolute EtOH to afford yellow needles (4.38 g, 75%). mp: 112-114 °C [lit. 99 
114-116 °C); IR (CHCh): Vmax 3692 (w), 3607 (w), 1632 (m) (C=C), 1515 (m), 1498 
(s), 1343 (s) cm-1 ; 1H NMR (300 MHz, COCh): & 8.16 (1 H, d, J = 14.0 Hz, H-2) 7.81 
(1H, d, J = 14.0 Hz, H-1), 7.41 (5H, m, ArH), 6.97 (3H, m, H-3', H-4', H-6'), 5.16 (2H, 
s, ArCH20), 3.79 (3H, s, OCH3); 13C NMR (75 MHz, COCh): & 153.8 (C-2'), 152.9 (C-
5'),138.6 (C-1), 136.1 (C-1"), 135.1 (C-2), 128.8 (C-2", C-6") , 128.4 (C-4") , 127.4 (C-
3", C-5"), 120.1 (C-1'), 119.1 (C-6'), 116.0 (C-4'), 114.3 (C-3'), 71.3 (ArCH20), 55.8 
- 111 -
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 6: Experimental 
(OCH3); EI HRMS: m/z found 285.09932. C16H1SN04 requires (M+) 285.10011; 
Found C, 67.37; H, 5.27; N, 5.00. C16H1SN04 requires C, 67.36; H, 5.30; N 4.91. 
2-(2-Benzyloxy-4-methoxyphenyl)-1-nitroethene (83b) 
2" (C" 3" ~ 0 I 2' 2 0 4" :::::..,. :::::..,.1 N 2 
3' ~ l' 
4' I 
Me :::::..,. 
2-Benzyloxy-4-methoxybenzaldehyde 85b (4.28 g, 17.7 mmol) was treated with 
nitromethane (120 mL) and ammonium acetate (1.36 g, 17.7 mmol). The mixture was 
heated at 70°C for 14 h. The solution was diluted with CH2Cb (80 mL) and washed 
with saturated NaCI solution (2 x 100 mL) and water (100 mL). The organic layer was 
dried over MgS04 and evaporated to dryness under reduced pressure. The crude 
product was recrystallised from EtOH to afford yellow needles (4.19 g, 83%). mp: 
109-112 °C [lit. 126 115-116 °C]; IR (CHCb): Vrnax 3691 (w), 3607 (w), 1606 (s) (C=C), 
1510 (m) cm-1 ; 1H NMR (400 MHz, CDCb): 88.12 (1H, d, J= 13.4 Hz, H-2), 7.79 (1H, 
d, J = 13.4 Hz, H-1), 7.41 (6H, m, ArH, H-6'), 6.56 (2H, m, H-3', H-5'), 5.18 (2H, s, 
CH20), 3.83 (3H, s, OCH3); 13C NMR (100 MHz, CDCb): 8 164.2 (C-2'), 160.1 (C-4'), 
136.1 (C-1), 135.5 (C-1"), 135.4 (C-2), 134.1 (C-6'), 128.8 (C-2", C-6"), 128.5 (C-4"), 
127.4 (C-3", C-5"), 112.6 (C-1'), 106.3 (C-5'), 100.0 (C-3'), 70.8 (OCH2), 55.5 (OCH3); 
EI HRMS: m/z found 285.09965. C16H1SN04 (M+) requires 285.10011; Found C , H, 
5.25; N, 4.95. C16H1SN04 requires C, 67.36; H, 5.30; N, 4.91. 
2-(2-Benzyloxy-5-methoxyphenyl)-ethylamine (80a) 
2" 
3" ~ 0 cc" ,.", I ~NH, 
OCH3 
A solution of nitroethene 83a (1.35 g, 4.7 mmol) in THF (20 mL) was added dropwise 
over a period of 1 h to a stirred and refluxing suspension of lithium aluminium hydride 
(0.72 g, 18.9 mmol) in THF (10 mL). The mixture was refluxed for 4 h, cooled to O°C 
and saturated aq. Na2S04 added cautiously. Stirring was continued for an additional 
30 min, the precipitate formed was filtered through a pad of Celite® and washed with 
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large volumes of MeOH. The filtrate was evaporated under reduced pressure and the 
crude product (1.04 g, 85%) used in the next step without further purification. 1H 
NMR (400 MHz, DMSO-d6): D 7.42 (2H, dd, J = 1.6,6.9 Hz, H-2", H-6"), 7.37 (2H, dd, 
H-3", H-5"), 7.30 (1 H, tt, J = 1.6, 6.9 Hz, H-4"), 6.91 (1 H, d, J = 8.8, H-3'), 6.72 (1 H, 
d, J = 3.0 Hz, H-6'), 6.69 (1 H, dd, J = 3.0, 8.8 Hz, H-4'), 3.66 (3H, s, OCH3), 3.25 (br 
s, NH2), 2.73 (2H, t, J = 7.1 Hz, H-2), 2.63 (2H, t, J = 7.1 Hz, H-1); 13C NMR (75 MHz, 
DMSO-d6): D 153.1 (C-5'), 150.2 (C-2'), 137.6 (C-1"), 129.9 (C-1'), 128.3 (C-3", C-5"), 
127.5 (C-4"), 127.2 (C-2", C-6") , 116.3 (C-6'), 113.2 (C-3'), 111.1 (C-4'), 69.8 
(ArCH20), 55.2 (OCH3), 42.1 (C-1), 34.6 (C-2). 
2-(2-Benzyloxy-4-methoxyphenyl)-ethylamine (SOb) 
2 1 N~ 
Me 
A solution of nitroethene 83b (1.55 g, 5.5 mmol) in THF (25 mL) was added dropwise 
to a stirred and refluxing suspension of LAH (0.83 g, 21.8 mmol) in THF (20 mL). The 
mixture was refluxed for 4 h, cooled to 0 °C, saturated aq. Na2S04 added cautiously, 
filtered and the filtrate evaporated. The crude product (1.12 g, 80%) was used in the 
next step without further purification. 1H NMR (300 MHz, CD30D): D 7.44 (2H, m, H-
2", H-6"), 7.37 (3H, m, H-3", H-4", H-5"), 7.05 (1H, d, J = 8.2 Hz, H-6'), 6.59 (1H, d, J 
= 2.2 Hz, H-3'), 6.46 (1 H, dd, J = 2.2, 8.2 Hz, H-5'), 5.07 (2H, s, ArCH20), 4.80 (3H, 
s, OCH3), 2.85 (2H, t, J = 7.3 Hz, H-1), 2.77 (2H, t, J = 7.3 Hz, H-2); 13C NMR (75 
MHz, CD30D): D 161.0 (C-2'), 158.9 (C-4'), 138.8 (C-1"), 131.9 (C-6'), 129.6 (C-3", C-
5"), 128.9 (C-4"), 128.5 (C-2", C-6") , 121.6 (C-1'), 105.9 (C-5'), 100.9 (C-3'), 71.1 
(ArCH20), 55.8 (OCH3), 42.9 (C-1), 34.5 (C-2). 
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N-[2-(2-Benzyloxy-5-methoxyphenyl)ethyl]-terl-butylcarbamate (82a) 
2" (T:" 3" ::/' 0 H I 2' 2 I 4"~ ~11' 1 ~Or: 
~ 0 
5' 
OMe 
Amine 80a (1,20 g, 4.7 mmol) in acetonitrile (10 mL), triethylamine (1,32 mL, 9,5 
mmol) and DMAP (0.02 g) were treated with di-terl-butyldicarbonate (3.11 g, 14,2 
mmol) in acetonitrile (5 mL) at room temperature for 20 h, The solvent was 
evaporated in vacuo and the residual mass subjected to column chromatography 
employing EtOAc I petroleum ether (15 I 85) to give carbamate 82a as colourless 
crystals (0.73 g, 58%), along with dicarbamate by-product 82c as a colourless oil 
(0.62 g, 28%). 
82a mp: 103-104 DC; IR (CHCb): V max 3691 (w), 3453 (w) (NH), 1707 (s) (CO), 1503 
(s) (C=C) cm-1 ; 1H NMR (CDCb, 400 MHz): 87.41 (5H, m, ArH), 6.84 (1 H, d, J = 8.1 
Hz, H-3'), 6.73 (1 H, dd, J = 3.2, 8.1 Hz, H-4'), 6.69 (1 H, d, J = 3.2 Hz, H-6'), 5.03 (2H, 
s, ArCH20) , 4.70 (1H, brs, NH), 3.76 (3H, s, OCH3), 3.37 (2H, q, J = 6.4 Hz, H-1), 
2.83 (2H, t, J = 6.4 Hz, H-2), 1.42 (9H, s, OC(CH3h); 13C NMR (CDCb, 100 MHz): 8 
155.9 (C=O), 153.9 (C-5'), 151.0 (C-2'), 137.4 (C-1"), 128.6 (C-3", C-5"), 128.0 (C-1'), 
127.9 (C-4"), 127.3 (C-2", C-6") , 116.8 (C-6'), 113.0 (C-4'), 112.0 (C-3'), 79,0 
(OC(CH3h), 70.9 (ArCH20), 55.7 (OCH3), 40.8 (C-1), 30.9 (C-2), 27.8 (OC(CH3h); EI 
HRMS: m/z found 301.13383 [(M+ - t-butyl) + H). C21 H27N04 requires 301,13409 [(M+ 
- t-butyl) + HJ; Found C, 70.50; H, 7.62; N, 3.86. C21H27N04 requires C, 70.56; H, 
7.61; N 3.92. 
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N-[2-( 2-Benzyloxy-5-methoxyphenyl)ethyl]-d i-( tert-butylcarbamate) 
(82c) 
T '+ 
C(:" 0 0 3"~ 0 Y I 2' 2 ,~ ~l(Y 
OMe 
82c: IR (CHCb): Ymax 3692 (w), 3610 (w), 2973 (m), 2936 (m), 1776 (s) (CO), 1736 
(s) (CO), 1691 (s) (C=C), 1594 (m), 1501 (s), 1455 (s) cm-1; 1H NMR (400 MHz, 
CDCb): 8 7.45 (2H, d, J = 7.2 Hz, H-2", H-6"), 7.36 (2H, t, J = 7.2 Hz, H-3", H-5"), 
7.29 (1 H, t, J = 7.2 Hz, H-4"), 6.80 (1 H, d, J = 8.8 Hz, H-3'), 6.73 (1 H, d, J = 3.2 Hz, 
H-6'), 6.68 (1 H, dd, J = 3.2, 8.8 Hz, H-4'), 5.04 (2H, s, ArCH20), 3.86 (2H, t, J = 7.4 
Hz, H-1), 3.74 (3H, s, OCH3), 2.95 (2H, t, J = 7.4 Hz, H-2), 1.44 (18H, s, 2 x 
OC(CH3h); 13C NMR (100 MHz, CDCb): 8 153.7 (C=O), 152.4 (C-5'), 151.1 (C-2'), 
137.7 (C-1"), 129.0 (C-1'), 128.4 (C-3", C-5"), 127.6 (C-4") , 127.2 (C-2"), 116.9 (C-
6'), 113.0 (C-3'), 112.0 (C-4'), 81.8 (2 x OC(CH3h), 70.8 (ArCH20), 55.6 (OCH3), 46.4 
(C-1), 30.1 (C-2), 28.0 (2 x OC(CH3h); EI HRMS: rnIz found 457.24465 (M+). 
C26H35N06 requires (M+) 457.24644. 
N-[2-( 2-Benzyloxy-4-methoxyphenyl)ethyl]-tert-butylcarbamate (82b) 
Amine 80b (1.12 g, 4.3 mmol) and triethylamine (1.21 mL, 8.7 mmol) in CH3CN (10 
mL) were treated with di-tert-butyldicarbonate (1.2 mL, 5.2 mmol) in CH3CN (5 mL) at 
rt for 20 h. After the reaction was complete, the solvent was evaporated in vacuo and 
the residual mass subjected to column chromatography employing EtOAc / 
petroleum ether (15 / 85) to give colourless crystals (1.13 g, 73%). mp: 84-85 °C 
(from hexane/EtOAc); IR (CHCb): Ymax 3692 (w), 3452 (m) (NH), 2981 (m), 2936 (m), 
1707 (s) (CO), 1614 (s) (C=C), 1589 (m), 1507 (s) cm-1; 1H NMR (300 MHz, CDCb): 
8 7.44 (2H, m, H-2", H-6") , 7.39 (2H, t, J = 7.2 Hz, H-3", H-5"), 7.34 (1H, m, H-4"), 
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7.06 (1 H, d, J = 8.4 Hz, H-6'), 6.53 (1 H, d, J = 2.0 Hz, H-3'), 6.46 (1 H, dd, J = 2.0, 8.4 
Hz, H-5'), 5.05 (2H, s, ArCH20), 4.76 (1 H, brs, NH), 3.77 (3H, s, OCH3), 3.36 (2H, d, 
J = 6.0 Hz, H-1), 2.80 (2H, t, J = 6.0 Hz, H-2), 1.44 (9H, s, OC(CH3h); 13C NMR (75 
MHz, CDCb): 0 159.4 (C-4'), 157.4 (C-2'), 155.8 (C=O), 136.8 (C-1"), 130.8 (C-6'), 
128.4 (C-3", C-5"), 127.8 (C-4") , 127.1 (C-2", 6"), 120.0 (C-1'), 104.4 (C-5'), 99.7 (C-
3'), 78.6 (OC(CH3h), 69.9 (ArCH20), 55.1 (OCH3), 40.8 (C-1), 29.9 (C-2), 28.3 
(OC(CH3h); EI HRMS: m/z found 357.19290 (M+). C21H27N04 (M+) requires 
357.19401; Found C, 70.57; H, 7.62; N, 3.95. C21H27N04 requires C, 70.56; H, 7.61; 
N,3.92. 
N-2-(2-t-Butyloxycarbonylaminoethyl)-4-methoxyphenol (81a) 
OH H 
I 
Z 1(CY: 
OMe 
Hydrogen gas was introduced at atmospheric pressure into a flask containing a 
suspension of the carbamate 82a (1.09 g, 3.1 mmol), 10% palladium-on-carbon (10 
mol %) and ethanol (20 mL). The mixture was stirred at room temperature for 5 h. 
The catalyst was filtered through a pad of Celite®, washed with EtOAc (3 x 10 mL) 
and the filtrate concentrated under reduced pressure. The crude product was purified 
by column chromatography using EtOAc I petroleum ether (3 I 7) to give colourless 
crystals (0.57 g, 69%). mp: 116-117 °C; IR (CHCb): Vmax 3602 (w), 3463 (m) (NH), 
3330 (br) (OH), 3016 (m), 2937 (w), 1690 (s) (CO), 1505 (s) (C=C) cm-1 ; 1H NMR 
(300 MHz, CDCb): 06.77 (1 H, d, J = 8.8 Hz, H-6), 6.69 (1 H, brs, OH), 6.67 (1 H, dd, J 
= 3.0, 8.8 Hz, H-5), 6.63 (1 H, d, J = 3.0 Hz, H-3), 4.92 (1 H, brs, NH), 3.74 (3H, s, 
OCH3), 3.30 (2H, q, J = 7.2 Hz, H-2'), 2.80 (2H, t, J = 7.2 Hz, H-1'), 1.45 (9H, s, 
OC(CH3h); 13C NMR (75 MHz, CDCI3): 0 156.9 (C=O), 153.2 (C-4), 148.7 (C-1), 
117.6 (C-2), 116.6 (C-6), 116.1 (C-3), 112.8 (C-5), 80.0 (OC(CH3h), 55.7 (OCH3), 
41.0 (C-2'), 31.4 (C-1'), 28.4 (OC(CH3h); EI HRMS: m/z found 267.14329 (M+). 
C14H21N04 (M+) requires 267.14706; Found C, 62.82; H, 7.92; N, 5.16. C14H21N04 
requires C, 62.94; H, 7.92; N, 5.24. 
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N-2-(2-bis{t-Butyloxycarbonyl}am inoethyl)-4-methoxyphenol (81 c) 
+ o~o 
OH I 
'z~l< 
OMe 
The carbamate 82c (0.62 g, 1.4 mmol) was subjected to hydrogenolysis over a 
palladium-on-carbon catalyst (20 mol %) for 22 h. The catalyst was removed by 
filtration through a pad of Celite and washed with large volumes of EtOAc. The crude 
product was purified by column chromatography employing ethyl acetate / pet ether 
(3 / 7) to give the title compound as a colourless oil (0.39 g, 79%). IR (CHCh): Ymax 
3691 (w), 3607 (w), 3393 (br) (OH), 1776 (s) (CO), 1721 (s) (CO), 1677 (s) (C=C) cm-
1; 1H NMR (400 MHz, COCh): () 6.78 (1H, d, J = 8.6 Hz, H-6), 6.67 (1H, dd, J = 3.1, 
8.6 Hz, H-5), 6.63 (1 H, d, J = 3.1 Hz, H-3), 6.56 (1 H, brs, OH), 3.72 (3H, s, OCH3), 
3.72 (2H, t, J = 7.8 Hz, H-2'), 2.85 (3H, t, J = 7.8 Hz, H-1'), 1.50 (18H, s, 2 x 
OC(CH3h); 13C NMR (100 MHz, COCh): () 153.2 (2 x C=O), 153.0 (C-4), 150.0 (C-1), 
124.9 (C-2), 116.7 (C-6), 116.0 (C-3), 113.3 (C-5), 83.0 (OC(CH3h), 55.7 (OCH3), 
46.2 (C-2'), 30.7 (C-1'), 28.0 (2 x OC(CH3h); EI HRMS: mlz found 367.19968 (M+). 
C19H29N06 (M+) requires 367.19949. 
N-2-(2-t-Butyloxycarbonylaminoethyl)-5-methoxyphenol (81 b) 
OH H 
l' I 
?" 12 2' ~Oy 
~ 3 0 I" 
Me 
Hydrogen gas was introduced at atmospheric pressure into a flask containing a 
suspension of the carbamate 82b (1.11 g, 3.1 mmol), 10% palladium-on-carbon (20 
mol %) and ethanol (20 mL). The mixture was stirred at room temperature for 20 h. 
The catalyst was filtered through a pad of Celite and the filtrate concentrated under 
reduced pressure. The crude product was purified by column chromatography using 
EtOAc / petroleum ether (3/7) to give colourless crystals (0.54 g, 65%). mp 100-101 
°C (from EtOAc); IR (CHCh): Ymax 3691 (w), 3600 (w), 3463 (m) (NH), 3295 (br) (OH), 
1686 (s) (CO), 1622 (s) (C=C), 1505 (s) cm-1; 1H NMR (400 MHz, COCh): () 7.68 (1H, 
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brs, OH), 6.93 (1 H, d, J = 8.1 Hz, H-3), 6.46 (1 H, d, J = 2.7 Hz, H-6), 6.38 (1 H, dd, J 
= 2.7, 8.1 Hz, H-4), 4.98 (1 H, brs, NH), 3.74 (3H, s, OCH3), 3.27 (2H, q, J = 6.6 Hz, 
H-2'), 2.76 (2H, t, J = 6.6 Hz, H-1'), 1.45 (9H, s, OC(CH3b); 13C NMR (100 MHz, 
COCh): 0 159.7 (C=O), 157.1 (C-1), 155.9 (C-5), 130.8 (C-3), 117.3 (C-2), 105.6 (C-
4), 102.0 (C-6), 80.1 (OC(CH3h), 55.2 (OCH3), 40.9 (C-2'), 30.5 (C-1') 28.4 
(OC(CH3b); EI HRMS: m/z found 267.14729 (M+). C14H21N04 (M+) requires 
267.14706; Found C, 63.03; H, 7.97; N, 5.25. C14H21N04 requires C, 62.94; H, 7.92; 
N,5.24. 
2-(2-Aminoethyl)-4-methoxyphenol (91 a) 
OH 
2' N~ 
OMe 
To a solution of the carbamate 81a (0.20 g, 0.8 mmol) in CH2CI2 (1.0 mL) was added 
trifluoroacetic acid (1.0 mL) in CH2CI2 (1.0 mL) at OoC. The mixture was stirred at O°C 
for 30 min. Oiisopropylethylamine (2.0 mL) was added and the solvent evaporated. 
The resulting amine was used in the next step without further purification. 
2-(2-Aminoethyl)-5-methoxyphenol (91 b) 
OH 
2' N~ 
Me 
Trifluoroacetic acid (1.0 mL) in CH2CI2 (1.0 mL) was added dropwise to a solution of 
the carbamate 81 b (0.20 g, 0.8 mmol) in CH2Cb (1.0 mL) at 0 °c. The mixture was 
stirred at 0 °c for 30 min. Oiisopropylethylamine (2.0 mL) was added and the solvent 
evaporated. The resultant amine was used in the next step without further 
purification. 1H NMR (300 MHz, C0300): 06.93 (1H, d, J = 8.3 Hz, H-3), 6.37 (1H, d, 
J = 2.7 Hz, H-6), 6.32 (1 H, dd, J = 2.7, 8.3 Hz, H-4), 3.71 (3H, s, OCH3), 2.93 (2H, m, 
H-2'), 2.74 (2H, t, J = 6.9 Hz, H-1'). 
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N-(5-Bromo-2-pyridyl)]-methoxy-thiocarbamate (90a) 
Br 4 ~3 S l,.~~OCH3 
1, 1'-Thiocarbonyldiimidazole (1.84 g, 10.3 mmol) and 2-amino-5-bromopyridine (1.78 
g, 10.3 mmol) were added to dry acetonitrile (10 mL) at room temperature. The 
reaction mixture was stirred for 12 h and the precipitate filtered, washed with cold 
acetonitrile and recrystallized from acetonitrile/methanol to afford gOa as colourless 
needles (2.91 g, 87%). mp: 150-151 DC; IR (KBr): Vmax 3468 (w) (NH), 1691 (m) 
C=C), 1134 (w) (C=S) cm-1; 1 H NMR (400 MHz, DMSO-d6): 3 11.56 (1 H, brs, NH), 
8.48 (1 H, d, J = 2.4 Hz, H-6), 8.03 (2H, m, H-3, H-4), 3.99 (OCH3); 13C NMR (75 
MHz, DMSO-d6): 3 188.7 (C=S), 150.1 (C-2), 148.6 (C-6), 140.2 (C-4), 117.9 (C-3), 
114.9 (C-5), 57.1 (OCH3); Found C, 34.18; H, 2.82; N, 11.25; S, 12.86. C7H7BrN20S 
requires C, 34.02; H, 2.86; N, 11.34; S, 12.97. 
N-( 5-ch loro-2-pyridyl)-methoxy-th iocarbamate (90b) 
4 
CIU S -:?' 3 " I, ~OCH3 
1,1'-Thiocarbonyldiimidazole (3.68 g, 20.6 mmol) was added to a solution of 2-amino-
5-chloropyridine (2.65 g, 20.6 mmol) in acetonitrile at room temperature. The mixture 
was stirred for 12 h and the precipitate filtered, washed with cold acetonitrile. The 
crude product was recrystallised from acetonitrile/methanol to give gOb as colourless 
needles (2.85 g, 58%). mp: 154-156DC; IR (KBr): Vmax 3468 (w) (NH), 1691 (m) C=C), 
1134 (w) (C=S) cm-1; 1H NMR (400 MHz, DMSO-d6): 3 11.53 (1H, br s, NH), 8.36 
(1H, d, J = 2.8 Hz, H-6), 7.88 (2H, dd, J = 2.8,8.8 Hz, H-3, H-4), 3.94 (3H, s, OCH3); 
13C NMR (100 MHz, DMSO-d6): 3 188.8 (C=S), 149.9 (C-2), 146.4 (C-6), 137.5 (C-4), 
126.5 (C-5), 117.6 (C-3), 57.2 (OCH3); Found C, 41.69; H, 3.43; N, 12.96; S, 15.14. 
C7H7CIN20S requires C, 41.49; H, 3.48; N, 13.82; S, 15.82. 
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N-[2-( 2-Benzyloxy-5-methoxyphenyl )ethyl]-N -[2-( 5-bromopyridyl)]-
thiourea (79) 
OMe 
5' BrX)" 4" ~ 1:,,1 1 6' ~ 4' 
1 h- 3' 
6" " r:r' f'~ ~4'" O~3'" 
2''' 
Amine 80a (0.18 g, 0.7 mmol) was added to a suspension of thiocarbonyl derivative 
89 (0.22 g, 0.8 mmol) in DMF (5 mL). The reaction mixture was heated to 100°C for 
16 h. The mixture was poured into ice-cold water (5 mL) and stirred for 30 min. The 
precipitate formed was filtered and washed with cold water (2 x 5 mL). The crude 
product was purified by column chromatography (30% EtOAc in pet ether) to give a 
yellow solid (0.12 g, 37%). mp: 141-142 °C (CHCb/MeOH); IR (CHCb): Vmax 3691 
(w), 3607 (w), 3416 (w) (NH), 1602 (w), 1505 (w), 1138 (w) (C=S) cm-1; 1 H NMR 
(300 MHz, CD3CI): 8 11.18 (1 H, brs, NH), 8.80 (1 H, brs, NH), 8.03 (1 H, d, J = 2.6, H-
6"), 7.65 (1 H, dd, J = 2.6, 8.7 Hz, H-4"), 7.37 (5H, m, ArH), 6.86 (1 H, d, J = 9.0 Hz, 
H-3'), 6.84 (1 H, d, J = 3.2 Hz, H-6'), 6.74 (1 H, dd, J = 3.2, 9.0 Hz, H-4'), 6.67 (1 H, d, J 
= 8.7 Hz, H-3"), 5.02 (2H, s, ArCH20), 4.03 (2H, dd, J = 6.6 Hz, H-1), 3.75 (3H, s, 
OCH3), 3.03 (2H, t, J = 6.6 Hz, H-2); 13C NMR (75 MHz, CDCb): 8 179.0 (C=S), 
153.6 (C-5'), 151.6 (C-2"), 151.1 (C-2'), 146.7 (C-6"), 141.1 (C-4"), 137.3 (C-1"'), 
128.8 (C-1'), 128.5 (C-3"', C-5"'), 127.8 (C-4"'), 127.2 (C-2"', C-6"'), 117.7 (C-6'), 
113.2 (C-3"), 112.9 (C-3'), 112.6 (C-5"), 111.5 (C-4'), 70.7 (ArCH20), 55.6 (OCH3), 
45.7 (C-1), 30.0 (C-2); EI HRMS: m/z found 471.05937 (M+). C22H22N302BrS (M+) 
requires 471.06161; Found C, 55.48; H, 4.68; N, 8.59; S, 6.17. C22H22N302BrS 
requires C, 55.94; H, 4.69; N, 8.90; S, 6.79. 
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N-[2-(2-Hydroxy-5-methoxyphenyl)ethyl]-N-[2-(5-bromopyridyl)]-
thiourea (73) 
OMe 
OH 
To a solution of amine 91a (0.18 g, 0.7 mmol) in DMF (20 mL), was added 
thiocarbonyl derivative 89 (0.22 g, 0.8 mmol). The reaction mixture was heated to 
100°C and stirred for 15 h. The reaction mixture was poured into ice-cold water (2 
mL) and the suspension was stirred for 30 min. The product was filtered, washed 
with water (5 mL), dried, and further purified by column chromatography using EtOAc 
I petroleum ether (2 18) to furnish the titled compound as a pale yellow solid (0.14 g, 
44%). mp: 201-203 °C (from EtOAc); IR (KBr): V max 3468 (w) (NH), 3300-3200 (br) 
(OH), 2959 (w), 1594 (s) (C=C), 1179 (m), 1115 (w) (C=S) cm-1; 1 H NMR (300 MHz, 
DMSO-d6): 8 11.12 (1 H, brs, NH), 10.59 (1 H, brs, NH), 8.90 (1 H, brs, OH), 8.15 (1 H, 
d, J = 2.4 Hz, H-6"), 7.92 (1 H, dd, J = 2.4, 9.0 Hz, H-4"), 7.09 (1 H, d, J = 9.0 Hz, H-
3"),6.73 (1H, d, J = 2.9 Hz, H-6'), 6.72 (1H, d, J = 8.7 Hz, H-3'), 6.63 (1H, dd, J = 2.9, 
8.7 Hz, H-6'), 3.78 (2H, q, J = 6.8 Hz, H-1), 3.62 (3H, s, OCH3), 2.84 (2H, t, J = 6.8 
Hz, H-2); 13C NMR (75 MHz, DMSO-d6): 8 179.0 (C=S), 152.2 (C-5'), 151.9 (C-2"), 
149.1 (C-2'), 145.7 (C-6"), 141.1 (C-4") , 125.8 (C-1'), 116.4 (C-6'), 115.3 (C-3'), 114.3 
(C-3"), 112.1 (C-4'), 111.6 (C-5"), 55.2 (OCH3), 44.9 (C-1), 28.8 (C-2); EI HRMS: m/z 
found 381.01454 (M+). C15H16N302BrS (M+) requires 381.01466; Found C, 47.09; H, 
4.38; N, 10.17. C15H16N302BrS requires C, 47.13; H, 4.22; N, 10.99. 
N-[2-(2-Hydroxy-4-methoxyphenyl)ethyl]-N-[2-(5-bromopyridyl)]-
thiourea (74) 
Thiocarbonyl derivative 89 (0.25 g, 0.9 mmol) was reacted with amine 91b (0.13 g, 
0.8 mmol) in DMF (10 mL) at 100°C for 16 h. The reaction mixture was poured into 
ice-cold water (5 mL) and the suspension was stirred for 30 min. The product was 
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filtered, washed with water (5 mL), dried, and further purified by column 
chromatography using ethyl acetate / petroleum ether (3 / 7) to furnish the title 
compound as a pale yellow crystals (0.12 g, 41%). mp: 192-194 °C (ethyl acetate); IR 
(KBr): Vmax 3468 (w) (NH), 3300-3200 (br) (OH), 2959 (w), 1594 (s) (C=C), 1179 (m), 
1115 (w) (C=S) cm-1; 1H NMR (300 MHz, DMSO-d6): () 11.11 (1H, brs, NH), 10.59 
(1H, brs, NH), 9.40 (1H, brs, OH), 8.18 (1H, d, J = 2.4 Hz, H-6"), 7.93 (1H, dd, J = 
2.4, 9.0 Hz, H-4"), 7.10 (1 H, d, J = 9.0 Hz, H-3"), 7.03 (1 H, d, J = 8.1 Hz, H-6'), 6.40 
(1 H, d, J = 2.4 Hz, H-3'), 6.35 (1 H, dd, J = 2.4, 8.1 Hz, H-5'), 3.74 (2H, q, J = 6.7 Hz, 
H-1), 3.67 (3H, s, OCH3), 2.80 (2H, t, J = 6.7 Hz, H-2); 13C NMR (75 MHz, DMSO-d6): 
() 179.0 (C=S), 158.9 (C-4'), 156.1 (C-2'), 152.3 (C-2"), 145.8 (C-6"), 141.2 (C-4"), 
130.8 (C-6'), 117.2 (C-1'), 114.3 (C-3"), 111.5 (C-5"), 1 04.1 (C-5'), 101.2 (C-3'), 54.8 
(OCH3), 45.2 (C-1), 27.9 (C-2); EI HRMS: m/z found 381.01454 (M+). 
C15H16N302BrS (M+) requires 381.01466; Found C, 47.39; H, 4.23; N, 10.76. 
C15H16N302BrS requires C, 47.13; H, 4.22; N, 10.99. 
N-[2-(2-Hydroxy-5-methoxyphenyl)ethyl]-N-[2-(5-chloropyridyl)]-
thiourea (75) 
-:?' 3" S ell)" 4" 
~ IT~ 
OH 
Thiocarbonyl derivative 90b (0.23 g, 1.0 mmol) was added to a solution of amine 91a 
(0.13 g, 0.7 mmol) in DMF (1.0 mL). The reaction mixture was heated at 100 °C for 
16 h. The mixture was poured into ice-cold water and the suspension stirred for 30 
min. The product was filtered, washed with cold water, dried and the crude product 
purified by column chromatography using ethyl acetate / pet ether (3/7) to furnish 75 
as colourless crystals (0.11 g, 43%). mp: 184-186 °C (ethyl acetate); IR (KBr): 3412 
(w) (NH), 3400-3300 (br) OH), 2940 (w), 1602 (s) (C=C), 1161 (m) (C=S); 1H NMR 
(400 MHz, DMSO-d6): () 11.10 (1 H, brt, J = 4.8 Hz, NH), 10.58 (1 H, brs, NH), 8.88 
(1 H, brs, OH), 8.04 (1 H, d, J = 2.8 Hz, H-6"), 7.79 (1 H, dd, J = 2.8, 8.8 Hz, H-4"), 
7.10 (1 H, d, J = 8.8 Hz, H-3"), 6.70 (1 H, d, J = 3.2 Hz, H-6'), 6.68 (1 H, d, J = 8.8 Hz, 
H-3'), 6.59 (1 H, dd, J = 3.2, 8.8 Hz, H-4'), 3.74 (2H, q, J = 6.8 Hz, H-1), 3.58 (3H, s, 
OCH3), 2.80 (2H, t, J = 6.8 Hz, H-2); 13C NMR (75 MHz, DMSO-d6): () 179.0 (C=S), 
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152.0 (C-5'), 151.9 (C-2"), 149.1 (C-2'), 143.5 (C-6"), 138.6 (C-4") , 125.8 (C-1'), 
123.5 (C-5"), 116.3 (C-6'), 115.3 (C-3'), 113.8 (C-3"), 112.1 (C-4'), 55.2 (OCH3), 44.9 
(C-1), 28.8 (C-2); Found C, 53.12; H, 4.77; N, 12.34. C15H1s02N3CIS requires C, 
53.33; H, 4.77; N. 12.44. 
N-[2-(2-Hydroxy-4-methoxyphenyl)ethyl]-N-[2-(5-chloropyridyl)]-
thiourea (76) 
CI'O" 4" OCH3 
-?' 3" 5 ~ 12"~ 1 I 4' ~ 2 l' ~ 3' 
2' 
OH 
Thiocarbonyl derivative 90b (0.31 g. 1.3 mmol) was reacted with crude amine 91b in 
DMF (1 mL) at 100°C for 16 h. The reaction mixture was poured into ice-cold water 
(5 mL) and the suspension was stirred for 30 min. The product was filtered. washed 
with water. dried. and further purified by column chromatography using ethyl acetate / 
petroleum ether (3 / 7) to furnish the title compound as pale yellow solid (0.20 g. 
70%). mp: 208-209 °C (from ethyl acetate); IR (KBr): 3464 (w) (NH). 3400-3300 (br) 
OH). 1685 (s) (C=C), 1209 (s). 1191 (m). 1135 (m) (C=S); 1H NMR (400 MHz, 
DMSO-ds): 8 11.07 (1 H. brt, J = 4.6 Hz. NH). 10.56 (1 H. brs, NH). 9.38 (1 H. brs. OH). 
8.06 (1H. d, J = 2.8 Hz, H-6"). 7.78 (1H. ddt J = 2.8.9.0 Hz. H-4"). 7.10 (1H. d. J = 
9.0 Hz, H-3"). 6.98 (1H, d. J = 8.3 Hz. H-6'). 6.35 (1H. d. J = 2.7 Hz. H-3'). 6.30 (1H. 
ddt J = 2.7.8.3 Hz. H-5'). 3.69 (2H. q. J = 6.8 Hz. H-1). 3.62 (3H. s. OCH3). 2.75 (2H. 
t, J = 6.8 Hz, H-2); 13C NMR (100 MHz. DMSO-ds): 8 179.0 (C=S). 158.9 (C-4'). 
156.2 (C-2'). 152.0 (C-2"). 143.6 (C-6"). 138.6 (C-4"). 130.8 (C-6'), 123.5 (C-5"). 
117.2 (C-1'), 113.9 (C-3"). 104.2 (C-5'). 101.2 (C-3'). 54.8 (OCH3). 45.2 (C-1). 28.0 
(C-2). 
4-Tosyloxybut-1-yne (92) 
~ ~\ ,,0 2' 1~(J'sn'-?' 3' 
3 I ~ 
~ C~ 
p-Toluenesulfonyl chloride (6.14 g. 29.7 mmol) in CH2Cb (5 mL) was added dropwise 
to an ice-cold solution of but-3-yn-1-ol (1.5 mL. 19.8 mmol) containing triethylamine 
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(4.12 mL, 29.7 mmol) and OMAP (0.02 g) in CH2Cb (10 mL). The mixture was stirred 
at 0 °C for 1 h. The organic layer was washed with NaHC03 (10 mL), water (2 x 10 
mL) and then dried (MgS04), and the solvent evaporated under reduced pressure. 
The crude product was purified by column chromatography using ethyl acetate I 
petroleum ether (15 I 85) to give a colourless oil (4.44 g, 100%).127 1H NMR (300 
MHz, COCh): b 7.75 (2H, d, J = 7.4 Hz, H-2', H-6'), 7.31 (2H, d, J = 7.4 Hz, H-3', H-
5'),4.06 (2H, t, J = 7.0 Hz, H-4), 2.50 (2H, td, J = 2.7, 7.0 Hz, H-3), 2.40 (3H, s, CH3), 
1.95 (1H, t, J = 2.7 Hz, H-1); 13C NMR (75 MHz, COCh): b 144.9 (C-1'), 132.6 (C-4'), 
129.7 (C-2'), 127.7 (C-3'), 78.3 (C-2), 70.6 (C-1), 67.3 (C-4), 21.4 (C-3), 19.2 (CH3). 
[2-(2-But-3-ynyloxy-5-methoxyphenyl)ethyl]-terl-butylcarbam ate (93) 
~ .. H 1"' 3~ 2" ~ 3'~OZI'" ~Oy 4'~ 0 I" 
5' 
OMe 
The tosylate 92 (1.69 g, 8.0 mmol) was added dropwise over 1 h (1.5 equiv. each 
day for 5 d) to a refluxing and stirring mixture of the phenol 81a (0.34 g, 1.3 mmol) 
and anhydrous potassium carbonate (1.11 g, 8.0 mmol) in dry acetonitrile (50 mL). 
The mixture was stirred at reflux for 5 d. The solid was removed by filtration and the 
filtrate concentrated in vacuo. Purification by silica-gel column chromatography (15% 
ethyl acetate in petroleum ether) afforded a colourless solid (0.10 g, 61% yield based 
on recovered starting material (0.20 g». mp: 76-77 °C (EtOAc/Pet ether); IR (CHCh): 
Vmax 3455 (w) (NH), 3309 (w) (=C-H), 2413 (w) (C=C), 1707 (s) (CO), 1602 (s, C=C) 
cm-1; 1H NMR (300 MHz, COCh): b 6.75 (3H, m, H-3', H-4', H-6'), 4.70 (1H, brs, NH), 
4.05 (2H, t, J = 6.8 Hz, H-1"), 3.75 (3H, s, OCH3), 3.36 (2H, q, J = 6.6 Hz, H-1), 2.79 
(2H, t, J = 6.6 Hz, H-2), 2.66 (2H, dt, J = 2.7, 6.8 Hz, H-2"), 2.03 (1 H, t, J = 2.7 Hz, H-
4"), 1.42 (9H, s, OC(CH3h); 13C NMR (75 MHz, COCI3): b 155.9 (C=O), 153.9 (C-5'), 
150.6 (C-2'), 129.3 (C-1'), 116.8 (C-6'), 112.8 (C-3'), 112.0 (C-4'), 80.7 (C-3"), 78.9 
(OC(CH3h), 69.8 (C-4"), 66.8 (C-1"), 55.6 (OCH3), 40.7 (C-1), 30.9 (C-2), 28.4 
(OC(CH3h), 19.7 (C-2"); EI HRMS: m/z found 319.17756 (M+). C1sH25N04 (M+) 
requires 319.17836. Found: C, 67.10; H, 7.66; N, 3.67. C1sH25N04 requires C, 67.89; 
H, 7.89; N, 4.39. 
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[2-(2-Prop-2-ynyloxy-5-methoxyphenyl)ethyl]-terl-butylcarbamate 
(94a) 
1" 
~" or'I' ' , ry0-y: 34- ~o~ 
~ 0 
5' 
OMe 
Propargyl bromide (2.00 mL, 22.4 mmol) in CH3CN (2 mL) was added dropwise to a 
stirring and refluxing suspension of the phenol 81a (1.00 g, 3.7 mmol) and potassium 
carbonate (0.78 g, 5.6 mmol) in CH3CN (20 mL). The mixture was refluxed for 48 h, 
K2C03 filtered through a pad of Celite and the filtrate evaporated under reduced 
pressure. Column chromatography of the residue employing ethyl acetate / 
petroleum ether (1 / 4) afforded the title compound as colourless crystals (0.86 g, 
75%). mp: 49-50°C (EtOAc/pet ether); IR (CHCh): Vmax 3691 (w), 3454 (w) (NH), 
3308 (w) (=C-H), 3022 (m), 2124 (w) (C=C), 1707 (s) (CO), 1501 (s, C=C) cm-1; 1H 
NMR (300 MHz, CDCb): b 6.90 (1 H, d, J = 9.3 Hz, H-3'), 6.72 (2H, m, H-4', H-6'), 
4.65 (3H, d, J = 2.4 Hz, H-1", NH), 3.75 (3H, s, OCH3), 3.35 (2H, q, J = 6.8 Hz, H-1), 
2.79 (2H, t, J = 6.8 Hz, H-2), 2.47 (1H, t, J = 2.4 Hz, H-3"), 1.42 (9H, s, OC(CH3h); 
13C NMR (75 MHz, CDCb): b 155.9 (C=O), 154.3 (C-5'), 149.8 (C-2'), 129.6 (C-1'), 
116.7 (C-6'), 113.6 (C-3'), 112.0 (C-4'), 79.0 (C-3", OC(CH3h), 75.2 (C-2"), 56.7 (C-
1"), 55.6 (OCH3), 40.6 (C-1), 30.9 (C-2), 28.4 (OC(CH3h); EI HRMS: rnIz found 
305.16244 (M+). C17H23N04 (M+) requires 305.16271; Found: C, 66.90; H, 7.54; N, 
4.54. C17H23N04 requires C, 66.86; H, 7.59; N, 4.59. 
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N-terl-Butyloxycarbonyl-[2-(2-prop-2-ynyloxy-5-methoxyphenyl) 
ethyl]-terl-butylcarbamate (94b) 
1" + ~~o, ~~(/o 
1
1
' n 1< 
~ 0 
5' 
OMe 
Propargyl bromide (80% in toluene, 0,3 mL, 3.2 mmol) in CH3CN (1 mL) was added 
dropwise to a stirring and refluxing suspension of phenol 81 b (0.39 g, 1,1 mmol) and 
potassium carbonate (0.44 g, 3.2 mmol) in CH3CN (10 mL). The mixture was refluxed 
for 1 h, filtered and the filtrate evaporated under reduced pressure. Column 
chromatography employing EtOAc / petroleum ether (1 / 5) afforded 94b as a 
colourless oil (0.32 g, 74%). IR (CHCI3): Vmax 3691 (w), 3308 (w) (:C-H), 3016 (m), 
3022 (s), 3024 (s), 1776 (w), 1737 (m) (CO), 1708 (m) (CO) cm-1; 1H NMR (300 MHz, 
CDCb): 06.91 (1 H, d, J = 9.9 Hz, H-3'), 6.71 (2H, m, H-4', H-6'), 4.65 (2H, d, J = 2.4 
Hz, H-1"), 3.79 (2H, t, J = 7.3 Hz, H-1), 3.75 (3H, s, OCH3), 2.89 (2H, t, J = 7.3 Hz, H-
2),2.45 (1H, t, J= 2.4 Hz, H-3"), 1.47 (18H, s, 2 x OC(CH3h); 13C NMR (100 MHz, 
CDCb): 0 154,3 (C-5'), 152.3 (2 x C=O), 150.1 (C-2'), 129.6 (C-1'), 116.8 (C-6'), 
113.8 (C-3'), 112.0 (C-4'), 81.9 (C(CH3h), 79.2 (C-2"), 75.1 (C-3"), 56.9 (C-1"), 55.6 
(OCH3), 46.5 (C-1), 30.1 (C-2), 28.0 (C(CH3h); EI HRMS: m/z found 405.21491 (M+). 
C22H31N06 (M+) requires 405.21514. 
N-[2-(2-Propyn-2-yloxy-5-methoxyphenyl)ethyl]-N -[2-( 5-bromo 
pyridyl)]-thiourea (78) 
1'" 
~'" 3~ 0 2" 2 HH:U 
3" ~ 1 1" 1 ~ 2' ~ 1 6' 
4"~ 6" 5 3'~ 5' 
5" 4' Br 
OMe 
Trifluoroacetic acid (0.1 mL) was added dropwise to an ice-cold solution of the 
carbamate 94 (0.35 g, 1.1 mmol) in CH2CI2 (1.0 mL). The mixture was stirred at 0 DC 
for 2 h. Diisopropylethylamine (0.3 mL) was added and the mixture stirred for an 
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additional 10 min. The solvent was evaporated and the crude amine dried under 
vacuum for 1 h. Thiocarbonyl reagent 89 (0.39 g, 1.4 mmol) was added to the crude 
amine in DMF (1.0 mL) and the mixture stirred at 100 °c for 1 h. DMF was removed 
by co-evaporation with toluene and the residue subjected to column chromatography 
employing 15% ethyl acetate in pet ether to give the title compound as colourless 
needles (0.08 g, 17%). mp: 121-122 °c (from pet ether/EtOAc); IR (CHCb): Vmax 3691 
(w), 3416 (w) (NH), 3307 (w) (=C-H), 3174 (br) (NH), 1602 (m) (C=C), 1137 (w) 
(C=S) cm-1; 1H NMR (400 MHz, CDCb): () 11.13 (1H, brs, NH), 8.29 (1H, brs, NH), 
8.12 (1H, d, J = 2.4 Hz, H-6'), 7.69 (1H, dd, J = 2.4,8.8 Hz, H-4'), 6.95 (1H, d, J = 8.8 
Hz, H-3'), 6.82 (1 H, d, J = 3.1 Hz, H-6") , 6.76 (1 H, dd, J = 3.1, 8.8 Hz, H-4") , 6.59 
(1H, d, J= 8.8 Hz, H-3"), 4.67 (2H, d, J= 2.2 Hz, H-1111), 4.01 (2H, q, J= 6.7 Hz, H-1), 
3.76 (3H, s, OCH3), 3.01 (2H, t, J = 6.7 Hz, H-2), 2.47 (1 H, t, J = 2.2 Hz, H-3111); 13C 
NMR (75 MHz, CDCb): () 179.1 (C=S), 154.2 (C-5"), 151.7 (C-2'), 150.0 (C-2"), 146.7 
(C-6'), 141.1 (C-4'), 129.2 (C-1"), 117.6 (C-6"), 113.5 (C-3"), 113.3 (C-3'), 112.6 (C-
5'), 111.5 (C-4") , 79.0 (C-2111) , 75.3 (C-3111), 56.8 (C-1111), 55.5 (OCH3), 45.7 (C-1), 29.8 
(C-2); Found: C, 51.23; H, 4.50; N, 8.62. C1sH1SBrN302S requires C, 51.44; H, 4.32; 
N,10.00. 
N-[2-(2-Butyn-3-yloxy-5-methoxyphenyl)ethyl]-N-[2-(5-bromopyridyl 
)]-thiourea (77) 
1'" 3,,¥H 
~:?' 
2" 21H~  
3" -7' 1 1" ~ 2' /" 1 6' 
4":::::-" 6" 5 3' :::::-.. 
5' Br 
4' 
OMe 
Trifluoroacetic acid (0.1 mL) was added dropwise to an ice-cold solution of the 
carbamate 93 (0.098 g, 0.37 mmol) in CH2Cb (1.0 mL). The mixture was stirred at 0 
°C for 30 min. Diisopropylethylamine (0.3 mL) was added and the mixture stirred for 
an additional 10 min. The solvent was evaporated and the crude amine dried under 
vacuum for 1 h. Thiocarbonyl reagent 89 (0.125 g, 0.44 mmol) was added to the 
crude amine in DMF (1.0 mL) and the mixture stirred at 100 °C for 1 h. DMF was 
removed by co-evaporation with toluene and the residue subjected to column 
chromatography employing 15% ethyl acetate in pet ether to give the title compound 
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77 as colourless needles (0.033 g, 25%). mp: 155-156 °C (from pet ether I EtOAc); 
IR (CHCI3): V max 3691 (w), 3415 (w) (NH), 3308 (w) (=C-H), 3176 (w), 3048 (w), 2360 
(w) (C=C), 1591 (m), 1578 (m), 1559 (m), 1511 (s), 1163 (w) (C=S), 1138 (m) (C=S), 
1097 (m) (C=S), 775 (w) (C-S) cm-1; 1H NMR (300 MHz, COCh): 0 11.13 (1H, brs, 
NH), 8.44 (1H, brs, NH), 8.10 (1H, d, J = 2.4 Hz, H-6'), 7.68 (1H, dd, J = 2.4,8.7 Hz, 
H-4'), 6.76 (3H, m, H-3', H-4",H-6"), 6.61 (1 H, d, J = 8.7 Hz, H-3"), 4.03 (4H, m, H-1, 
H-1111), 3.75 (3H, s, OCH3), 3.00 (2H, t, J = 6.6 Hz, H-2), 2.68 (2H, td, J = 2.6, 6.9 Hz, 
H-2111) , 2.04 (1 H, t, J = 2.6 Hz, H-4I11); 13C NMR (75 MHz, COCh): 0 179.2 (C=S), 
153.8 (C-5"), 151.6 (C-2"), 150.9 (C-2'), 146.9 (C-6'), 141.2 (C-4'), 128.9 (C-1"), 
117.8 (C-6"), 113.1 (C-3'), 112.8 (C-3"), 112.7 (C-5'), 111.6 (C-4"), 80.8 (C-4I11) 69.9 
(C-3111), 66.9 (C-1111), 55.6 (OCH3), 45.8 (C-1), 30.0 (C-2), 19.8 (C-2111); Found: C, 
52.01; H, 4.46; N, 9.00. C19H2oBrN302S requires C, 52.54; H, 4.64; N, 9.67. 
2-Benzyloxyethanol (130) 
2' 2 
U' _./'-....1/0H 3' -:?' U".......,.. 4' ~ I 
Benzyl bromide (7.60 mL, 64.4 mmol) was added dropwise to a suspension of NaH 
(60% in mineral oil, 1.55 g, 64.4 mmol) and 1, 2-ethanediol (10.80 mL, 193.4 mmol) 
in THF (40 mL). The mixture was refluxed for 20 h. The mixture was dissolved in 
EtOAc (60 mL) and washed with NH4CI (40 mL) and H20 (2 x 40 mL). The EtOAc 
solution was dried over MgS04, the solvent evaporated and the crude product 
purified by distillation (bp: 102 °C/O.7 mm Hg [lit.117 90-95 °C/O.7 mm Hg]) to give 130 
(5.19 g, 53%) as a colourless oil. 1H NMR (300 MHz, COCh): 0 7.34 (5H, m, ArH), 
4,56 (2H, s, ArCH20), 3.74 (2H, t, J = 4.6 Hz, H-2), 3.58 (2H, t, J = 4.6 Hz, H-1), 2.52 
(1H, s, OH); 13C NMR (75 MHz. COCb): 0 138.0 (C-1'), 128.7, 128.4, 127.8, (ArCH), 
73.3 (ArCH20), 71.5 (C-2), 61.8 (C-1). 
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2-(2-Benzyloxyethoxy)ethanol (130b) 
3" -:Y U- '-" ~ 'OH cr
2
" 1" _~1,/O'2~ 
4" ~ I 
Benzyl bromide (2,24 mL, 18.9 mmol) was added dropwise to a suspension of NaH 
(60% in mineral oil, 0,76 g, 31.4 mmol) and diethylene glycol (6,00 g, 56.5 mmol) in 
THF (40 mL). The mixture was refluxed for 20 h. The mixture was dissolved in EtOAc 
(60 mL) and washed with NH4CI (40 mL) and H20 (2 x 40 mL). The EtOAc solution 
was dried over MgS04, the solvent evaporated and the crude product purified by 
distillation (bp: 180 °C/0.7 mm Hg [lit. 128 171-173 °C) to give 130b (2.22 g, 60% yield) 
as a colourless oil. 1H NMR (300 MHz, CDCb): 0 7.33 (5H, m, ArH), 4.56 (2H, s, 
ArCH20), 3.64 (8H, m, 4 x CH20), 2.79 (1 H, brs, OH); 13C NMR (75 MHz, CDCb): 0 
137.8 (C-1"), 128.1, 127.5, 127.4 (ArCH), 73.0 (ArCH20), 72.3 (C-2'), 70.1 (OCH2), 
69.2 (OCH2), 61.4 (C-1). 
2-Benzyloxy-1-bromoethane (131) 
cr
2
' l' _~ 1 /Br 
3' -:Y U '-/" 
I 
4' ~ 
To a solution of the alcohol 130 (2.00 g, 13.1 mmol) and PPh3 (4.14 g, 15.8 mmol) in 
CH2CI2 (20 mL) was added CBr4 (5.23 g, 15.8 mmol) at O°C. The reaction mixture 
was stirred at O°C for 30 min and the solvent evaporated. The crude product was 
purified by column chromatography using CH2Cb I pet ether (2 I 8) to give a 
colourless oil (2.68 g, 95%).129 1H NMR (300 MHz, CDCb): 07.36 (5H, m, ArH), 4.60 
(2H, s, ArCH20), 3.80 (2H, t, J = 6.2 Hz, H-2), 3.50 (2H, t, J = 6.2 Hz, H-1); 13C NMR 
(75 MHz, CDCb): 0 137.8 (C-1'), 128.5, 127.8, 127.7 (ArCH), 73.1 (ArCH20), 70.0 (C-
2), 30.4 (C-1). 
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2-(2-Benzyloxy)ethoxy-1-bromoethane (131 b) 
T 2 1 
OJ" -~ 1'/O~ 2/'... 3" -:? V '-/ .............., ~Br 4" ~ 1 
To a solution of the alcohol 130b (1.96 g, 1,0 mmol) and PPh3 (3,14 g, 12,0 mmol) in 
CH2Cb (20 mL) was added CBr4 (3,98 g, 12.0 mmol) at O°C, The reaction mixture 
was stirred at O°C for 30 min and the solvent evaporated. The crude product was 
purified by column chromatography using CH2CI2 / pet ether (3 / 7) to give a 
colourless oil (2,36 g, 91%), 1H NMR (300 MHz, COCh): 8 7,36 (5H, m, ArH), 4.59 
(2H, s, ArC H20) , 3,81 (2H, t, J = 6,3 Hz, H-2), 3.67 (4H, m, 2 x CH20), 3.47 (2H, t, J 
= 6,3 Hz, H-1); 13C NMR (75 MHz, COCh): 8 138,0 (C-1"), 128.1 (C-2", C-6"), 127.4 
(C-3", C-5"), 127,3 (C-4") , 73,0 (ArCH20), 70.9 (C-2'), 70.3 (CH20), 69.2 (CH20), 
30,1 (C-1); EI HRMS: m/z found 258.02407 (M+). C11 H15Br02 (M+) requires 
258.02554. 
3-(2-t-Butyloxycarbonylaminoethyl)-4-(2-benzyloxyethoxy)anisole 
(132) 
~'" 3~4'" l' 0 1",1 ~ h-
1" H 
Z irai< 
OMe 
Bromide 131 (0.73 g, 3.4 mmol) in CH3CN (1 mL) was added dropwise to a stirring 
and refluxing suspension of K2C03 (0.47 g, 3.4 mmol) in a solution of phenol 81a 
(0,30 g, 1,1 mmol) dissolved in CH3CN (10 mL), The mixture was refluxed for 20 h, 
the K2C03 filtered through a pad of Celite, the latter washed with ethyl acetate (3 x 
30 mL) and the solvent reduced in vacuo, The crude product was purified by column 
chromatography using ethyl acetate / pet ether (2 / 8) to afford 132 as colourless 
crystals (0.39 g, 87%). mp: 56-58 °C (from EtOAc/pet ether); IR (CHCh): Vmax 3692 
(w), 3452 (w) (NH), 1706 (s) (CO), 1502 (s) (C=C) cm-1; 1H NMR (400 MHz, COCh): 
8 7.36 (5H, m, ArH), 6.78 (1 H, d, J = 8.8 Hz, H-5), 6.72 (1 H, d, J = 3.0 Hz, H-2), 6.70 
(1 H, dd, J = 3.0, 8.8 Hz, H-6), 4.73 (1 H, brs, NH), 4.63 (2H, s, ArCH20), 4.11 (2H, t, J 
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= 4.8 Hz, H-1'), 3.83 (2H, t, J = 4.8 Hz, H-2'), 3.76 (3H, s, OCH3), 3.35 (2H, d, J = 6.4 
Hz, H-2"), 2.80 (2H, t, J = 6.4 Hz, H-1"), 1.42 (9H, s, OC(CH3h); 13C NMR (100 MHz, 
CDCb): 8156.0 (C=O), 153.8 (C-1), 151.0 (C-4) , 138.1 (C-1"'), 129.3 (C-3), 128.4 (C-
2"', C-6"'), 127.7 (C-4"') , 127.6 (C-3"', C-5"') , 116.7 (C-2), 113.0 (C-5), 112.0 (C-6), 
78.8 (OC(CH3h), 73.3 (ArCH20), 68.8 (CH20), 68.4 (OCH2), 55.7 (OCH3), 40.7 (C-
2"), 31.0 (C-1"), 28.4 (OC(CH3h); EI HRMS: m/z Found 401.22044 (M+). C23H31NOs 
(M+) requires 401.22022; Found C, 68.90; H, 7.80; N, 3.37. C23H31NOs requires C, 
68.80; H, 7.78; N, 3.49. 
3-(2-tert-Butyloxycarbonylaminoethyl)-4-(5-benzyloxy-3-oxapentyl 
oxy)anisole (132b) 
l' 3' 5' 2'" 
_/"--....2' /o~ 4' /"'.....~'" U" ......, '-../' ':?' 3'" 
4 H 0 1 4", 
':?' 1" ~ ~ 
5 1 3 2" I 
6 ~1 2 0'1< 
OMe 
Bromide 131b (0.52 g, 2.0 mmol) in DME (4 mL) was added dropwise to a stirring 
and refluxing suspension of NaH (0.06 g, 2.5 mmol) in a solution of phenol 81a (0.27 
g, 1.0 mmol) dissolved in DME (16 mL). The mixture was refluxed for 20 h, the crude 
product dissolved in EtOAc (20 mL) and washed with NH4CI (10 mL) and H20 (2 x 10 
mL). The organic layer was dried over MgS04, filtered and the solvent reduced in 
vacuo. The crude product was purified by column chromatography using ethyl 
acetate 1 pet ether (3 17) to afford 132b as a colourless oil (0.35 g, 78%). IR (CHCb): 
V max 3691 (w), 3684 (w), 3453 (w) (NH), 3011 (m), 2933 (m), 1706 (s) (CO), 1502 (s) 
(C=C) cm-1; 1H NMR (400 MHz, CDCb): 87.30 (5H, m, ArH), 6.78 (1H, d, J = 8.7 Hz, 
H-5), 6.71 (1 H, d, J = 2.8 Hz, H-2), 6.69 (1 H, dd, J = 2.8, 8.7 Hz, H-6), 4.88 (1 H, brs, 
NH), 4.58 (2H, s, ArCH20), 4.09 (2H, t, J = 4.9 Hz, CH20), 3.84 (2H, t, J = 4.9 Hz, 
CH20), 3.74 (5H, m, CH20, OCH3), 3.65 (2H, m, CH20), 3.34 (2H, m, J = 6.4 Hz, H-
2"), 2.79 (2H, t, J = 6.4 Hz, H-1"), 1.41 (9H, s, OC(CH3h); 13C NMR (100 MHz, 
CDCb): 8 156.0 (C=O), 153.8 (C-1), 151.0 (C-4), 138.2 (C-1"'), 129.4 (C-3), 128.3 
(ArCH), 127.7 (ArCH), 127.6 (ArCH), 116.6 (C-2), 113.1 (C-5), 112.0 (C-6), 78.8 
(OC(CH3h), 73.2 (CH20), 70.8 (CH20), 69.9 (CH20), 69.5 (CH20), 68.5 (CH20), 55.6 
(OCH3), 40.7 (C-2"), 31.0 (C-1"), 28.4 (OC(CH3h); EI HRMS: m/z Found 445.24814 
(M+). C2sH3SNOs (M+) requires 445.24644. 
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2-[2-(2-tert-Butyloxycarbonylaminoethyl)-4-methoxy]phenoxy-1-
ethanol (133) 
OMe 
Hydrogen gas was introduced at atmospheric pressure to the carbamate 132 (0.37 g, 
0.9 mmol) and a suspension of 10% palladium-on-carbon (10 mol%) in ethanol (5 
mL). The mixture was stirred at room temperature for 18 h. The catalyst was filtered 
through a pad of Celite, washed with EtOAc (3 x 10 mL) and the filtrate evaporated in 
vacuo. The crude product was purified by column chromatography using EtOAc / pet 
ether (4 / 6) to give 133 as colourless crystals (0.25 g, 87%). mp: 84-85 °C (from 
EtOAc/pet ether); IR (CHCh): Vmax 3691 (w), 3458 (m, br) (NH, OH), 2934 (m), 1704 
(s) (CO), 1502 (s) (C=C) cm-1; 1H NMR (400 MHz, CDCh): 06.70 (3H, m, H-3', H-5', 
H-6'), 4.87 (1H, brs, NH), 4.03 (2H, t, J = 4.1 Hz, H-2), 3.95 (2H, t, J = 4.1 Hz, H-1), 
3.75 (3H, s, OCH3), 3.31 (2H, m, J = 6.7 Hz, H-2"), 2.78 (2H, t, J = 6.7 Hz, H-1"), 
1.42 (9H, s, OC(CH3h), 1.25 (1H, brs, OH); 13C NMR (100 MHz, CDCh): 0 156.5 
(C=O), 153.9 (C-4'), 151.4 (C-1'), 128.9 (C-2'), 117.1 (C-3'), 112.6 (C-6'), 112.0 (C-
5'), 79.7 (OC(CH3h), 70.6 (C-2), 61.6 (C-1), 55.9 (OCH3), 41.0 (C-2"), 32.6 (C-1"), 
28.6 (OC(CH3h); EI HRMS: m/z found 311.17278 (M+). C16H25N05 (M+) requires 
311.17327. Found: C, 61.70; H, 8.03; N, 4.14. C16H25N05 requires C, 61.72; H, 8.09; 
N,4.50. 
5-[2-(2-tert-Butyloxycarbonylaminoethyl)-4-methoxy]phenoxy-3-oxa-
1-pentanol (133b) 
5 3 1 ~O~OH 
1" H 
, !r0i< 
OMe 
Hydrogen gas was introduced at atmospheric pressure to the carbamate 132b (0.22 
g, 0.5 mmol) and a suspension of 10% palladium-on-carbon (10 mol%) in ethanol (15 
mL). The mixture was stirred at room temperature for 18 h. The catalyst was filtered 
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through a pad of Celite, washed with EtOAc (3 x 10 mL) and the filtrate evaporated in 
vacuo. The crude product was purified by column chromatography using EtOAc 1 pet 
ether (1/1) to give 133b as a colourless oil (0.16 g, 92%). IR (CHCI3): Vmax 3692 (w), 
3604 (w), 3452 (w) (NH), 3392 (br) (OH), 3011 (m), 2980 (m), 2934 (m), 1705 (s) 
(CO), 1503 (s) (C=C); 1H NMR (300 MHz, CDCb): 8 6.78 (1 H, d, J = 9.3 Hz, H-6'), 
6.70 (2H, m, H-5', H-3'), 4.89 (1 H, brs, NH), 4.10 (2H, t, J = 4.6 Hz, CH20), 3.85 (2H, 
t, J = 4.6 Hz, CH20), 3.75 (5H, m, OCH3, CH20), 3.67 (2H, m, CH20), 3.36 (2H, m, J 
= 6.2 Hz, H-2"), 2.79 (2H, t, J = 6.2 Hz, H-1"), 1.63 (1H, brs, OH), 1.40 (9H, s, 
OC(CH3h); 13C NMR (75 MHz, CDCI3): 8 156.0 (C=O), 153.9 (C-4'), 151.0 (C-1'), 
129.3 (C-2'), 116.7 (C-3'), 113.0 (C-6'), 112.0 (C-5'), 72.6 (C-5), 69.8 (CH20), 68.4 
(CH20), 61.8 (C-1), 55.6 (OCH3), 40.8 (C-2"), 31.1 (C-1"), 28.4 (OC(CH3h); EI 
HRMS: m/z found 355.19828 (M+). C1sH2906N (M+) requires 355.19949. 
3-( 2-tett-Butyloxycarbonylam i noethyl)-4-(2-p-tol uenesu I phonyloxy 
ethoxy)anisole (134a) 
~OR 
H a 2"~i< 
T 
0=5=0 
9'" R = 7' 1 2'" ::::,.... 3'" 4'" OMe 
p-Toluenesulfonyl chloride (0.29 g, 1.5 mmol) was added portionwise to a stirring 
solution of the alcohol 133 (0.24 g, 0.8 mmol) containing triethylamine (0.2 mL, 1.5 
mmol) and a catalytic amount of DMAP (0.02 g) in CH2Cb (10 mL) at O°C. The 
reaction mixture was stirred at room temperature for 20 h. The solvent was 
evaporated under reduced pressure and the crude product subjected to column 
chromatography employing EtOAc 1 pet ether (3 1 7) to afford the title compound as a 
colourless oil (0.27 g, 76%). IR (CHCb): Vmax 3690 (w), 3451 (w) (NH), 1706 (s) (CO), 
1367 (s) (S(=Oh), 1164 (s) (S(=Oh) cm-1; 1H NMR (400 MHz, CDCb): 87.75 (2H, d, 
J = 8.2 Hz, H-2'" , H-6'"), 7.28 (2H, d, J = 8.2 Hz, H-3'" , H-5"'), 6.62 (3H, m, H-2, H-5, 
H-6), 4.77 (1H, brs, NH), 4.30 (2H, t, J = 4.7 Hz, H-2'), 4.05 (2H, t, J = 4.7 Hz, H-1'), 
3.68 (3H, s, OCH3), 3.22 (2H, q, J = 6.8 Hz, H-2"), 2.65 (2H, t, J = 6.8 Hz, H-1"), 2.38 
(3H, s, CH3), 1.38 (9H, S, OC(CH3}J); 13C NMR (100 MHz, CDCb): 8 155.9 (C=O), 
154.1 (C-1), 150.2 (C-4), 145.0 (C-1"'), 132.9 (C-4"') , 129.9 (C-3"', C-5"'), 129.3 (C-
3), 127.8 (C-2"', C-6"') , 116.7 (C-2), 112.0 (C-5), 111.9 (C-6), 78.8 (OC(CH3}J), 68.4 
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(C-1'), 66.4 (C-2'), 55.5 (OCH3), 40.5 (C-2"), 30.9 (C-1"), 28.4 (OC(CH3h), 21.5 
(CH3); EI HRMS: m/z found 465.18130 (M+). C23H31N07S (M+) requires 465.18212. 
3-( 2-tett-Butyloxycarbonylam i noethyl )-4-( 5-p-tol uenes u I phonyloxy-
3-oxa-pentyloxy)-anisole (134b) 
l' 3' 5' ~O~OR T 
H 0 2"~r< 
OMe 
0=5=0 
9'" R = -:;:/ 1 2'" ::::,.... 3'" 4'" 
p-Toluenesulfonyl chloride (0.18 g, 1.0 mmol) was added portionwise to a stirring 
solution of the alcohol 133b (0.17 g, 0.5 mmol) containing triethylamine (0.07 mL, 0.5 
mmol) and DMAP (cat.) in CH2CI2 (15 mL) at O°C. The reaction mixture was stirred at 
room temperature for 20 h. The solvent was evaporated under reduced pressure and 
the crude product subjected to column chromatography employing EtOAc / pet ether 
(4/6) to afford the title compound 134b as a colourless oil (0.16 g, 83%). IR (CHCb): 
Vmax 3693 (w), 3453 (w) (NH), 3023 (m), 3007 (m), 2980 (m), 2934 (m), 1706 (s) 
(CO), 1502 (s) (C=C), 1367 (s) (S(=Oh), 1168 (s) (S(=Oh), 1064-1021 (w) (S=O); 1H 
NMR (400 MHz, CDCb): 0 7.76 (2H, d, J = 7.9 Hz, H-2'" , H-6"'), 7.28 (2H, d, J = 7.9 
Hz, H-3"', H-5"'), 6.73 (1 H, d, J = 8.8 Hz, H-5), 6.68 (2H, m, H-2, H-6), 4.80 (1 H, brs, 
NH), 4.17 (2H, t, J = 4.7 Hz, H-5'), 3.98 (2H, t, J = 4.7 Hz, H-4'), 3.75 (4H, m, 2 x 
CH20), 3.73 (3H, s, OCH3), 3.29 (2H, q, J = 6.7 Hz, H-2"), 2.74 (2H, t, J = 6.7 Hz, H-
1 "), 2.39 (3H, s, CH3), 1.39 (9H, s, OC(CH3h); 13C NMR (100 MHz, CDCb): 0 155.9 
(C=O), 153.9 (C-1), 150.9 (C-4), 144.8 (C-1"'), 133.1 (C-4"'), 129.8 (C-2"'), 129.3 (C-
3), 127.9 (C-3"'), 116.6 (C-2), 113.0 (C-5), 112.0 (C-6), 78.8 (02C(CH3h), 70.0 
(CH20), 69.3 (CH20), 68.8 (CH20), 68.3 (CH20), 55.6 (OCH3), 40.6 (H-2"), 31.0 (H-
1 "), 28.4 (OC(CH3h), 21.5 (CH3); EI HRMS: m/z found 509.20675 (M+). C25H35NOsS 
(M+) requires 509.20834. 
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3-(2-tett-Butyloxycarbonylaminoethyl)-4-(3-oxahex-5-ynyloxy) 
anisole (135a) 
6' H 
l' 3' S'd" 
~O~ 
1" H 
'"1fT< 
OMe 
Propargyl alcohol (0.20 mL, 3.52 mmol) was added dropwise to a suspension of NaH 
(60% in mineral oil, 0.056 g, 2.35 mmol) in THF (10 mL) at 0 ac. The mixture was 
stirred for 1 h and the tosylate 134a (0.27 g, 0.59 mmol) added. The mixture was 
heated at reflux for 20 h. The crude product was dissolved into EtOAc (15 mL), 
washed with NH4CI (10 mL), water (2 x 10 mL), dried (MgS04), and the solvent 
evaporated under reduced pressure. The crude product was purified by column 
chromatography employing EtOAc I pet ether (3 I 7) to furnish the title compound 
135a as a colourless oil (0.15 g, 74%). IR (CHCb): Vmax 3674 (w), 3452 (m) (NH), 
3307 (m) (=C-H), 2121 (w) (C=C), 1703 (s) (CO) cm-1; 1H NMR (300 MHz, CDCb): 0 
6.78 (1H, d, J = 7.8 Hz, H-5), 6.69 (2H, m, H-2, H-6), 4.79 (1H, brs, NH), 4.26 (2H, d, 
J = 2.3 Hz, H-4'), 4.10 (2H, m, H-1'), 3.88 (2H, m, H-2'), 3.75 (3H, s, OCH3), 3.35 (2H, 
q, J = 6.7 Hz, H-2"), 2.80 (2H, t, J = 6.7 Hz, H-1"), 2.45 (1H, t, J = 2.3 Hz, H-6'), 1.42 
(9H, s, OC(CH3h); 13C NMR (75 MHz, CDCb): 0 156.0 (C=O), 153.9 (C-1), 150.9 (C-
4), 129.4 (C-3), 116.7 (C-2), 113.0 (C-5), 112.0 (C-6) , 79.6 (C-5'), 78.9 (OC(CH3h), 
74.7 (C-6'), 68.4 (CH20), 68.3 (CH20), 58.5 (C-4'), 55.7 (OCH3), 40.8 (C-2"), 31.0 (C-
1"), 28.4 (OC(CH3h); EI HRMS: m/z found 349.18937 (M+). C19H27NOS (M+) requires 
349.18892. 
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3-(2-tert-Butyloxycarbonylaminoethyl)-4-(3,6-dioxanon-8-ynyloxy) 
anisole (135b) 
3' 
l' 5' 7' ~O~~9' 
1" H ~ ~ ~4 2" ~Oy H 
5 I 3 II I "-
6:::-"" 2 0 
OMe 
Propargyl alcohol (0.24 mL, 4.0 mmol) was added dropwise to a suspension of NaH 
(60% mineral oil, 0.05 g, 2.2 mmol) in THF (10 mL) at 0 cC. The mixture was stirred 
for 1 h and the tosylate 134b (0.17 g, 0.3 mmol) added. The mixture was heated at 
reflux for 20 h. The crude product was dissolved into EtOAc (15 mL), washed with 
NH4CI (10 mL), water (2 x 10 mL), dried (MgS04), and the solvent evaporated under 
reduced pressure. The crude product was purified by column chromatography 
employing EtOAc / pet ether (4/6) to furnish the title compound 135b as a colourless 
oil (0.12 g, 91 %). IR (CHCb): Vmax 3693 (w), 3607 (w), 3453 (w), 3308 (m), 3012 (m), 
2980 (m), 2934 (m), 2120 (w) (C:C), 1706 (s) (CO), 1502 (s) (C=C); 1H NMR (400 
MHz, CDCb): 8 6.74 (1 H, d, J = 8.6 Hz, H-5), 6.66 (2H, m, H-2, H-6), 4.90 (1 H, brs, 
NH), 4.17 (2H, d, J = 2.4 Hz, H-7'), 4.05 (2H, t, J = 4.9 Hz, H-1'), 3.80 (2H, t, J = 4.9 
Hz, H-2'), 3.71 (3H, s, OCH3), 3.70 (4H, m, 2 x CH20), 3.31 (2H, q, J = 6.7 Hz, H-2"), 
2.76 (2H, t, J = 6.7 Hz, H-1"), 2.42 (1H, t, J = 2.4 Hz, H-9'), 1.39 (9H, s, OC(CH3h); 
13C NMR (100 MHz, CDCb): 8 156.0 (C=O), 153.8 (C-1), 151.0 (C-4), 129.4 (C-3), 
116.6 (C-2), 113.1 (C-5), 112.0 (C-6), 79.6 (C-8'), 78.7 (OC(CH3h), 74.6 (C-9'), 70.5 
(C-1'), 69.8 (OCH2), 69.1 (OCH2), 68.5 (OCH2), 58.3 (C-7'), 55.6 (OCH3), 40.7 (C-2"), 
31,0 (C-1"), 28.4 (OC(CH3h); EI HRMS: m/z found 393.21448 (M+). C21H31N06 (M+) 
requires 393.21514. 
4-Benzyloxybut-1-yne (146) 
3-Butyn-1-ol (2.50 mL, 33.4 mmol) was added dropwise to a suspension of NaH 
(60% mineral oil, 1.60 g, 40.1 mmol) in THF (20 mL) and the mixture was stirred for 
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30 minutes at O°C. Benzyl bromide (4.80 mL, 40.1 mmol) was added dropwise 
followed by tetrabutylammonium iodide (1.24 g, 3.4 mmol). This was stirred for 12 h 
at room temperature. The reaction mixture was quenched using MeOH (10 mL). The 
methanol was evaporated under reduced pressure. Water was added to the mixture 
and the product extracted using EtOAc (3 x 30 mL), dried over MgS04 and the 
solvent removed in vacuo. The crude product was purified by column 
chromatography using increasing amounts of ethyl acetate in petroleum ether to 
afford 146 as a colourless oil (3.45 g, 65%).120 1H NMR (400 MHz, COCh): 8 7.37 
(5H, m, ArH), 4.58 (2H, s, ArCH20), 3.63 (2H, t, J = 7.0, H-4), 2.52 (2H, td, J = 2.6, 
7.0, H-3), 2.02 (1H, t, J= 2.6, H-1); 13C NMR (100 MHz, COCh): 8138.1 (C-1'), 128.4 
(C-2', C-6'), 127.6 (C-3', C-5'), 127.6 (C-4') , 81.3 (C-2), 72.9 (C-1), 69.4 (ArCH20), 
68.2 (C-4), 19.9 (C-3). 
4-(4-Methoxybenzyloxy)but-1-yne (147a) 
To a stirred suspension of NaH (0.51 g, 21.4 mmol) in OMSO (2 mL) was added 
dropwise a THF solution (30 mL) of 3-butyn-1-01 (1.08 mL, 14.3 mmol) under 
nitrogen. After ca. 30 min at 0 °C, a solution of p-methoxybenzyl chloride (2.90 mL, 
21.4 mmol) in TH F (30 mL) was added and stirring continued for 12 h. The mixture 
was poured into saturated NH4CI (50 mL) and then extracted with ether (3 x 50 mL). 
The organic extracts were washed with sat. NaCI (2 x 100 mL), dried over MgS04 
and the solvent evaporated under reduced pressure. The product was purified by 
column chromatography to afford a colourless oil (2.46 g, 91%).121 1H NMR (300 
MHz, COCI3): 8 7.27 (2H, d, J = 8.6 Hz, H-2', H-6'), 6.88 (2H, d, J = 8.6 Hz, H-3', H-
5'), 4.49 (2H, s, ArCH20), 3.80 (3H, s, OCH3), 3.58 (2H, t, J = 7.0 Hz, H-4), 2.49 (2H, 
td, J = 2.6,7.0 Hz, H-3), 1.99 (1H, t, J = 2.6 Hz, H-1); 13C NMR (75 MHz, COCh): 8 
159.3 (C-4'), 130.1 (C-1'), 129.3 (C-2', C-6'), 113.8 (C-3', C-5'), 81.3 (C-2), 72.6 
(ArCH20), 69.2 (C-1), 67.8 (C-4), 55.2 (OCH3), 19.8 (C-3). 
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4-(4-Methoxyphenoxy)but-1-yne (147b) 
~340n'/} 1~ "/ 3' 9' 1 4, ~ OMe 
A mixture of 3-butyn-1-01 (1,00 mL, 13.4 mmol), p-methoxyphenol (4.98 g, 40.1 
mmol), triphenylphosphine (4.56 g, 17.4 mmol) and diisopropylazodicarboxylate (3.40 
mL, 17.4 mmol) in CH2CI2 (15 mL) were heated at reflux for 20 h. The solvent was 
removed in vacuo and the crude product purified by column chromatography 
employing ethyl acetate 1 pet ether (1 19) to give 147b as colourless crystals (0.50 g, 
51 %). mp: 44-45 °c (from pet ether/EtOAc); 1H NMR (300 MHz, CDCb): 86.87 (2H, 
d, J = 9.2 Hz, ArH), 6.82 (2H, d, J = 9.2 Hz, ArH), 4.05 (2H, t, J = 7.1 Hz, H-4), 3.77 
(3H, s, OCH3), 2.64 (2H, td, J = 2.8,7.1 Hz, H-3), 2.00 (1H, t, J = 2.8 Hz, H-1); 13C 
NMR (75 MHz, CDCb): 8 154.2 (C-4'), 152.6 (C-1'), 115.9 (C-2', C-6'), 114.7 (C-3', C-
5'), 80.6 (C-2), 69.8 (C-1), 66.9 (C-4), 55.7 (OCH3), 19.6 (C-3); Found C, 74.65; H, 
6.95. C11H1202 requires C, 74.98; H, 6.86. 
4-(2-Tetrahydropyranyloxy) but-1-yne (148) 
4' 
~;o 
To a stirred ice-cold solution of 3-butyn-1-01 (5.00 mL, 66.8 mmol) and 3,4-dihydro-
2H-pyran (6.70 mL, 73.5 mmol) in dry dichloromethane (80 mL) was added p-
toluenesulphonic acid (0.13 g, 0.7 mmol). The mixture was stirred for 10 min, the ice-
bath removed and the solution stirred at rt for 1 h. The mixture was partitioned 
between ether (150 mL) and a solution made up of saturated brine (40 mL), 
saturated sodium bicarbonate (40 mL) and of water (50 mL). The organic phase was 
washed twice with saturated brine (100 mL), dried (MgS04) and the solvent 
evaporated. The product was purified by distillation at 51 °c 10.7 mm Hg to give a 
colourless liquid (9.76 g, 95%).122 1H NMR (400 MHz, CDCb): 84.62 (1H, t, J = 3.2 
Hz, H-2'), 3.86 (1 H, m, H-6'), 3.80 (1 H, m, H-4), 3.55 (1 H, m, H-4), 3.49 (1 H, m, H-6'), 
2.46 (2H, td, J = 2.6, 7.0 Hz, H-3), 1.95 (1 H, t, J = 2.6 Hz, H-1), 1.81 (1 H, m, H-5'), 
1.69 (1 H, tt, H-3'), 1.58 (1 H, m, H-3') 1.56 (2H, m, H-4'), 1.51 (1 H, m, H-5'); 13C NMR 
- 138-
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 6: Experimental 
(100 MHz, CDCb): D 98.7 (C-2'), 81.3 (C-2), 69.0 (C-1), 65.4 (C-4), 62.1 (C-6'), 30.4 
(C-3'), 25.3 (C-4'), 19.8 (C-3), 19.3 (C-5'). 
5-lodouridine (110) 
A suspension of uridine (10.00 g, 41.0 mmol) in methanol (200 mL) was sequentially 
treated with silver nitrate (6.97 g, 41.0 mmol) and iodine (10.41 g, 41.0 mmol) at O°C, 
under nitrogen. The mixture was stirred for 30 minutes. A pale yellow precipitate 
formed which was filtered through a pad of Celite and washed with large volumes of 
methanol. The filtrate was concentrated in vacuo and methylene chloride added to 
induce crystallization. The product was recrystallized from methanol to afford 5-
iodouridine as colourless crystals (12.63 g, 83%). [a]~ -28.5° (c 1.00, MeOH); mp: 
205-206 °c (dec) (1it. 114,115 207-209 °C); 1H NMR (400 MHz, DMSO-ds) D 11.63 (1H, 
s, NH), 8.45 (1H, s, H-6), 5.71 (1H, d, J = 5.0 Hz, H-1'), 5.35 (1H, d, J = 5.0, 2'-OH, 
exchanges with D20), 5.20 (1 H, t, J = 4.4 Hz, 5'-OH, exchanges with D20), 5.01 (1 H, 
d, J = 5.0 Hz, 3'-OH, exchanges with D20), 4.02 (1 H, dd, J = 5.0, 9.4 Hz, H-2'), 3.97 
(1 H, dd, J = 5.0, 9.4 Hz, H-3'), 3.85 (1 H, m, H-4'), 3.67 (1 H, ddd, J = 2.8, 4.4, 12.0 
Hz, H-5'), 3.56 (1 H, ddd, J = 2.8,4.4, 12.0 Hz, H-5'); 13C NMR (100 MHz, DMSO-ds) 
D 161.1 (C-4), 151.0 (C-2), 145.8 (C-6), 89.0 (C-1'), 85.4 (C-4'), 74.6 (C-2'), 70.1 (C-
3'), 69.9 (C-5), 60.9 (C-5'); Found: C, 29.92; H, 3.05; N, 8.00. CgH111N20s requires C, 
29.21; H, 3.00; N, 7.57. 
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2' ,3' -O-isopropyl idene-5-iodou rid ine (142) 
o 
~71 
HOioJ, 
4H' Ox 
Experimental 
A mixture of 5-iodouridine 110 (1.00 g, 2.7 mmol) in acetone (40 mL), anhydrous 
copper sulphate (0.43 g, 2.7 mmol) and sulphuric acid (0.1 mL, 2.7 mmol) was stirred 
between 0-25 °c for 4 h. The reaction mixture was quenched with potassium 
hydroxide (0.30 g, 5.4 mmol). The precipitate formed was filtered through a pad of 
Celite and then washed with large volumes of methanol. The solvent was evaporated 
under reduced pressure to give a crude product (1.05 g, 95%) which was 
recrystallised from methanol to give white fluffy needles. [a]~ -45.r (c 1.00, MeOH); 
mp: 216-218 °c (lit. 13o 225-227 °C); 1H NMR (300 MHz, DMSO-d6): 8 11.71 (1H, brs, 
NH), 8.32 (1 H, s, H-6), 5.82 (1 H, d, J = 2.5 Hz, H-1'), 5.15 (1 H, t, J = 5.1 Hz, 5'-OH), 
4.91 (1 H, dd, J = 2.5, 6.5 Hz, H-2'), 4.75 (1 H, dd, J = 3.8, 6.5, H-3'), 4.09 (1 H, q, J = 
3.8 Hz, H-4'), 3.58 (2H, m, H-5'), 1.48 (3H, s, CH3), 1.28 (3H, s, CH3); 13C NMR (75 
MHz, DMSO): 8 160.5 (C-4) , 150.0 (C-2), 146.0 (C-6), 112.8 (02C(CH3h), 91.3 (C-
1'), 86.8 (C-4'), 83.8 (C-2'), 80.2 (C-3'), 69.4 (C-5), 61.1 (C-5'), 26.9 (02C(CH3h), 
25.1 (02C(CH3h); Found: C, 35.52; H, 3.54; N, 6.87. C12H151N206 requires C, 35.14; 
H, 3.69; N, 6.83. 
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2' ,3'-O-(lsopropylidene )-5'-O-triisopropylsilyl-5-iodouridine (143a) 
o 
~Jz71 
rfi °'tOJ /'--.. 'H: Ox 
Nucleoside 142 (0.50 g, 1.2 mmol) was dissolved in DMF (5 mL) and imidazole (0.17 
g, 2.4 mmol) was added with stirring. Triisopropylsilyl chloride (0.4 mL, 1.8 mmol) 
was added dropwise and the mixture stirred at room temperature for 24 h. The work-
up involved adding EtOAc (20 mL) to the contents of the flask and washing with 
water (3 x 10 mL). The organic layer was dried over anhydrous MgS04, filtered and 
the solvent evaporated under reduced pressure. The residue was purified by column 
chromatography using 20% EtOAc in petroleum ether to afford the title compound 
143a as a colourless oil (0.53 g, 77%). [a]~ -44.4 0 (c 1.10, CHCb); IR (CHCb): Vmax 
3380 (w) (NH), 1718 (s) (CO), 1693 (s) (CO) cm-1; 1H NMR (300 MHz, CDCb): B 8.51 
(1 H, brs, NH), 7.89 (1 H, s, H-6), 5.90 (1 H, d, J = 3.2, H-1 '), 4.85 (1 H, dd, J = 2.8, 6.4 
Hz, H-3'), 4.70 (1 H, dd, J = 3.2, 6.4 Hz, H-2'), 4.30 (1 H, m, H-4'), 4.01 (1 H, dd, J = 
3.2, 11.6 Hz, H-5'), 3.89 (1 H, dd, J = 2.6, 11.6 Hz, H-5'), 1.59 (3H, s, CH3), 1.36 (3H, 
s, CH3), 1.18 (3H, m, 3 x CH), 1.09 (18H, d, J = 6.0 Hz, 6 x CH3); 13C NMR (75 MHz, 
CDCI3): B 159.6 (C-4), 149.6 (C-2), 144.6 (C-6), 114.5 (02C(CH3)2), 92.1 (C-1') 86.5 
(C-4'), 85.0 (C-2'), 80.1 (C-3'), 68.4 (C-5), 63.3 (C-5'), 27.2 (02C(CH3h), 25.3 
(02C(CH3h), 18.0 (3 x CH(CH3h), 12.0 (3 x CH(CH3h). 
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5' -0-( terl-Butyld i phenylsilyl )-5-iodou rid i ne (144) 
5-iodouridine 110 (2.21 g, 6.0 mmol) was dissolved in dry DMF (20 mL) and 
imidazole (0.81 g, 12.0 mmol) added. tert-Butyldiphenylsilyl chloride (2.3 mL, 9.0 
mmol) was added dropwise under nitrogen and the mixture stirred at room 
temperature for 12 h. The mixture was diluted with NaHC03 and extracted with 
EtOAc (3 x 50 mL). The organic layer was washed with H20 (3 x 100 mL), dried over 
MgS04 and the solvent evaporated under reduced pressure. Purification by column 
chromatography employing petroleum ether I ethyl acetate (1 I 1) yielded 144 as a 
white solid (1.79 g, 54%). [a]2~ -8.6° (c 1.00, MeOH); mp 194-195 °c (from 
MeOH/CH2Cb); 1H NMR (400 MHz, CD30D): 6 8.03 (1 H, s, H-6), 7.71 (4H, m, ArH), 
7.43 (2H, m, ArH), 7.41 (4H, m, ArH), 5.93 (1H, d, J = 4.8 Hz, H-1'), 4.23 (2H, m, H-
2', H-3'), 4.05 (1 H, m, H-4'), 3.98 (1 H, dd, J = 2.1, 11.7 Hz, H-5'), 3.83 (1 H, dd, J = 
3.3,11.7 Hz, H-5'), 1.12 (9H, s, C(CH3h); 13C NMR (100 MHz, CD30D): 6 161.4 (C-
4), 150.4 (C-2), 144.8 (C-6), 135.7 (C-2", C-6"), 135.5 (C-2", C-6"), 133.0 (C-1"), 
132.7 (C-1"), 130.0 (C-4") , 129.9 (C-4") , 127.9 (C-3", C-5"), 127.8 (C-3", C-5"), 88.9 
(C-1'), 85.5 (C-4'), 74.5 (C-2'), 70.4 (C-3'), 68.3 (C-5), 63.9 (C-5'), 26.6 (C(CH3h), 
19.1 (C(CH3h); FABHRMS: m/z found 609.09286 (M+ + H). C25H291N206Si (M+ + H) 
requires 609.09178. 
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2' ,5' -0-8;5-( tett-Butyld i phenylsi lyl)-5-iodou rid i ne (145) 
o 
~'ll 
RO~oJ, 
41-<:' 
HO OR 
Q 
R= 1-st-f ((2" V 3" 
4" 
Experimental 
Obtained from the 144 procedure as a white solid (1.51 g, 30%). [aY~ +25.6° (c 1.98, 
CHCh); mp: 162-164 °C (from MeOH/CH2Cb); IR (CHCh): Vmax 3383 (w) (NH), 1722 
(s) (CO), 1694 (s) (CO) cm-1; 1H NMR (300 MHz, COCh): b 8.21 (1 H, brs, NH), 7.60 -
7.26 (20H, m, ArH), 7.37 (1H, s, H-6), 6.12 (1H, d, J = 6.9 Hz, H-1'), 4.39 (2H, m, H-
2', H-3'), 4.18 (1 H, brs, H-4'), 3.86 (1 H, dd, J = 1.8, 11.7 Hz, H-5'), 3.72 (1 H, dd, J = 
2.4,11.7 Hz, H-5'), 3.15 (1H, d, J = 1.2 Hz, OH), 1.12 (9H, s, C(CH3h), 0.94 (9H, s, 
C(CH3h); 13C NMR (100 MHz, COCh): b 159.2 (C-4), 149.6 (C-2), 143.2 (C-6), 135.6, 
135.6, 135.4, 135.3 (C-2", C-6") , 132.3, 132.0, 131.9, 131.5 (C-1"), 130.7, 130.5, 
130.2, 130.0 (C-4") , 128.3, 128.1, 128.0, 128.0 (C-3", C-5"), 86.9 (C-1'), 85.4 (C-4'), 
75.2 (C-2'), 71.7 (C-3'), 69.8 (C-5), 64.3 (C-5'), 27.2 (C(CH3h), 26.9 (C(CH3h), 19.2 
(C(CH3h), 19.0 (C(CH3h); FABHRMS: m/z found 847.20800 (M+ + H). 
C41H471N20sSi2 (M+ + H) requires 847.20955. 
2' , 3' -Isopropyl idene-5' -0-( tett-butyld i phenylsi lyl)-5-iodourid i ne 
(143b) 
4" 0 
~3"~&1 
-t-
y ,. J{:l 
6
Si o~~ 0 I ~ 4' l' 
~ 3' 2' 
°XO 
To a solution of the nucleoside 144 (3.53 g, 5.8 mmol) in dry CH2CI2 (40 mL) was 
added 2,2'-dimethoxypropane (20 mL) and a catalytic amount of p-toluenesulphonic 
acid monohydrate. The mixture was stirred at room temperature for 24 h. The solvent 
was concentrated in vacuo and the compound subjected to column chromatography 
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using ethyl acetate I petroleum ether (4 16) to give a colourless solid (2.84 g, 76%). 
[a]~ -11.2° (c 1.00, CHCb); mp: 217-218 °C (from MeOH/CHCb); IR (CHCb): Vmax 
3380 (w) (NH), 1718 (s) (CO), 1694 (s) (CO) cm-1; 1H NMR (300 MHz, CDCb): 88.80 
(1 H, brs, NH), 7.89 (1 H, s, H-6), 7.65 (4H, m, 2 x H-2", 2 x H-6"), 7.43 (4H, m, 2 x H-
3",2 X H-5"), 7.38 (2H, m, 2 x H-4") , 5.82 (1H, d, J = 3.3 Hz, H-1'), 4.77 (1H, dd, J = 
3.3, 6.3 Hz, H-2'), 4.70 (1 H, dd, J = 3.0, 6.3 Hz, H-3'), 4.29 (1 H, m, H-4'), 3.98 (1 H, 
dd, J = 3.0, 11.7 Hz, H-5'), 3.82 (1 H, dd, J = 4.2, 11.7 Hz, H-5'), 1.57 (3H, s, 
02C(CH3h), 1.33 (3H, s, 02C(CH3)2), 1.09 (9H, s, C(CH3h); 13C NMR (75 MHz, 
CDCb): 8 159.8 (C-4) , 149.6 (C-2), 144.9 (C-6), 135.6 (C-2", C-6"), 135.5 (C-2", C-
6"),132.7 (C-1"), 132.6 (C-1"), 130.1 (C-4") , 130.0 (C-4"), 127.9 (C-3", C-5"), 127.9 
(C-3", C-5"), 114.4 (02C(CH3h), 92.8 (C-1'), 86.5 (C-4'), 84.7 (C-2'), 80.4 (C-3'), 68.5 
(C-5), 64.0 (C-5'), 27.2 (02C(CH3h), 27.1 (C(CH3h), 25.3 (02C(CH3h), 19.3 
(C(CH3h); Found C, 52.10; H, 5.15; N, 4.34. C2sH331N20sSi requires C, 51.85; H, 
5.13; N, 4.32. 
N-Benzoyl-2' ,3' -isopropylidene-S' -0-( tert-butyldiphenylsi Iyl)-S-
iodouridine (162) 
NaH (60% in mineral oil, 0.15 g, 6.1 mmol) was added to a solution of 143b (1.97 g, 
3.0 mmol) dissolved in freshly distilled 1,2-dimethoxyethane (DME) (30 mL) at 0 °C. 
The mixture was stirred at room temperature for 30 min and cooled to -78°C for 
another 30 min. Benzoyl chloride (0.4 mL, 3.0 mmol) was added dropwise and the 
mixture allowed to warm to room temperature over 1 h. The solvent was removed 
under reduced pressure and the residual mass dissolved in ethyl acetate (50 mL). 
The organic layer was washed with aq. NH4CI (40 mL), water (2 x 40 mL), dried with 
MgS04 and filtered. After removal of the solvent under reduced pressure, the residue 
was purified by column chromatography using petroleum ether I EtOAc (7 I 3) to 
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afford the title compound 162 as a colourless solid (1.50 g, 65%). 1H NMR (400 MHz, 
COCh): 88.07 (1 H, s, H-6), 7.88 (2H, d, J = 7.6 Hz, H-2"', H-6"'), 7.68 (4H, m, 2 x H-
2", 2 X H-6"), 7.62 (1 H, t, J = 7.6 Hz, H-4"') , 7.43 (8H, m, 2 x H-3", 2 x H-4", 2 x H-5", 
H-3"', H-5"'), 5.83 (1 H, d, J = 2.8 Hz, H-1'), 4.86 (1 H, d, J = 2.8, 6.3 Hz, H-2'), 4.68 
(1 H, d, J = 3.3, 6.3 Hz, H-3'), 4.33 (1 H, m, H-4'), 3.98 (1 H, d, J = 3.0, 11.7 Hz, H-5'), 
3.82 (1 H, d, J = 4.4, 11.7 Hz, H-5'), 1.53 (3H, s, 02C(CH3h), 1.30 (3H, s, 02C(CH3h) , 
1.12 (9H, s, C(CH3h); 13C NMR (100 MHz, COCh): 8 167.4 (ArGO), 158.8 (C-4), 
148.9 (C-2), 144.9 (C-6), 135.6 (C-2", C-6"), 135.5 (C-2", C-6"), 135.1 (C-4"') 132.6 
(C-4"), 132.6 (C-4") , 130.5 (C-2"', 6"'), 130.1 (C-1"), 130.1 (C-1" ), 129.1 (C-1"'), 
127.9 (C-3", C-5"), 127.9 (C-3", C-5"), 127.9 (C-3"', C-5"'), 114.2 (02G(CH3h), 93.8 
(C-1'), 87.0 (C-4'), 84.9 (C-3'), 80.7 (C-2'), 68.1 (C-5), 64.1 (C-5'), 27.1 (02C(GH3h), 
27.1 (C(GH3h), 25.2 (02C(GH3h), 19.2 (G(CH3h). 
N-Benzoyl-S' -0-( tert-butyld iphenylsi Iyl )-S-iodou rid ine (163) 
Q oyQ::::. I 1'" 2'" ~ °eco s. ~3 4 -t-6'~~>oy 'h' I 
I \2" ~3H~: 
o 3" HO OH 
4" 
A saturated solution of HCI in ethyl acetate (40 mL) was added to the nucleoside 162 
(5.01 g, 6.7 mmol). The mixture was stirred for 30 min and the reaction quenched 
with saturated Na2C03. The organic layer was washed with water (3 x 20 mL), dried 
over MgS04, filtered and the solvent removed in vacuo. Purification by column 
chromatography yielded a colourless solid (3.09 g, 82%). [a.]~ +2.2° (c 0.94, CHCh); 
mp: 79-82 °C; IR (CHCh): Vmax 3534 (OH), 1754 (m) (CO), 1701 (m) (CO), 1663 (s) 
(C=C) cm-1; 1H NMR (400 MHz, COCh): 88.19 (1H, s, H-6), 7.90 (2H, d, J = 7.5 Hz, 
H-2"', H-6"'), 7.65 (5H, m, 2 x H-2", 2 x H-6", H-4"') , 7.46 (8H, m, 2 x H-3", 2 x H-4", 
2 x H-5", H-3"', H-5"') , 5.84 (1H, d, J = 5.3 Hz, H-1'), 4.34 (1H, t, J = 5.3 Hz, H-2'), 
4.28 (1H, m, H-3'), 4.19 (1H, d, J = 2.4 Hz, H-4'), 3.97 (1H, dd, J = 2.0,12.0 Hz, H-
5'),3.79 (1H, dd, J = 2.8,12.0 Hz, H-5'), 1.12 (9H, s, C(CH3h); 13C NMR (100 MHz, 
COCh): 8 167.5 (C6H50GN), 158.8 (C-4), 150.2 (C-2), 143.9 (C-6), 135.7 (C-2", C-
6"), 135.6 (C-2", C-6"), 135.5 (C-4"') , 133.7 (C-4") , 133.7 (C-4"), 132.5 (C-1"), 132.3 
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(C-1"), 130.9 (C-1"'), 130.2 (C-2"', C-6"'), 128.5 (C-3"', C-5"'), 128.1 (C-3", C-5"), 
128.1 (C-3", C-5"), 91.3 (C-1'), 86.6 (C-4'), 76.1 (C-3'), 71.3 (C-2'), 68.5 (C-5), 63.7 
(C-5'), 27.2 (C(CH3h), 19.4 (C(CH3h); Found C, 53.90; H, 4.76; N, 3.79. 
C32H331N207Si requires C, 53.94; H, 4.67; N, 3.93. 
General Procedure for Sonogashira Coupling (GP1) 
Distilled triethylamine (2 equiv.), protected butyne (2 equiv.) and THF (5 mL) were 
added to a stirring solution of 5-iodouridine (1 equiv.) in dry DMF (2.5 mL). The 
mixture was thoroughly degassed with nitrogen for 1 h. Cui (0.5 equiv.) and (PPh3)4 
Pd (0.1 equiv.) were added to the degassed solution under a nitrogen atmosphere. 
The mixture was left stirring at room temperature for 4 h. The solvent was removed 
under reduced pressure and the residue dissolved in CHCb (50 mL), washed twice 
successively with 25 mL portions of 5% aq disodium EDT A, water and then dried 
over MgS04 . Following removal of solvent, the residue was purified by column 
chromatography using EtOAc in petroleum ether. 
5-(4-Benzyloxybutyn-1-yl)-2' ,3'-O-(isopropylidene )-5'-O-triisopropyl 
silyluridine (149) 
~4'" 3" I 4" 0 0 3'" 1'" 
2'" 
According to GP1: Nucleoside 143 (0.68 g, 1.2 mmol), 4-benzyloxybut-1-yne 146 
(0.29 g, 1.8 mmol), Cui (0.05 g, 0.2 mmol), (PPh3)4 Pd (0.14 g, 0.12 mmol), 24 h. 
Purification by column chromatography using 20% EtOAc in petroleum ether gave 
149 as a yellow oil (0.20 g, 36%) and a cyclic by-product 150 as a colourless oil 
(0.077 g, 14%). 
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149: IR (CHCh): Vmax 3691 (w), 3384 (w) (NH), 3029 (w), 2946 (w), 2867 (w), 1718 
(s) (CO), 1602 (m) (C=C) cm-1; 1H NMR (400 MHz, COCh): 87.68 (1H, s, H-6), 7.30 
(SH, m, ArH), S.92 (1H, d, J = 3.2 Hz, H-1'), 4.82 (1H, dd, J = 3.3, 6.2 Hz, H-3'), 4.68 
(1 H, dd, J = 3.2, 6.2 Hz, H-2'), 4.S3 (2H, s, ArCH20), 4.27 (1 H, m, H-4'), 3.97 (1 H, dd, 
J = 2.4, 11.4 Hz, H-S'), 3.87 (1 H, dd, J = 3.0, 11.4 Hz, H-S'), 3.62 (2H, t, J = 7.4 Hz, 
H-4"), 2.68 (2H, t, J = 7.4 Hz, H-3"), 1.S7 (3H, s, 02C(CH3h), 1.34 (3H, s, 
02C(CH3h), 1.10 (3H, m, 3 x CH(CH3h), 1.0S (18H, d, J = 6.4 Hz, 3 x CH(CH3h); 13C 
NMR (100 MHz, COCh): 8 161.8 (C-4), 149.3 (C-2), 142.1 (C-6), 138.0 (C-1"'), 128.3 
(C-2"', 6"'), 127.7 (C-3"', SIll), 127.6 (C-4"'), 114.3 (OC(CH3h), 100.S (C-2"), 91.8 (C-
1 '), 91.4 (C-1 "), 86.4 (C-4'), 84.9 (C-2'), 80.1 (C-3'), 72.9 (ArCH20), 72.2 (C-S), 68.1 
(C-4") , 63.3 (C-S'), 27.2 (02C(CH3h), 2S.3 (02C(CH3h), 20.9 (C-3"), 17.9 (CH(CH3h), 
11.8 (CH(CH3h). 
6-(2-Benzyloxylethyl)-3-(2' ,3' -isopropylidene-S' -O-triisopropylsilyl 
tetrahydrofuran-2-yl)-3H-furo [2,3-d] pyrimidin-2-one (1S0) 
2'" 3'" 
Y 0y,~~OJcI '"< >,. >-Si-~~6 1" A 4' l' 4 5 
3' 2' 
o~ 
150: [a]~ -0.6 0 (c 2.8, CHCh); IR (CHCh): V max 3691 (w), 3384 (w) (NH), 294S (m), 
2868 (m), 1716 (s) (CO), 1679 (s) (C=C) cm-1; 1H NMR (400 MHz, COCh): 8 8.34 
(1H, s, H-4), 7.30 (SH, m, ArH), 6.13 (1H, d, J= 0.9 Hz, H-S), 6.10 (1H, d, J= 1.8 Hz, 
H-1'), 4.82 (1H, dd, J = 3.6, 6.2 Hz, H-3'), 4.76 (1H, dd, J = 1.8,6.2 Hz, H-2'), 4.S2 
(2H, s, OCH2Ar) , 4.39 (1 H, m, H-4'), 4.08 (1 H, dd, J = 2.4, 11.7 Hz, H-S'), 3.90 (1 H, 
dd, J = 3.6, 11.7 Hz, H-S'), 3.77 (2H, t, J = 6.S Hz, H-2"), 2.94 (2H, td, J = 0.9, 6.S Hz, 
H-1 "), 1.S9 (3H, s, 02C(CH3h), 1.3S (3H, 5, 02C(CH3h), 1.08 (3H, m, CH(CH3h), 
1.0S (9H, d, J = S.4 Hz, CH(CH3h), 1.04 (9H, d, J = 6.0 Hz, CH(CH3h); 13C NMR 
(100 MHz, COCh): 8171.9 (C-7a), 1S6.7 (C-6), 1S4.S (C-2), 137.8 (C-1"'), 13S.6 (C-
4), 128.3 (C-2"', C-6"') , 127.7 (C-3"', C-S"'), 127.6 (C-4"') , 113.9 (02C(CH3h), 107.3 
(C-4a), 100.1 (C-S), 94.2 (C-1 '), 88.1 (C-4'), 86.4 (C-2'), 79.3 (C-3'), 73.1 (OCH2Ar), 
66.7 (C-2"), 63.2 (C-S'), 29.2 (C-1"), 27.2 (02C(CH3h), 2S.3 (02C(CH3h), 17.9 
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(CH(CH3h), 11.8 (CH(CH3h); FABHRMS: mlz found 599.31533 (M+ + Na). 
C32H46N207Si (M+ + Na) requires 599.31524. 
2' ,3' -Isopropylidene-S' -O-(triisopropylsilyl)-S-[4-(4-methoxy 
phenoxy)-butyn-1-yl]uridine (149b) 
o 2" 3" 4" 0'0'" 2'" 
1" Y" 3'" ~ 1 4", ~ OCH3 
According to GP1: Nucleoside 143a (0.26 g, 0.5 mmol), 4-(4-methoxyphenoxy)but-1-
yne 147b (0.02 g, 1.4 mmol), (Ph3P)4Pd (0.054 g, 0.05 mmol), Cui (0.026 g, 0.14 
mmol), Et3N (0.13 mL, 0.9 mmol), DMF (1.3 mL), THF (2.0 mL), rt, 22 h. Purification 
by column chromatography employing petroleum ether I EtOAc (2 I 3) gave a pale 
yellow oil (0.14 g, 50%). 
IR (CHCb): Vmax 1H NMR (400 MHz, CDCb): () 9.16 (1H, brs, NH), 7.73 (1H, s, H-6), 
6.84 (2H, d, J = 9.4 Hz, ArH), 6.82 (2H, d, J = 9.4 Hz, ArH), 5.94 (1 H, d, J = 3.2 Hz, 
H-1'), 4.84 (1 H, dd, J = 2.8, 6.4 Hz, H-3'), 4.70 (1 H, dd, J = 3.2, 6.4 Hz, H-2'), 4.29 
(1 H, m, H-4'), 4.08 (2H, t, J = 7.3 Hz, H-4"), 4.00 (1 H, dd, J = 2.2, 11.4 Hz, H-5'), 3.89 
(1 H, dd, J = 3.0, 11.4 Hz, H-5'), 3.75 (3H, s, OCH3), 2.83 (2H, t, J = 7.3 Hz, H-3"), 
1.58 (3H, s, 02C(CH3h), 1.35 (3H, s, 02C(CH3h), 1.16 (3H, m, 3 x CH(CH3h), 1.07 
(18H, d, J = 6.4 Hz, 3 x CH(CH3h); 13C NMR (75 MHz, CDCb): () 161.6 (C-4) , 154.1 
(C-4"'), 152.5 (C-1"'), 149.1 (C-2), 142.3 (C-6), 115.8 (C-3"', C-5"'), 114.6 (C-2"', C-
6'"), 114.3 (02C(CH3h), 100.3 (C-2"), 91.9 (C-1"), 90.8 (C-1'), 86.5 (C-4'), 85.0 (C-2'), 
80.0 (C-3'), 72.5 (C-5), 66.6 (C-4"), 63.3 (C-5'), 55.7 (OCH3), 27.2 (02C(CH3h), 25.3 
(02C(CH3h), 20.6 (C-3"), 17.9 (CH(CH3h), 11.8 (CH(CH3h). 
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5-[4-(2-Tetrahydropyranyloxy)-but-1-ynyl]-5'-O-( terl-butyldiphenyl 
silyl)uridine (154) 
o 
QI ~ 4 ~ A1!1 ~6"Si o~~ 0
2" 1 ~ 4' l' 
3" ,Q 3' 2' 
2'" 3'" 4'" 0lg0 
1":'-:::::: 2"" 6"" 
;;/' 3"" 5"" 
4"" 
4" HO OH 
According to GP1: Triethylamine (0.8 mL, 5.6 mmol), nucleoside 144 (1.70 g, 2.8 
mmol), dry THF (30 mL), DMF (15 mL), 4-(2-tetrahydropyranyloxy)but-1-yne 148 
(1.29 g, 8.4 mmol), (Ph3P)4Pd (0.33 g, 0.3 mmol) and Cui (0.27 g, 1.4 mmol). The 
mixture was stirred for 3 hours and the product purified by column chromatography 
using petroleum ether I ethyl acetate (1 I 8) to give 154 as a yellow solid (1.73 g, 
98%). 
[at~ +31.0° (c 1.09, CHCh); mp 165-167 °C (from CHCh); IR (CHCh): Vmax 3690 (w), 
3386 (w) (NH), 3500 (br) (OH), 2947 (m), 2933 (m), 2860 (m), 2241 (w) (C=C), 1694 
(s) (CO), 1620 (w) (C=C) cm-1 ; 1H NMR (300 MHz, DMSO-ds): () 11.59 (1H, s, NH), 
7.79 (1H, s, H-6), 7.62 (4H, m, ArH), 7.44 (6H, m, ArH), 5.80 (1H, d, J = 5.9 Hz, H-1'), 
5.41 (1 H, d, J = 5.1 Hz, 2'-OH), 5.10 (1 H, d, J = 4.2 Hz, 3'-OH), 4.52 (1 H, dd, J = 3.3, 
3.6 Hz, H-2""), 4.11 (1 H, t, J = 5.1, 5.9 Hz, H-2'), 4.04 (1 H, d, J = 4.2 Hz, H-3'), 3.92 
(1 H, m, H-4'), 3.84 (1 H, dd, J = 2.9, 11.6 Hz, H-5'), 3.71 (2H, m, H-5', H-6""), 3.52 
(1H, m, H-4"') , 3.35 (1H, m, H-6""), 3.32 (1H, m, H-4"'), 2.41 (2H, t, J = 6.9 Hz, H-3"'), 
1.65 (2H, m, H-4""), 1.56 (2H, m, H-3""), 1.41 (2H, m, H-5""), 1.02 (9H, s, C(CH3h); 
13C NMR (75 MHz, DMSO-ds): () 161.4 (C-4), 149.6 (C-2), 142.1 (C-6) , 135.1 (C-2", 
C-6"), 134.9 (C-2", C-6"), 132.4 (C-1"),132.2 (C-1"), 129.9 (C-4"), 129.8 (C-4") 127.9 
(C-3", C-5"), 127.9 (C-3", C-5"), 99.4 (C-2"'), 97.8 (C-2""), 90.5 (C-1"'), 87.7 (C-1'), 
84.4 (C-4'), 73.3 (C-2'), 72.9 (C-5), 69.7 (C-3'), 64.6 (C-4"') , 63.8 (C-5'), 61.3 (C-6""), 
30.0 (CH2), 26.6 (C(CH3h), 24.9 (CH2), 20.2 (C-3"'), 18.9 (C(CH3h), 18.7 (CH2); 
Found C, 64.05; H, 6.04; N, 4.21. C34H42N20aSi requires C, 64.33; H, 6.67; N, 4.41. 
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N-Benzoyl-5' -0-( terl-butyld i phenylsi Iyl )-5-[4-( 2-tetrahyd ropyranyl 
oxy)butynyl]uridine (164) 
Q 0 ,(j:: I y,y ~ 0 0 
4"'" 1- y3 Si-~1 5 0" # 4' l' ~ 2" I 3' 2' J) 5"'" 1"" 3'"'' 2'''' ~ 4"" 2"'" 3"" h- 3" HO OH 
4" 
According to GP1; Nucleoside 163 (1,12 g, 1,6 mmol), Et3N (0.43 mL, 3,1 mmol),4-
(2-tetrahydropyranyloxy)but-1-yne 148 (0.48 g, 3,1 mmol), (Ph3P)4Pd (0,18 g, 0.16 
mmol) and Cui (0,15 g, 0,8 mmol), DMF (2 mL), THF (20 mL), rt, 2 h, Column 
chromatography employing EtOAc / pet ether (1 / 1) gave a colourless oil (0,89 g, 
77%), 
IR (CHCb): Vmax 3693 (w), 3531 (br) (OH), 3026 (w), 3011 (w), 2947 (m), 2860 (w), 
2241 (w) (C:C), 1755 (s) (CO), 1708 (s) (CO), 1669 (s) (CO); 1 H NMR (400 MHz, 
CDCb): 3 8.02 (1 H, s, H-6), 7,89 (2H, m, H-2111/6111), 7,65 (5H, m, 2 x H-2"/6", H-4111), 
7.44 (8H, m, 2 x H-3"/5", 2 x H-4", 2 x H-3111/5111), 5.82 (1H, d, J = 5,2 Hz, H-1'), 4,56 
(1 H, m, H-2"111), 4,30 (1 H, t, J = 5,2 Hz, H-2'), 4,25 (1 H, t, J = 5.2 Hz, H-3'), 4.15 (1 H, 
m, H-4'), 4.03 (1 H, brs, OH), 3.95 (1 H, dd, J = 2.4, 11,6 Hz, H-5'), 3,81 (1 H, m, H-
6"111),3,73 (2H, m, H-5', H-4""), 3.45 (2H, m, H-4"", H-6"111), 3.17 (1H, brs, OH), 2.52 
(2H, t, H-3""), 1.78 (1 H, m, CH2), 1,67 (1 H, m, CH2), 1,51 (4H, m, CH2), 1,09 (9H, s, 
C(CH3h); 13C NMR (100 MHz, CDCb): 3 168,0 (CsHsOCN), 160,9 (C-4), 149,6 (C-2), 
141.3 (C-6), 135.8 (C-2", C-6"), 135.7 (C-2", C-6"), 135.5 (C-4111), 132.6 (C-1"), 132.5 
(C-1"), 131.4 (C-1111), 130.8 (C-2111, C-6111), 130.4 (C-4"), 130.3 (C-4"), 129.4 (C-3111 , C-
5111),128.2 (C-3", C-5"), 128.2 (C-3", C-5"), 101.2 (C-2""), 99.1 (C-2"111), 93.0 (C-1""), 
91.4 (C-1'), 86.6 (C-4'), 76.3 (C-2'), 71.7 (C-5), 71.4 (C-3'), 65.5 (C-6"111), 63,8 (C-5'), 
62.5 (C-4""), 30.7 (CH2), 27.2 (C(CH3h), 25.6 (CH2), 21.2 (C-3"111), 19.7 (CH2), 19.4 
(C(CH3h); FABHRMS: m/z found 761.28827 (M+ + Na). C41H4sN20gSi (M+ + Na) 
requires 761.28701. 
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5-( 4-Hyd roxybutyl )-2' ,3' -( isopropyl idene )-5' -O-(tri isopropylsi Iyl) 
uridine (155) 
o 
~ OH 
y J:1 51 >-Si-O~O A 5' 0 
4' l' 
3' 2' 
°XO 
A solution of the nucleoside (0.20 g, 0,3 mmol) in ethanol was hydrogenated over a 
palladium-on-carbon catalyst (10 mol%) at atmospheric pressure and temperature for 
2 days. After removal of the catalyst by filtration, the solvent was evaporated under 
reduced pressure and the crude product purified by column chromatography 
employing EtOAc 1 pet ether (1/1) to give a colourless oil (0.12 g, 71%). [a]~ -15.3 0 
(c 1.30, CHCb); IR (CHCb): Ymax 3690 (w), 3390 (m) (NH), 3192 (br) (OH), 2945 (s) 
(CO), 1688 (s) (CO), 1603 (w) (C=C) cm-1; 1H NMR (400 MHz, CDCb): 3 9.51 (1 H, 
brs, NH), 7.18 (1H, s, H-6), 5.84 (1H, d, J = 2.8 Hz, H-1'), 4.76 (1H, dd, J = 2.8,6.3 
Hz, H-2'), 4.81 (1 H, dd, J = 3.4, 6.3 Hz, H-3'), 4.18 (1 H, m, H-4'), 3.93 (1 H, dd, J = 
2.8, 11.1 Hz, H-5'), 3.86 (1 H, dd, J = 4.2, 11.1 Hz, H-5'), 3.62 (2H, S, H-4") , 2.30 (2H, 
s, H-1 "), 2.28 (2H, S, H-3"), 1.55 (3H, s, 02C(CH3)z) , 1.33 (3H, s, 02C(CH3)z) , 1.10 
(3H, m, 3 x CH(CH3)z), 1.05 (20H, m, 3 x CH(CH3)z, H-2"); 13C NMR (100 MHz, 
CDCb): 3 163.8 (C-4), 150.2 (C-2), 136.9 (C-6), 115.2 (C-5), 114.5 (02C(CH3)z), 91.9 
(C-1'), 86.3 (C-4'), 84.2 (C-2'), 80.1 (C-3'), 63.4 (C-5'), 62.2 (C-4"), 32.1 (C-1"), 27.2 
(02C(CH3)z), 26.7 (C-2"), 25.4 (02C(CH3)z), 25.2 (C-3"), 17.9 (CH(CH3)z), 11.9 
(CH(CH3)z); FABHRMS: mlz found 513.30041 (M+ + H). C25H44N207Si (M+ + H) 
requires 513.29959. 
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5-[4-(4-Methoxybenzyl)-butyl]-2' ,3' -(isopropylidene)-5' -O-(tri 
isopropylsilyl)uridine (156) 
3'" 2'" Me~ 0 
y ~151 ~Si-OpO  5' 0 
4' l' 
3' 2' 
oxO 
OH 
1" 3" 
2" 4" 
To a stirred suspension of NaH (60% in mineral oil, 0,03 g, 1.0 mmol) in OMSO (1,0 
mL) was added dropwise a THF solution (4 mL) of the nucleoside 155 (0.35 g, 0.7 
mmol) under N2. After 45 min at room temperature, p-methoxybenzyl chloride (0.16 
g, 1.0 mmol) was added and stirring continued for 20 hours at rt. The mixture was 
poured into saturated NH4CI (10 mL) (ice-mixture) and extracted with EtOAc (3 x 15 
mL). The combined organic extracts were washed with water (2 x 10 mL), dried over 
MgS04 and the solvent evaporated under reduced pressure. The product was 
purified by column chromatography using pet ether I ethyl acetate (1 I 5) to give the 
title compound 156 as a colourless oil (0.32 g, 75%). 1H NMR (300 MHz, COCh): 8 
7.41 (2H, d, J = 8.6 Hz, H-2"', H-6"'), 7.18 (1 H, s, H-6), 6.78 (2H, d, J = 8.6 Hz, H-3"', 
H-5"'), 5.82 (1H, d, J = 2.8 Hz, H-1'), 5.04 (1H, d, J = 13.5 Hz, ArCH20), 4.96 (1H, d, 
J = 13.5 Hz, ArCH20), 4.82 (1H, dd, J = 3.4, 6.3 Hz, H-3'), 4.75 (1H, dd, J = 2.8,6.3 
Hz, H-2'), 4.20 (1 H, m, H-4'), 3.93 (1 H, dd, J = 2.8, 11.1 Hz, H-5'), 3.84 (1 H, dd, J = 
4.2, 11.1 Hz, H-5'), 3.73 (3H, s, OCH3), 3.61 (2H, t, J = 6.2 Hz, H-4") , 2.28 (3H, m, H-
1", OH), 1.55 (7H, m, H-2", H-3", 02C(CH3h), 1.33 (3H, s, 02C(CH3)2), 1.04 (21 H, m, 
3 x CH(CH3h, 3 x CH(CH3h); 13C NMR (75 MHz, COCh): 8 163.0 (C-4), 158.9 (C-
4"'),150.6 (C-2), 134.8 (C-6), 130.7 (C-2"', C-6"'), 128.9 (C-1"'), 114.2 (02C(CH3h), 
114.2 (C-5), 113.5 (C-3"', C-5"') , 93.0 (C-1 '), 86.2 (C-4'), 84.6 (C-2'), 80.2 (C-3'), 63.3 
(C-5'), 62.1 (C-4") , 55.0 (OCH3), 43.8 (ArCH20), 32.1 (C-3"), 27.4 (C-1 "), 27.1 
(02C(CH3h), 25.3 (02C(CH3h), 25.1 (C-2"), 17.8 (3 x CH(CH3h), 17.8 (3 x 
CH(CH3h), 11.8 (3 x CH(CH3h). 
- 152-
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 6: Experimental 
S-[4-(2-Tetrahydropyranyloxy)-butyl]-S'-O-(tert-butyldiphenylsilyl) 
uridine (160) 
4" 0 0: ~I' 'I '" ~~00A.1 
T6~'0 '-'::: 4' l' I ~ 3' 2' 
3'" 
4'" 01)""06",, 
3"" 5'" 
4"" 
HO OH 
Hydrogen gas was added at atmospheric pressure to a suspension of the nucleoside 
154 (0.58 g, 0.9 mmol), 10% palladium-on-carbon (10 mol %) and a catalytic amount 
of EhN (0.5 mL) in ethanol (5 mL). The reaction mixture was stirred at room 
temperature for 20 h. The residue was filtered over a pad of Celite, washed with large 
volumes of MeOH and the filtrate evaporated in vacuo. The crude product was 
purified by column chromatography employing 80% EtOAc in petroleum ether to give 
160 as a colourless oil (0.49 g, 84%). [a]~ +180 (c 1.00, CHCh); IR (CHCh): Ymax 
3690 (w), 3391 (m) (NH), 3210-3500 (br) (OH), 2932 (s), 2860 (m), 1683 (s) (CO), 
1465 (m) cm-1; 1H NMR (300 MHz, CD30D): 87.70 (4H, m, 2 x H-2", 2 x H-6"), 7.42 
(6H, m, 2 x H-3", 2 x H-4", 2 x H-5"), 7.39 (1 H, s, H-6), 6.00 (1 H, d, J = 5.4 Hz, H-1'), 
4.49 (1 H, t, J = 3.3 Hz, H-2""), 4.31 (2H, m, H-2', H-3'), 4.06 (2H, m, H-4', H-5'), 3.91 
(1 H, dd, J = 2.5, 11.2 Hz, H-5'), 3.80 (1 H, m, H-4I11) , 3.53 (1 H, m, H-6""), 3.46 (1 H, m, 
H-6""), 3.19 (1H, m, H-4I11) , 1.92 (1H, m, H-1111), 1.64 (1H, m, H-1111), 1.81 (2H, m, 
CH2), 1.50 (4H, m, 2 x CH2), 1.32 (4H, m, 2 x CH2), 1.10 (9H, s, C(CH3h); 13C NMR 
(100 MHz, CD30D): 8 164.5 (C-4), 151.4 (C-2), 136.3 (C-6), 135.5 (C-2", C-6") , 135.3 
(C-2", C-6"), 133.6 (C-1"), 132.7 (C-1"), 130.1 (C-4"), 130.0 (C-4") , 127.9 (C-3", C-
5"), 127.9 (C-3", C-5"), 115.1 (C-5), 99.0 (C-2""), 88.4 (C-1'), 85.1 (C-4'), 74.2 (C-3'), 
70.4 (C-2'), 67.2 (C-6""), 64.1 (C-5'), 62.2 (C-4"'), 30.7 (C-3111), 29.3 (C-5""), 26.5 
(C(CH3h), 25.7 (C-1111), 25.4 (C-2111), 19.5 (CH2), 19.2 (C(CH3h); FABHRMS: m/z 
found 661.29314 (M+ + Na). C34H46N20sSi (M+ + Na) requires 661.29212. 
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N-Benzoyl-5'-O-(terl-butyldiphenylsilyl)-5-[4-(2-tetrahydropyranyl 
oxy)butyl]uridine (165) 
~ I yQ 4'" '9'" 0 h- 3'" y,. 0y, , [; , . .' .. 0 •• I 3 1'" \_Si_~:r{~O 2"" 4"" ~ T6 0, ~~'c;6"'" ~ 4' 1 
I 3' 2' 
h- HO OH 
Nucleoside 164 (0.81 g, 1.1 mmol) was hydrogenated over palladium-on-carbon 
catalyst (0.06 g, 0.6 mmol) in EtOH (5 mL) to give 165 as a colourless oil (0.67 g, 
83%). IR (CHCI3): Vmax 3694 (w), 3594 (w), 3028 (w), 3010 (w), 2945 (m), 2861 
(w), 1752 (s) (CO), 1706 (CO), 1666 (s) (CO); 1H NMR (400 MHz, CDCb): () 7.89 
(2H, dd, J = 1.6, 8.4 Hz, H-2"'), 7.65 (5H, m, ArH), 7.53 (1 H, s, H-6), 7.42 (8H, m, 
ArH), 5.85 (1H, d, J = 6.0 Hz, H-1'), 4.50 (1H, t, J = 3.6,5.2 Hz, H-2"'''), 4.30 (2H, m, 
H-2', H-3'), 4.15 (1H, m, H-4'), 4.00 (1H, dd, J= 2.4,11.7 Hz, H-5'), 3.83 (1H, dd, J= 
3.0, 11.7 Hz, H-5'), 3.78 (1 H, m, OCH2), 3.62 (1 H, m, OCH2), 3.46 (1 H, m, OCH2), 
3.26 (1H, m, OCH2), 2.17 (1H, m, H-1"1I), 2.04 (1H, m, H-1""), 1.78 (1H, m, CH2), 1.66 
(1 H, m, CH2), 1.46 (8H, m, 4 x CH2), 1.08 (9H, s, C(CH3h); 13C NMR (100 MHz, 
CDCb): () 168.7 (C6HsOCN), 162.3 (C-4) , 150.2 (C-2), 135.5 (C-2", C-6"), 135.3 (C-
2", C-6"), 135.1 (C-4"') , 132.8 (C-1"'), 132.3 (C-1"), 131.5 (C-1"), 130.4 (C-4"), 130.1 
(C-4") , 130.1 (C-2"', C-6"'), 129.9 (C-3"', C-5"'), 129.2 (C-6), 128.0 (C-3", C-5"), 127.9 
(C-3", C-5") , 115.4 (C-5), 98.8 (C-2""'), 90.5 (C-1'), 85.8 (C-4'), 75.5 (C-3'), 70.9 (C-
2'),67.2 (C-6""'), 63.6 (C-5'), 62.3 (C-4""), 30.7 (C-3""), 29.4 (C-5""'), 27.1 (C-1""), 
27.0 (C(CH3h), 25.4 (C-2""), 22.7 (CH2), 19.6 (CH2), 19.3 (C(CH3h). 
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5-[4-( S-Methyld ith iocarbonyloxy)butyl]-51 -0-( tert-butyld i phenyl 
silyl)-21 ,31-bis-(S-methyldithiocarbonyloxy)uridine (161 b) 
4" 0 
(') 3" ~ 1'" 2'" 3'" 4'" 0 SCH3 y2" ~ 51 Y -t-6S~ 0ioj S 
~ ~H2 
C~S~O OCS~H3 
To a solution of the nucleoside 160 (0.92 g, 1.4 mmols) in dry THF under nitrogen 
were added a catalytic amount of imidazole (0.02 g) and NaH (60% in mineral oil, 
0.13 g, 5.4 mmol) at 0 °C. After 10 minutes, CS2 (0.6 mL, 10.1 mmols) was added 
dropwise. Stirring was continued for an additional 30 min and iodomethane (0.5 mL, 
8.1 mmols) was added. The mixture was stirred at room temperature overnight. The 
suspension was hydrolysed with H20 (40 mL) and extracted with EtOAc (3 x 40 mL). 
The combined organic extracts were washed with saturated aqueous NH4CI solution 
(100 mL) and brine (100 mL), dried over MgS04 and concentrated under reduced 
pressure. The product was purified by column chromatography using pet ether I 
EtOAc (1 I 8) to give 161b as a colourless oil (0.08 g, 7%), along with three by-
products, also all as colourless oils. 
161b: [a]~ -9.3 0 (c 1.00, CHCb); IR (CHCb): Vmax 3691 (w), 3388 (w) (NH), 2930 (m), 
2859 (w), 1716 (s) (CO), 1692 (s) (CO), 1602 (w), 1463 (m), 1114 (s) (C=S), 1095 (s) 
(C=S), 1076 (s) (C=S), 621 (C-S) cm-1; 1H NMR (300 MHz, COCb): () 8.66 (1H, brs, 
NH), 7.69 (4H, m, 2 x H-2"/H-6"), 7.42 (6H, m, 2 x H-3"/H-5", 2 x H-4"), 7.37 (1H, s, 
H-6), 6.52 (1H, d, J = 7.6 Hz, H-1'), 6.47 (1H, dd, J = 2.0,5.8 Hz, H-3'), 6.25 (1H, dd, 
J = 5.8, 7.6 Hz, H-2'), 4.43 (2H, t, J = 6.5 Hz, H-4"'), 4.41 (1 H, m, H-4'), 4.13 (1 H, d, J 
= 11.3 Hz, H-5'), 4.03 (1 H, dd, J = 1.9, 11.3 Hz, H-5'), 2.60 (3H, s, SCH3), 2.58 (3H, 
s, SCH3), 2.54 (3H, s, SCH3), 1.99 (1H, m, H-1"'), 1.84 (1H, m, H-1"'), 1.55 (2H, m, H-
3"'), 1.39 (2H, m, H-2"'), 1.14 (9H, s, C(CH3h); 13C NMR (75 MHz, COCb): () 215.8 
(C=S), 214.7 (C=S), 214.6 (C=S), 162.7 (C-4), 150.3 (C-2), 135.6 (C-2", C-6"), 135.3 
(C-2", C-6"), 132.8 (C-1"), 131.8 (C-1") 130.3 (C-4"), 130.1 (C-4"), 128.1 (C-3", C-5"), 
128.0 (C-3", C-5"), 116.0 (C-5), 84.8 (C-1'), 78.0 (C-3'), 78.8 (C-2'), 73.6 (C-4"'), 83.7 
(C-4'), 63.8 (C-5'), 27.9 (C-3"'), 27.1 (C(CH3h), 26.7 (C-1"'), 25.3 (C-2"'), 19.4 
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(SCH3), 19.4 (SCH3), 19.3 (SCH3), 18.9 (C(CH3h); FABHRMS: m/z found 847.11197 
(M+ + Na). C35H44N207S6Si (M+ + Na) requires 847.11397. 
3-N-Methyl-S-[ 4-( S-methylth iocarbonyloxy)-butyl]-S' -0-( tert-butyI 
diphenylsilyl)-2' ,3' -bis-( S-methyldithiocarbonyloxy)uridine (161 a) 
4" 0 Q 1'" 3'" 3" I CH3"--... 3 5 2'" 4'" 0 SCH3 2"~ I I Y f6
1
"Si o~o:' s 
I ~ 4' :' 
h- 3' 2 
CHaS~O OCS~H3 
161a (253 mg, 22%): [ar~ -5.0° (c 1.00, CHCb); IR (CHCb): Vmax 3692 (w), 3606 (w), 
2959 (m), 2932 (m), 2860 (w), 1710 (s) (CO), 1669 (s) (CO), 1645 (s) (C=C), 1465 
(m), 1099 (s) (C=S), 1077 (s) (C=S) cm-1; 1H NMR (300 MHz, CDCb): 07.69 (4H, m, 
2 x H-2"/6"), 7.40 (6H, m, 2 x H-3"/5", 2 x H-4"), 7.34 (1 H, s, H-6), 6.55 (1 H, d, J = 
7.4 Hz, H-1'), 6.47 (1H, dd, J = 2.4, 6.0 Hz, H-3'), 6.26 (1H, t, J = 6.0, 7.4 Hz, H-2'), 
4.44 (2H, t, J = 6.5 Hz, H-4"'), 4.39 (1 H, d, J = 2.4 Hz, H-4'), 4.13 (1 H, d, J = 12.2 Hz, 
H-5'), 4.02 (1 H, d, J = 12.2 Hz, H-5'), 3.32 (3H, s, NCH3), 2.60 (3H, s, SCH3), 2.58 
(3H, s, SCH3), 2.58 (3H, s, SCH3), 2.01 (1H, m, H-1"'), 1.90 (1H, m, H-1"'), 1.56 (2H, 
m, H-3"'), 1.38 (2H, m, H-2"'), 1.14 (9H, s, C(CH3h); 13C NMR (75 MHz, CDCI3): 0 
215.7 (C=S), 214.6 (C=S), 214.5 (C=S), 162.8 (C-4), 151.1 (C-2), 135.5 (C-2", C-6"), 
135.3 (C-2", C-6"), 133.3 (C-6), 132.8 (C-1"), 131.9 (C-1"), 130.2 (C-4"), 130.1 (C-
4"), 128.1 (C-3", C-5"), 128.0 (C-3", C-5"), 114.9 (C-5), 85.9 (C-1'), 83.5 (C-4'), 78.9 
(C-2'), 77.9 (C-3'), 73.6 (C-4"'), 63.7 (C-5'), 28.0 (C-3"'), 27.9 (C-1"'), 27.1 (C(CH3h), 
27.0 (NCH3), 25.3 (C-2"'), 19.4 (SCH3), 19.3 (SCH3), 19.3 (SCH3), 18.9 (C(CH3h); 
FABHRMS: m/z found 861.13098 (M+ + Na). C36H46N207S6Si (M+ + Na) requires 
861.12961. 
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3-N-Methyl-S-(4-hydroxybutyl)-SI -0-( tert-butyld iphenylsilyl)-21 ,31 -bis-
(S-methyldithiocarbonyloxy)uridine (161 c) 
4" 0 Q 1'" 3'" 3" I CH:t-.,. 3 5 2''' 4'" OH 2"~ AI f'Si-O~O 1 6~ :,0:, ~ 3' 2 
C~S~O OCS~H3 
161c (288 mg, 29%): [at~ -2.5° (c 1.00, CHCb); IR (CHCb): Vmax 3691 (w), 3612 (w), 
3483 (br) (OH), 2932 (m), 2860 (m), 1709 (s) (CO), 1667 (s) (CO), 1644 (s) (C=C), 
1466 (m), 1100 (s) (C=S), 1078 (s) (C=S), 720 (w) (C-S) cm-1; 1H NMR (400 MHz, 
CDCb): 87.69 (4H, m, 2 x H-2"/6") , 7.42 (2H, m, 2 x H-4"), 7.37 (4H, m, 2 x H-3"/5"), 
7.33 (1 H, s, H-6), 6.52 (1 H, d, J = 7.2 Hz, H-1'), 6.46 (1 H, dd, J = 2.4, 5.9 Hz, H-3'), 
6.24 (1 H, dd, J = 5.9, 7.2 Hz, H-2'), 4.38 (1 H, m, H-4'), 4.10 (1 H, dd, J = 2.4, 11.4 Hz, 
H-5'), 4.00 (1 H, dd, J = 2.0, 11.4 Hz, H-5'), 3.49 (2H, t, J = 6.2 Hz, H-4"') , 3.31 (3H, s, 
NCH3), 2.59 (3H, s, SCH3), 2.57 (3H, s, SCH3), 2.02 (1 H, m, H-1"'), 1.90 (1 H, m, H-
1"'), 1.35 (4H, m, H-2"', H-3"'), 1.13 (9H, s, C(CH3h); 13C NMR (100 MHz, CDCI3): 8 
214.6 (C=S), 214.5 (C=S), 163.0 (C-4) , 151.0 (C-2), 135.6 (C-2", C-6") , 135.3 (C-2", 
C-6"), 133.3 (C-6), 132.9 (C-1 "), 132.0 (C-1 "), 130.2 (C-4") , 130.0 (C-4"), 128.1 (C-
3", C-5"), 128.0 (C-3", C-5"), 115.4 (C-5), 86.1 (C-1'), 83.4 (C-4'), 79.0 (C-2'), 77.9 
(C-3'), 63.7 (C-5'), 62.2 (C-4"'), 32.1 (C-3"'), 28.0 (NCH3), 27.2 (C-1"'), 27.1 
(C(CH3h), 25.1 (C-2"'), 19.4 (SCH3), 19.4 (SCH3), 19.3 (C(CH3h); FABHRMS: m/z 
found 771.17104 (M+ + Na). C34H44N207S4Si (M+ + Na) requires 771.16982. 
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5-(4-Hydroxybutyl)-5'-O-(tert-butyldiphenylsilyl)-2' ,3'-bis( s-
methyldithiocarbonyloxy)uridine (161 d) 
4" 0 
3'" 4'" OH 
I ~ 4' :. 
~ 3' 2 
C~S~O OCS~H3 
161d (147 mg, 15%): [a]2~ -4.10 (c 1.00, CHCb); IR (CHCb): V max 3691 (w), 3602 (w), 
3389 (m), (NH), 2931 (s), 2860 (m), 1715 (s) (CO), 1691 (s) (CO), 1602 (w), 1463 
(m), 1114 (s) (C=S), 1095 (s) (C=S), 1077 (s) (C=S), 669 (C-S) cm-\ 1H NMR (400 
MHz, COCI3): 09.44 (1H, brs, NH), 7.69 (4H, m, 2 x H-2"/6"), 7.39 (2H, m, 2 x H-4"), 
7.38 (4H, m, 2 x H-3"/5"), 7.35 (1H, s, H-6), 6.52 (1H, d, J = 7.2 Hz, H-1'), 6.46 (1H, 
dd, J = 2.2,6.1 Hz, H-3'), 6.23 (1H, t, J = 6.1,7.2 Hz, H-2'), 4.37 (1H, m, H-4'), 4.12 
(1 H, dd, J = 2.2, 11.6 Hz, H-5'), 4.01 (1 H, dd, J = 1.4, 11.6 Hz, H-5'), 3.49 (2H, t, J = 
6.0 Hz, H-4"') , 2.59 (3H, s, SCH3), 2.57 (3H, s, SCH3), 1.90 (1H, m, H-1"'), 1.86 (1H, 
m, H-1"'), 1.34 (4H, m, 2 x H-2"', 2 x H-3"'), 1.13 (9H, s, C(CH3h); 13C NMR (100 
MHz, COCb): 0214.7 (C=S), 214.5 (C=S), 163.4 (C-4), 150.5 (C-2), 135.6 (C-2", C-
6"),135.3 (C-2", C-6"), 135.1 (C-6), 132.8 (C-1"), 131.9 (C-1"), 130.2 (C-4"), 130.1 
(C-4"), 128.1 (C-3", C-5"), 128.0 (C-3", C-5"), 116.5 (C-5), 84.8 (C-1'), 83.6 (C-4') , 
78.8 (C-2'), 78.0 (C-3'), 63.7 (C-5'), 62.2 (C-4"'), 32.1 (C-3"'), 27.1 (C(CH3h), 26.5 (C-
1 "'), 25.1 (C-2"'), 19.4 (SCH3), 19.4 (SCH3), 19.3 (C(CH3h); FABHRMS: mlz found 
757.15491 (M+ + Na). C33H42N207S4Si (M+ + Na) requires 757.15417. 
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S-[4-(2-Tetrahydropyranyloxy)-butyl]-S' -0-( tert-butyldiphenylsilyl)-2', 
3' -O-thiocarbonyluridine (168) 
°lO,,,,O 6 
4'" 
3'''' 5"" 
4"" 
1,1 '-Thiocarbonyldiimidazole (0.69 g, 3.9 mmols) was added to a solution of the 
nucleoside (0.62 g, 1.0 mmols) in 1, 2-dichloroethane (10 mL). The reaction mixture 
was refluxed for 1 h. The solvent was evaporated and the product purified by column 
chromatography using petroleum ether / ethyl acetate (1 / 1) to give 168 as a 
colourless oil (0.52 g, 79%). [a]~ + 9.6 0 (c 1.50, CHCb); IR (CHCb): Ymax 3693 (w), 
3386 (w) (NH), 2946 (w), 2860 (w), 1810 (m), 1694 (s) (CO), 1134 (m) (C=S), 1090 
(m) (C=S) cm-1; 1H NMR (400 MHz, CDCb): 09.43 (1H, brs, NH), 7.61 (4H, t, J = 7.9 
Hz, 2 x H-2"/6"), 7.39 (2H, m, 2 x H-4"), 7.32 (4H, m, 2 x H-3"/5"), 7.00 (1H, s, H-6), 
5.62 (1H, d, J = 7.5 Hz, H-2'), 5.56 (1H, s, H-1'), 5.48 (1H, dd, J = 3.8, 7.5 Hz, H-3'), 
4.51 (1 H, t, J = 2.8, 4.4 Hz, H-2""), 4.42 (1 H, m, H-4'), 3.86 (3H, m, 2 x H-5', H-4111) , 
3.73 (1 H, m, H-6""), 3.46 (1 H, m, H-4111), 3.38 (1 H, m, H-6""), 2.31 (2H, m, H-1 III), 1.59 
(2H, m, H-4""), 1.56 (4H, m, H-2111, H-5""), 1.52 (4H, m, H-3111 , H-3""), 1.03 (9H, s, 
C(CH3h); 13C NMR (75 MHz, CDCb): 0 189.4 (C=S), 163.3 (C-4) , 149.9 (C-2), 138.6 
(C-6), 135.4 (C-2", C-6") , 135.4 (C-2", C-6"), 132.7 (C-1"), 132.6 (C-1"), 129.9 (C-4"), 
129.9 (C-4") , 127.8 (C-3", C-5"), 127.7 (C-3", C-5"), 116.0 (C-5), 99.0 (C-2""), 95.1 
(C-1 '), 88.0 (C-2'), 87.7 (C-4'), 85.5 (C-3'), 67.1 (C-6""), 63.3 (C-5'), 62.4 (C-4111) , 29.2 
(C-5""), 26.7 (C(CH3h), 26.3 (C-1111), 25.4 (C-3111 , C-3""), 24.9 (C-2111, C-4'III) , 19.6 
(C(CH3h); FABHRMS: mlz found 703.24944 [M+Nat. C35H44N20sSSi [M+Nat 
requires 703.24852. 
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5-[4-(2-Tetrahydropyranyloxy)-butyl]-5'-O-(terl-butyldiphenylsilyl)-
2' ,3' -didehydro-2' ,3' -dideoxyuridine (169) 
4" 0 
0:~" ~ '" 
-",-Yo 0"'" ' T6tj' 0 ~ 4' l' 
I h 3' - 2' 
0'10",,0 6 4'" 
3"" 5"" 
4"" 
Thionocarbonate 168 (0.30 g, 0.5 mmol) was heated at 160 °C in triethylphosphite (2 
mL) for 4 h. After conversion of the starting material had been indicated by TLC, the 
solvent was removed under reduced pressure and the crude product subjected 
directly to chromatographic purification using 40% ethyl acetate in petroleum ether to 
give 169 as a colourless oil (0.20 g, 75%). [(l]~ +3.2 ° (c 1.50, CHCh); IR (CHCh): 
Vmax 3690 (w), 2943 (m), 2861 (w), 1700 (m) (CO), 1664 (s) (CO), 1640 (s) (CO) cm-1; 
1H NMR (300 MHz, COCh): 8 7.94 (4H, m, 2 x H-2", 2 x H-6"), 7.38 ( 6H, m, 2 x H-
3", 2 x H-4", 2 x H-5"), 7.04 (1 H, m, H-1'), 6.97 (1 H, s, H-6), 6.37 (1 H, dq, J = 1.6,6.1 
Hz, H-3'), 5.85 (1 H, dq, J = 1.6, 2.0, 6.1 Hz, H-2'), 4.91 (1 H, m, H-4'), 4.51 (1 H, t, J = 
3.3,4.2 Hz, H-2""), 3.83 (3H, m, 2 x H-4111 , H-5'), 3.63 (1H, m, H-6""), 3.47 (1H, m, H-
5'), 3.26 (1 H, m, H-6""), 2.06 (2H, m, H-1 III), 1.64 (1 H, m, CH2), 1.51 (5H, m, CH2), 
1.44 (2H, m, CH2), 1.36 (2H, m, CH2), 1.06 (9H, s, C(CH3h); 13C NMR (75 MHz, 
COCh): 8 162.7 (C-4), 151.2 (C-2), 135.5 (C-2", C-6") , 135.4 (C-2", C-6") , 134.8 (C-
3'), 133.3 (C-6), 132.9 (C-1"), 132.9 (C-1"), 130.0 (C-4") , 129.9 (C-4") , 127.8 (C-3", 
C-5"), 127.8 (C-3", C-5"), 126.3 (C-2'), 114.6 (C-5), 98.9 (C-2""), 90.6 (C-1'), 86.7 (C-
4'), 67.3 (C-4"'), 65.9 (C-6""), 62.3 (C-5'), 30.7 (CH2), 29.4 (CH2), 27.4 (C-1111), 26.9 
(C(CH3h), 25.5 (CH2), 25.3 (CH2), 19.7 (CH2), 19.3 (C(CH3h). 
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S-(4-Hydroxybutyl)-S' -O-(terl-butyldiphenylsilyl)-2' ,3' -didehydro-2' ,3'-
dideoxyuridine (170) 
OH 
MgBr2 (0.06 g, 0.5 mmol) was added to a solution of the nucleoside (0.11 g, 0.2 
mmol) in ether (5 mL). The resulting suspension was stirred at room temperature for 
12 h. Methanol (2 mL) was added dropwise and the solution stirred for 30 min. The 
solvent was removed under reduced pressure and the residue subjected to column 
chromatography employing EtOAc I petroleum ether (8 I 2) to give the title compound 
170 as a colourless oil (0.08 g, 83%). IR (CHCb): V max 3691 (w), 3391 (w) (NH), 3178 
(br) (OH), 2933 (w), 2860 (w), 1810 (w), 1688 (s) (CO) cm-1; 1H NMR (400 MHz, 
CDCb): 88.21 (1H, brs, NH), 7.64 (4H, m, 2 x H-21/H-6"), 7.39 (6H, m, 2 x H-4", 2 X 
H-3"/H-5"), 6.99 (1H, s, H-6), 6.98 (1H, dd, J = 1.4, 3.4 Hz, H-1'), 6.37 (1H, dt, J = 
1.6, 6.1 Hz, H-3'), 5.84 (1 H, dq, J = 1.6, 6.1 Hz, H-2'), 4.92 (1 H, m, H-4'), 3.83 (2H, t, 
J = 4.8 Hz, H-5'), 3.48 (2H, t, J = 6.2 Hz, H-4"') , 2.04 (1H, m, H-1"'), 1.94 (1H, m, H-
1 III), 1.61 (1 H, brs, OH), 1.33 (4H, m, H-2"', H-3"'), 1.08 (9H, s, C(CH3h); 13C NMR 
(75 MHz, CD30D): 8 165.8 (C-4) , 152.7 (C-2), 137.5 (C-6), 136.6 (C-2", C-6") , 136.5 
(C-2", C-6") , 135.9 (C-3'), 134.8 (C-1"), 134.3 (C-1"), 131.1 (C-4") , 131.0 (C-4") , 
128.9 (C-3", C-5"), 128.8 (C-3", C-5"), 127.2 (C-2'), 116.1 (C-5), 91.3 (C-1'), 88.7 (C-
4'), 67.3 (C-4"') , 62.6 (C-5'), 33.1 (C-3"'), 27.5 (C(CH3h), 27.4 (C-1 "'), 25.9 (C-2"'), 
20.2 (C(CH3h). 
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S-[4-(Methanesulfonyloxy)-butyl]-S'-O-(terl-butyldiphenyIsilyloxy)-
2' ,3'-didehydro-2' ,3'-dideoxyuridine (172) 
4'" 
EhN (0.03 mL, 0.2 mmol) and a catalytic amount of dimethyaminopyridine (0.01 g) 
were added to a solution of the nucleoside (0.05 g, 0.1 mmol) in CH2CI2 (2 mL). The 
mixture was cooled to O°C and MsCI (0.01 mL, 0.1 mmol) was added dropwise. The 
mixture was stirred at room temperature for 12 h. The residue was dissolved in 
CH2Cb (10 mL), washed with H20 (3 x 5 mL), dried with MgS04, filtered and the 
solvent evaporated under reduced pressure. Column chromatography using 
petroleum ether / EtOAc (4/6) gave a colourless oil (25 mg, 46%). 
Uridine-2' ,3' ,S'-trimesylate (121) 
o 
~4 
Methanesulfonyl chloride (8.7 mL, 113 mmol) was added to a cold and stirring 
solution of uridine 120 (6.1 g, 25 mmol) in pyridine (38 mL) at 0 °C. The reaction 
mixture was stirred at 0 °C for 5 h and then poured into ice-water (250 mL) with 
stirring. The mixture was stirred for 5 min. The precipitate formed was collected by 
filtration and washed with water (3 x 100 mL) and dried to give 121 as a white solid 
(8.49 g, 71%). mp: 170-171 °C (lit. 13o 184-186 °C (dec»; 1H NMR (400 MHz, DMSO-
ds) D 11.51 (1 H, d, J = 1.6 Hz, NH), 7.69 (1 H, d, J = 8.0 Hz, H-6), 5.97 (1 H, d, J = 4.4 
Hz, H-1'), 5.69 (1 H, dd, J = 1.6, 8.0 Hz, H-5), 5.60 (1 H, t, J = 5.3 Hz, H-2'), 5.35 (1 H, 
t, J = 5.3 Hz, H-3'), 4.53 (1 H, m, H-4'), 4.46 (2H, m, H-5'), 3.35 (3H, s, 03SCH3), 3.33 
(3H, s, 03SCH3), 3.22 (3H, s, 03SCH3); 13C NMR (75 MHz, DMSO-ds) D 162.9 (C-4) , 
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150.3 (C-2), 141.5 (C-6), 102.3 (C-5), 88.7 (C-1'), 78.5 (C-4') , 76.0 (C-2'), 74.0 (C-3'), 
67.3 (C-5'), 37.9 (03SCH3), 37.9 (03SCH3), 36.9 (03SCH3). 
5'-O-Benzoyl-3'-O-methanesulfonyl-2'-anhydrouridine (122) 
o 
'~ a*w) I~'O~~' 
,,3r2' 
CHaS03 
Trimesylate 121 (3.0 g, 6.3 mmol) was added to a stirred slurry of sodium benzoate 
(3.16 g, 21.9 mmol) in acetamide (25 g) at 115°C. The reaction mixture was stirred 
at 115 °c for 65 min and then poured into ice-water (600 mL). The mixture was 
stirred at 0 °c for 15 min. The white solid was filtered, washed with water and dried to 
give 122 (1.93 g, 75%) as colourless needles. mp: 243-244 °c (lit. 13o 226-227 °c 
(dec)); 1H NMR (400 MHz, DMSO-d6) 8 7.89 (3H, m, H-6, H-2", H-6"), 7.65 (1 H, m, 
H-4"), 7.49 (2H, t, J = 7.8 Hz, H-3", H-5"), 6.45 (1 H, d, J = 5.6 Hz, H-1'), 5.87 (1 H, d, 
J = 7.6 Hz, H-5), 5.69 (1 H, d, J = 5.6 Hz, H-2'), 5.62 (1 H, d, J = 2.4 Hz, H-3'), 4.77 
(1H, m, H-4'), 4.33 (1H, dd, J = 4.8,12.1 Hz, H-5'), 4.22 (1H, dd, J = 7.4,12.1 Hz, H-
5'),3.43 (3H, s, 03SCH3); 13C NMR (100 MHz, DMSO-(6) 8 170.6 (C=O), 165.1 (C-
4), 159.2 (C-2), 136.5 (C-6), 133.5 (C-4"), 129.2 (C-2", C-6"), 128.9 (C-1"), 128.7 (C-
3", C-5"), 109.0 (C-5), 89.7 (C-1'), 86.0 (C-2'), 82.1 (C-4'), 80.9 (C-3'), 62.5 (C-5'), 
37.5 (03SCH3). 
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5' -O-Benzoyl-2' -bromo-3' -O-methanesu Ifonyl-2' -deoxyu rid i ne (123) 
o 
'.~ Jz~ Ih'·o~, 
c~so: ;r 
Acetyl bromide (2.5 mL, 33.9 mmol) was added dropwise to a stirring mixture of 5'-
benzoyl-3'-O-methanesulfonyl-2'-anhydrouridine 122 (1.90 g, 4.8 mmol) in ethyl 
acetate (50 mL) and MeOH (5 mL). The mixture was refluxed for 1 h and then 
cooled. EtOAc (50 mL) was added and the organic layer washed with saturated aq. 
NaHC03 (50 mL) followed by brine (50 mL). The organic layer was dried over 
MgS04, the solvent removed in vacuo and the crude product recrystallized from 
EtOAclpet ether to give 123 as a white solid (2.23 g, 97%). 1H NMR (300 MHz, 
COCh): () 9.49 (1 H, brs, NH), 8.01 (2H, m, H-2", H-6"), 7.60 (1 H, m, H-4"), 7.46 (2H, 
m, H-3", H-5"), 7.31 (1H, d, J= 8.1 Hz, H-6), 6.12 (1H, d, J= 5.4 Hz, H-1'), 5.60 (1H, 
d, J = 8.1 Hz, H-5), 5.27 (1 H, m, H-3'), 4.74 (1 H, m, H-2'), 4.65 (3H, m, H-4', H-5'), 
3.18 (3H, s, SCH3); 13C NMR (75 MHz, COCh): () 165.9 (C6H50CO), 162.8 (C-4), 
150.0 (C-2), 139.6 (C-6), 133.8 (C-4"), 129.6 (C-2", C-6"), 129.0 (C-1"), 128.7 (C-3", 
C-5"), 1 03.4 (C-5), 91.9 (C-1'), 80.7 (C-4'), 75.6 (C-3'), 62.2 (C-5'), 47.5 (C-2'), 38.8 
(03SCH3). 
5'-Benzoyl-2',3'-didehydro-2',3'-dideoxyuridine (124) 
o 
,~: ~O ~ooA~ 
o )/0,( 
4'
3
U_ 2' 
Acetic acid (0.25 mL) and zinc dust (0.50 g, 7.69 mmol) were added to a suspension 
of 123 (2.19 g, 4.61 mmol) in a mixture of EtOAc (40 mL) and MeOH (13 mL) at 18 
cC. After 3.5 h, the excess Zn was removed by filtration and the cake was washed 
with a 3: 1 mixture of EtOAc/MeOH (2 x 20 mL). The solvent was removed in vacuo 
and more 3:1 mixture of EtOAclMeOH (6 mL) added. To this solution was then added 
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water (75 mL) and the solution stirred for 30 min. The resulting precipitate was 
filtered and the product washed with water and dried to give 124 as colourless 
crystals (1.14 g, 83%). mp: 141-142 °C (lit. 82c 138.5-139 °C); 1H NMR (300 MHz, 
COCh): 89.10 (1H, brs, NH), 7.99 (2H, m, H-2", H-6"), 7.60 (1H, m, H-4"), 7.46 (2H, 
m, H-3", H-5"), 7.34 (1H, d, J= 8.3 Hz, H-6), 7.00 (1H, m, H-1'), 6.39 (1H, dt, J= 1.7, 
5.9 Hz, H-3'), 5.89 (1 H. dq, J = 1.4, 5.9 Hz, H-2'), 5.33 (1 H, d, J = 8.3 Hz, H-5), 5.16 
(1H, m, H-4'), 4.70 (1H, dd, J = 3.6,12.7 Hz, H-5'), 4.53 (1H, dd, J = 2.9,12.7 Hz, H-
5'); 1H NMR (300 MHz, COCh): 8 166.1 (CsHsOCO), 163.0 (C-4), 150.6 (C-2), 139.8 
(C-6), 133.6 (C-4"), 135.6 (C-3'), 129.6 (C-2", C-6"), 128.6 (C-3", C-5"), 127.2 (C-2'), 
102.7 (C-5), 89.8 (C-1'), 84.8 (C-4'), 64.6 (C-5'). 
51 -Benzoyl-21 ,31 -didehydro-21 ,31 -dideoxy-5-iodouridine (100) 
o 
,.~: ~rrl ~oo)zj 
o )/0,( 
4'3U_ 2' 
Cerium ammonium nitrate (IV) (0.77 g, 1.4 mmol) and iodine (0.43 g, 1.68 mmol) 
were added to a solution of 5'-benzoyl-2',3'-didehydro-2',3'-dideoxyuridine 124 (0.88 
g, 2.8 mmol) in CH3CN (40 mL). The mixture was stirred at 35°C for 4 h. EtOAc (170 
mL) was added to the residue and the solid product formed was removed by filtration. 
The filtrate was washed with a solution of NaHS03 (2 x 100 mL), water (2 x 100 mL), 
the organic layer dried over MgS04 and the solvent removed under reduced 
pressure. Recrystallization using CH2Cb/pet ether gave 100 as white needles (1.05 
g, 85%). mp: 167-168 °C; IR (CHCh): Vmax 3694 (w) (NH), 3606 (w), 3381 (w), 3020 
(w), 1720 (s) (CO), 1694 (s) (CO), 1638 (m) cm-1; 1H NMR (300 MHz, Acetone-ds): 8 
10.37 (1H, brs, NH), 8.04 (2H, m, H-2", H-6"), 7.86 (1H, s, H-6), 7.64 (1H, m, H-4"), 
7.53 (2H, m, H-3", H-5"), 6.88 (1H, m, H-1'), 6.60 (1H, dt, J = 1.7,6.1 Hz, H-3'), 6.16 
(1H, dq, J = 1.1,6.1 Hz, H-2'), 5.25 (1H, m, H-4'), 4.63 (1H, dd, J = 4.4,12.3 Hz, H-
5'), 4.57 (1H, dd, J = 3.2, 12.3 Hz, H-5'); 13C NMR (100 MHz, COCh): 8 166.4 
(CsHsOCO), 159.9 (C-4), 150.2 (C-2), 144.1 (C-6), 133.5 (C-4"), 133.5 (C-3'), 129.8 
(C-2", C-6"), 129.3 (C-1"), 128.8 (C-3", C-5"), 127.1 (C-2'), 90.6 (C-1'), 85.1 (C-4'), 
68.9 (C-5), 65.0 (C-5'). 
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5-[4-{2-(2-tert-Butoxycarbonylaminoethyl)-4-methoxyphenoxy}but-1-
ynyl]-5'-O-benzoyl-2' ,3'-didehydro-2' ,3'-dideoxyuridine (125) 
o 
2"'" U 1/ 
3'" 2"" I o 2'" 4'" 0 1"" H tS;"'" ~~ 1"0 -:?' 3"" -:?' I 4"" ~ OCH3 
According to GP1: Nucleoside 100 (0.07 g, 0.2 mmol), alkyne 93 (0.10 g, 0.3 mmol), 
(PPh3)4Pd (0.02 g, 0.02 mmol), Cui (0.02 g, 0.1 mmol), triethylamine (0.05 mL, 0.3 
mmol), OMF (2.5 mL), THF (5.0 mL). The residue was purified by column 
chromatography using a gradient from petroleum ether / EtOAc (1 / 1) to EtOAc / 
MeOH (9/ 1) to give the coupled product as a yellow oil (0.095 g, 94%). [a]~ -14.4 0 
(c 1.60, CHCh); IR (CHCh): Vmax 3692 (w), 3606 (w), 3451 (w) (NH), 3385 (w) (NH), 
3011 (m), 2934 (m), 2243 (w) (C=C), 1707 (s) (CO), 1502 (s), 1453 (m); 1 H NMR 
(300 MHz, COCh): 8 8.79 (1H, brs, NH), 8.00 (2H, d, J = 8.6 Hz, H-2", H-6"), 7.61 
(1H, s, H-6), 7.53 (1H, t, J = 7.7 Hz, H-4"), 7.42 (2H, t, J = 7.7,8.6 Hz, H-3", H-5"), 
6.91 (1 H, m, H-1'), 6.70 (3H, m, H-3"" , H-5"", H-6""), 6.39 (1 H, dt, J = 1.7, 5.8 Hz, H-
3'), 5.99 (1 H, dq, J = 1.4, 5.8 Hz, H-2'), 5.20 (1 H, m, H-4'), 4.83 (1 H, brs, NH), 4.64 
(1 H, dd, J = 4.3, 12.5 Hz, H-5'), 4.50 (1 H, dd, J = 3.0, 12.5 Hz, H-5'), 3.94 (2H, t, J = 
6.8 Hz, H-4"'), 3.74 (3H, s, OCH3), 3.32 (2H, m, H-2"III), 2.77 (2H, t, J = 6.9 Hz, H-
1"111), 2.68 (2H, t, J = 6.8 Hz, H-3I11), 1.40 (9H, s, OC(CH3h); 13C NMR (75 MHz, 
COCh): 8 166.2 (C6H50CO), 161.4 (C-4), 153.9 (C-4""), 153.9 (NHCO), 150.5 (C-
1""), 149.4 (C-2), 141.6 (C-6), 133.5 (C-3'), 133.3 (C-4"), 132.0 (C-1"), 129.7 (C-2", 
C-6"), 129.2 (C-2""), 128.6 (C-3", C-5"), 127.0 (C-2'), 116.7 (C-3""), 112.9 (C-6""), 
112.0 (C-5""), 1 00.7 (C-2I11), 91.3 (C-1I11), 90.7 (C-1'), 85.0 (C-4'), 78.8 (02C(CH3h), 
72.4 (C-5), 66.7 (C-4I11) , 65.1 (C-5'), 55.6 (OCH3), 40.6 (C-2"III), 31.0 (C-1"III), 28.4 
(OC(CH3h), 20.8 (C-3"'); FABHRMS: m/z found 654.24300 [M+Nar. C34H37N30g 
[M+Nar requires 654.24274. 
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5-[3-{2-( 2-bis( terl-butoxycarbonylam i noethyl)-4-methoxyphenoxy} 
prop-1-ynyl]-5' -O-benzoyl-2' ,3' -didehydro-2' ,3' -dideoxyuridine (127) 
o 2'" 
1'::"':::: ~ 
3'" 
2 ..... 
According to GP1: Nucleoside 100 (0.19 g, 0.4 mmol), alkyne 94b (0.28 g, 0.7 
mmol), (PPh3)4Pd (0.05 g, 0.04 mmol), Cui (0.04 g, 0.1 mmol), triethylamine (0.1 mL, 
0.8 mmol), OMF (2.5 mL), THF (5.0 mL). Purification by column chromatography 
employing ethyl acetate 1 petroleum ether (6 14) afforded a yellow oil (0.26 g, 84%). 
[at~ -20 0 (c 0.30, CHCb); IR (CHCb): Vmax 3691 (w), 3606 (w), 3384 (w) (NH), 2930 
(m), 2855 (w), 2243 (w) (C=C), 1777 (m) (CO), 1721 (s) (CO) cm-1; 1H NMR (300 
MHz, COCh): 0 9.05 (1 H, brs, NH), 7.98 (2H, m, H-2", H-6"), 7.67 (1 H, s, H-6), 7.53 
(1 H, tt, J = 1.6, 7.5 Hz, H-4") , 7.42 (2H, t, J = 7.5 Hz, H-3", H-5"), 6.88 (1 H, t, J = 1.5 
Hz, H-1'), 6.87 (1 H, d, J = 8.4 Hz, H-6""), 6.68 (1 H, dd, J = 3.0, 8.4 Hz, H-5""), 6.65 
(1H, d, J= 3.0 Hz, H-3""), 6.36 (1H, dt, J= 1.6,6.0 Hz, H-3'), 5.96 (1H, dq, J= 1.2, 
6.0 Hz, H-2'), 5.19 (1H, m, H-4'), 4.67 (3H, m, 1 x H-5', 2 x H-3111), 4.47 (1H, dd, J = 
2.8, 12.4 Hz, H-5'), 3.75 (2H, t, J = 7.3 Hz, H-2"III), 3.71 (3H, s, OCH3), 2.83 (2H, t, J 
= 7.3 Hz, H-1"III), 1.44 (18H, s, 2 x OC(CH3h); 13C NMR (100 MHz, COCb): 0 166.1 
(CSH50CO), 161.1 (C-4), 154.1 (C-4""), 152.4 (NCO), 150.2 (C-1 ""), 149.5 (C-2), 
142.7 (C-6), 133.4 (C-4"), 133.4 (C-3'), 129.7 (C-2", C-6") , 129.3 (C-1"), 129.1 (C-
2""), 128.6 (C-3", C-5"), 127.0 (C-2'), 116.8 (C-3'III), 113.9 (C-6""), 112.0 (C-5""), 99.8 
(C-2111), 90.9 (C-1'), 89.7 (C-1111), 85.3 (C-4'), 81.9 (OC(CH3h), 77.7 (C-5), 64.9 (C-5'), 
57.6 (C-3111), 55.6 (OCH3), 46.4 (C-2"III), 30.0 (C-111111), 28.0 (2 x OC(CH3h); 
FABHRMS: m/z found 740.28021 [M+Nat C3sH43N3011 [M+Nar requires 
740.27951. 
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5-[4-{2-(2-terl-Butoxycarbonylaminoethyl)-4-methoxyphenoxy}hexa-
4-oxa-1-ynyl]-5' -O-benzoyl-2' ,3' -didehydro-2' ,3'-dideoxyuridine (136) 
2"'" U 1/ tt'''''~~ r ~ _ H 2''' !:'/'.,. 6",/0 1"" 2 1'~ U - ~ r '/" I 4"" ~ OMe o ~ 3" 3 4"~2" A1 51 
I "" '" O{o.1 
o 4'U_ l' 
3' 2' 
According to GP 1: Nucleoside 100 (0.27 g, 0,6 mmol), alkyne 135a (0.32 g, 0,9 
mmol), (PPh3)4Pd (0,07 g, 0.06 mmol), Cui (0,06 g, 0.3 mmol), EtJN (0.17 mL, 1.2 
mmol), OMF (2,5 mL), THF (5.0 mL). The crude product was purified by column 
chromatography employing EtOAc I pet ether (6 14) to give the title compound 136 
as a yellow oil (0.36 g, 92%). 1H NMR (300 MHz, COCh): 8 9.36 (1 H, brs, NH), 7.98 
(2H, m, H-2", H-6"), 7.66 (1 H, s, H-6), 7.52 (1 H, m, H-4") , 7.43 (2H, m, H-3", H-5"), 
6.90 (1H, m, H-1'), 6.74 (1H, d, J = 9.0 Hz, H-6"II), 6.66 (2H, m, H-3"", H-5""), 6.37 
(1 H, dt, J = 1.6, 5.9 Hz, H-3'), 5.97 (1 H, dq, J = 1.6, 5.9 Hz, H-2'), 5.18 (1 H, m, H-4'), 
4.94 (1H, brs, NH), 4.66 (1H, dd, J = 4.4, 12.5 Hz, H-5'), 4.48 (1H, dd, J = 2.9, 12,5 
Hz, H-5'), 4.25 (2H, S, H-3111) , 4.05 (2H, m, CH20), 3.83 (2H, m, OCH2), 3.72 (3H, s, 
OCH3), 3.32 (2H, m, H-2"111), 2.76 (2H, t, J = 6.2 Hz, H-1"1II), 1.39 (9H, s, OC(CH3h); 
13C NMR (75 MHz, COCh): 8 166.1 (CsHsOCO), 161.3 (C-4), 156.0 (NHCO) 153.7 
(C-4""), 150.9 (C-1"II), 149.5 (C-2), 142.2 (C-6), 133.4 (C-4"), 133.3 (C-3'), 129.6 (C-
2", C-6") , 129.3 (C-1"), 129.1 (C-2""), 128.6 (C-3", C-5"), 127.0 (C-2'), 116.5 (C-3""), 
113.0 (C-6""), 111.9 (C-5""), 99.8 (C-2111), 90.7 (C-1'), 89.9 (C-1111), 85.0 (C-4'), 78.8 
(02C(CH3h), 77.2 (C-5), 68.3 (OCH2), 68.1 (OCH2), 65.0 (C-5'), 58.9 (C-3111), 55.5 
(OCH3), 40.6 (C-2""), 30.8 (C-1 1111), 28.3 (OC(CH3h). 
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S-[9-{2-(2-terl-Butyloxycarbonylaminoethyl)-4-methoxyphenoxy}-
nona-4, 7 -dioxa-1-ynyl]-S' -O-benzoyl-2' ,3' -didehydro-2' ,3' -dideoxy 
uridine (138) 
o 
,,' ~4""OCH3 
T ~ 7 r _I 
2'" !'~6"/O~ 1 0 3"" 1"~ U '-/ 2'" H ~ '""r)'Oy H--. 4"~~2" ~151 
10 1" 0tj0 
5' 0 
o 4' _ l' 
3' 2' 
According to GP 1: Nucleoside 100 (0.110 g, 0,25 mmol), alkyne 135b (0.119 g, 0.30 
mmol), (PPh3)4Pd (0.029 g, 0,025 mmol), Cui (0.024 g, 0,125 mmol), Et3N (0.07 mL, 
0.5 mmol), DMF (5 mL), THF (10 mL). Column chromatography employing EtOAc I 
pet ether (1 I 1) gave the title compound 138 as a yellow oil (0.154 g, 82%). [at~ 
+30.6 0 (c 1.20, CHCb); IR (CHCI3): Vmax 3693 (w), 3607 (w), 3452 (w) (NH), 3384 (w) 
(NH), 3011 (w), 2980 (w), 2935 (w), 1703 (s) (CO), 1502 (m) (C=C); 1 H NMR (300 
MHz, CDCb): 8 9.58 (1 H, brs, NH), 7,98 (2H, m, H-2", H-6"), 7.64 (1 H, s, H-6), 7,54 
(1 H, m, H-4"), 7.42 (2H, t, J = 7.8 Hz, H-3", H-5"), 6.88 (1 H, m, H-1'), 6,73 (1 H, d, J = 
8.8 Hz, H-6"1), 6.66 (2H, m, H-3"1, H-5"1), 6.35 (1 H, d, J = 6.1 Hz, H-3'), 5.95 (1 H, m, 
H-2'), 5.17 ( 1H, m, H-4'), 4.98 (1H, brs, NH), 4.65 (1H, dd, J = 4.3, 12.5 Hz, H-5'), 
4.47 (1H, dd, J = 2.8, 12.5 Hz, H-5'), 4.21 (2H, S, H-3111) , 4.05 (2H, t, J = 4.9 Hz, 
CH20), 3.80 (2H, t, J = 4.9 Hz, CH20), 3.71 (3H, s, OCH3), 3.69 (4H, m, 2 x CH20), 
3.32 (2H, brs, H-2"I'), 2.76 (2H, t, J = 6.8 Hz, H-1"I'), 1.39 (9H, s, OC(CH3h); 13C 
NMR (75 MHz, CDCb): 8 166.2 (C6H50CO), 161.5 (C-4), 156.0 (NHCO), 153.7 (C-
4""), 151.0 (C-1"1), 149.6 (C-2), 142.3 (C-6), 133.4 (C-3'), 133.4 (C-4"), 129.7 (C-2", 
C-6"), 129.3 (C-1"), 129.2 (C-2""), 128.6 (C-3", C-5"), 127.0 (C-2'), 116.6 (C-3"1), 
113.1 (C-6""), 112.0 (C-5"1I), 99.9 (C-2111), 90.7 (C-1'), 90.0 (C-1111), 85.1 (C-4'), 78.8 
(02C(CH3h), 70.5 (2 x OCH2), 69.8 (OCH2), 69.1 (C-5), 68.4 (OCH2), 65.0 (C-5'), 
58.9 (C-3"'), 55.6 (OCH3), 40.6 (C-2"II'), 31.0 (C-1"111), 28.4 (OC(CH3h); FABHRMS: 
m/z found 728.27796 [M+Nat C37H43N3011 [M+Nat requires 728.27951. 
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5-[4-{2-(2-tert-Butoxycarbonylaminoethyl)-4-methoxyphenoxy}but-1-
ynyl]-2' ,3'-didehydro-2' ,3'-dideoxyuridine (126) 
o 
Zoo, U 1/ 
~""~~ 3" 2'" I o 2" 4" 0 1'" H 1""';::: -:?' 3'" ~ 1 4", ~ OCH3 
The nucleoside 125 (0.085 g, 0,1 mmol) was dissolved in MeOH (1 mL) and the 
residue cooled to 0 °c. Sodium methoxide in methanol (0.1 mL, 1 M, 0.1 mmol) was 
added and the mixture stirred at 0 °c for 20 min. Water (5 mL) was added to the 
mixture and the residue extracted with ethyl acetate (3 x 15 mL). The organic 
extracts were combined, dried (MgS04), filtered and the solvent evaporated in vacuo. 
Column chromatography employing petroleum ether I ethyl acetate (2 I 8) gave 126 
as a colourless oil (0.056 g, 79%). IR (CHCb): Vmax 3690 (w), 3521 (br) (OH), 3386 
(w) (NH), 2411 (w) (C=C), 1697 (s) (CO), 1602 (w) cm-1; 1H NMR (300 MHz, CDCb): 
(58.98 (1H, brs, NH), 8.00 (1H, s, H-6), 6.97 (1H, m, H-1'), 6.75 (1H, d, J = 9.6 Hz, H-
6"'), 6,69 (2H, m, H-3"', H-5"'), 6.36 (1 H, dt, J = 1.7, 5.8 Hz, H-3'), 5.82 (1 H, dq, J = 
1.7, 5.8 Hz, H-2'), 4.90 (2H, brs, H-4', NH), 4.05 (2H, t, J = 6.1, Hz, H-4"), 3.88 (1 H, 
dd, J = 2.7, 12.4 Hz, H-5'), 3,78 (1H, dd, J = 3.0, 12.4 Hz, H-5'), 3.74 (3H, s, OCH3), 
3.33 (2H, m, H-2""), 2.82 (2H, t, J = 6.1 Hz, H-3"), 2.77 (2H, m, J = 6.3 Hz, H-1""), 
1.96 (1H, brs, OH), 1.40 (9H, s, OC(CH3h); 13C NMR (75 MHz, CDCb): (5 161.9 (C-
4), 156.4 (NHCO), 153.8 (C-4"') , 150.7 (C-1"'), 149.8 (C-2), 143.7 (C-6), 135.2 (C-3'), 
129.3 (C-2"'), 125.9 (C-2'), 116.8 (C-3"'), 113.0 (C-6"'), 111.9 (C-5"'), 1 00.1 (C-2"), 
91.3 (C-1"), 90.2 (C-1'), 87.6 (C-4'), 79.3 (OC(CH3h), 72.4 (C-5), 66.8 (C-4"), 62.9 
(C-5'), 55.6 (OCH3), 40.5 (C-2""), 31.1 (C-1""), 28.4 (OC(CH3h), 20.9 (C-3"). 
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5-[3-{2-(2-bis-(tert-Butoxycarbonylaminoethyl)-4-methoxyPhenoxy}-
prop-1-ynyl]-2' ,3'-didehydro-2' ,3'-dideoxyuridine (128) 
Sodium methoxide in methanol (0.1 mL, 1 M, 0.1 mmol) was added to a solution of 
the nucleoside 127 (0.067 g, 0.09 mmol) in MeOH (1.0 mL) at 0 °C, and the mixture 
was stirred at 0 °C for 90 min. H20 (5 mL) was added and the product extracted with 
ethyl acetate (3 x 10 mL). The organic extracts were combined, dried (MgS04), 
filtered and the solvent evaporated under reduced pressure. The product was purified 
by column chromatography employing a gradient of ethyl acetate 1 petroleum ether (8 
12) to 100% ethyl acetate to give the title compound 128 as a colourless oil (0.042 g, 
74%). [al~ +22.4 ° (c 0.70, CHCI3); IR (CHCb): V max 3693 (w), 3539 (br) (OH), 3385 
(w) (NH), 2243 (w) (C=C), 1777 (m) (CO), 1697 (s) (CO) cm-1; 1H NMR (300 MHz, 
CDCb): 8 8.72 (1 H, brs, NH), 8.34 (1 H, s, H-6), 6.95 (1 H, m, H-1 '), 6.93 (1 H, d, J = 
9.2 Hz, H-6"'), 6.70 (2H, m, H-3'" , H-5"'), 6.33 (1 H, dt, J = 1.8,6.2 Hz, H-3'), 5.82 (1 H, 
dt, J = 1.8, 6.2 Hz, H-2'), 4.92 (1 H, m, H-4'), 4.78 (2H, s, H-3"), 3.92 (1 H, brd, J = 
11.2 Hz, H-5'), 3.79 (3H, m, 1 x H-5', 2 x H-2""), 3.73 (3H, s, OCH3), 3.18 (1H, brs, 
OH), 2.91 (1H, m, H-1""), 2.84 (1H, m, H-1""), 1.41 (18H, s, 2 x OC(CH3h); 13C NMR 
(100 MHz, CDCb): 8 161.3 (C-4), 154.0 (C-4"'), 152.4 (N(COh), 150.2 (C-1"'), 149.6 
(C-2), 145.5 (C-6), 134.8 (C-3'), 129.5 (C-2"'), 126.1 (C-2'), 117.0 (C-3"'), 113 (C-6"'), 
111.9 (C-5"'), 99.1 (C-2"), 90.3 (C-1'), 88.6 (C-1"), 87.7 (C-5), 82.1 (C-4'), 78.1 
(02C(CH3h), 62.7 (C-5'), 57.5 (C-3"), 55.6 (OCH3), 46.9 (C-2""), 29.9 (C-1""), 27.9 (2 
x OC(CH3h). 
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5-[4-{2-(2-tert-Butoxycarbonylaminoethyl)-4-methoxyphenoxy}hexa-
4-oxa-1-ynyl]-2',3'-didehydro-2',3'-dideoxyuridine (137) 
o 
2"" U 1/ 
t§"" ~~ 3" 5" 2'" H o 2" 1:.~6"/O 1'" 1'~ U - ~ ~ ~ 14'" 
::::c-.. OMe 
To an ice-cold solution of the nucleoside 136 (0.36 g, 0.6 mmol) in MeOH (2 mL) was 
added NaOMe in methanol (0.1 mL, 1 M, 0.1 mmol). The mixture was stirred at 0 °C 
for 30 min. The residue was diluted with H20 (5 mL) and extracted with ethyl acetate 
(3 x 20 mL). The combined organic extracts were dried over MgS04, filtered and the 
solvent evaporated under reduced pressure. The crude product was purified by 
column chromatography employing ethyl acetate I pet ether (6 14) to give 137 as a 
colourless oil (0.21 g, 69%). [a]~ +28.3 ° (c 1.10, CHCb); IR (CHCb): Vmax 3692 (w), 
3535 (br) (OH), 3383 (w) (NH), 2344 (w) (C:C), 1713 (s) (CO) cm-1; 1 H NMR (300 
MHz, CDCb): 89.03 (1H, brs, NH), 8.21 (1H, s, C-6), 6.97 (1H, m, H-1'), 6.76 (1H, d, 
J = 9.3 Hz, H-6"'), 6.67 (2H, m, H-3"', H-5"'), 6.34 (1 H, dt, J = 1.7, 6.0 Hz, H-3'), 5.83 
(1H, dq, J = 1.7,6.0 Hz, H-2'), 4.96 (1H, brs, NH), 4.91 (1H, s, H-4'), 4.40 (2H, s, H-
3"), 4.08 (2H, t, J = 4.6 Hz, CH20), 3.90 (1 H, brd, J = 11.1 Hz, H-5'), 3.88 (2H, t, J = 
4.6 Hz, CH20), 3.79 (1 H, d, J = 11.1 Hz, H-5'), 3.73 (3H, s, OCH3), 3.62 (1 H, brs, 
OH), 3.34 (2H, m, H-2""), 2.77 (2H, t, J = 6.1 Hz, H-1""), 1.40 (9H, s, OC(CH3h); 13C 
NMR (75 MHz, CDCb): 8 161.6 (C-4), 156.4 (NHC02), 153.8 (C-4"'), 150.9 (C-1"'), 
149.7 (C-2), 144.7 (C-6), 135.1 (C-3'), 129.3 (C-2"'), 126.0 (C-2'), 116.8 (C-3"'), 113.2 
(C-6"'), 111.8 (C-5"'), 99.2 (C-2"), 90.2 (C-1'), 89.2 (C-1"), 87.7 (C-4'), 79.2 
(02C(CH3h), 77.0 (C-5), 68.4 (CH20), 68.2 (CH20), 62.7 (C-5'), 59.1 (C-3"), 55.6 
(OCH3), 40.5 (C-2""), 31.0 (C-1""), 28.4 (OC(CH3h). 
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5-[ 4-{2-( 2-terl-Butoxycarbonylam inoethyl)-4-methoxyphenoxy}nona-
4,7 -d ioxa-1-ynyl]-21 ,31 -didehyd ro-21 ,31 -d ideoxyu rid i ne (139) 
o ~4 .. ,OCH3 3" 5" 7" 9" 1'" I 2" ~/'--... 6" ...... o~ 8" /"--... ~ 3'" 1"~ U - ~ ~ r H ~ 1.... ~/0J< 
2.... n 
o 
To a cold solution of the nucleoside 138 (0.095 g, 0.13 mmol) in MeOH (2 mL) was 
added NaOMe (0.1 mL, 1 M, 0.1 mmol). The mixture was stirred at 0 °C for 30 min. 
The base was diluted with H20 (5 mL) and extracted with ethyl acetate (3 x 20 mL). 
The combined organic extracts were dried over MgS04 , filtered and the solvent 
evaporated under reduced pressure. The crude product was purified by column 
chromatography employing ethyl acetate I pet ether (6 I 4) to give 139 as a 
colourless oil (0.07 g, 86%). [af~ -16.8 ° (c 0.50, CHCb); IR (CHCI3): Vmax 3692 (w), 
3611 (w), 3500-3200 (br) (OH), 3449 (w) (NH), 3387 (w), 3012 (m), 2933 (m), 2877 
(m), 2240 (w) (C=C), 1697 (s) (CO), 1502 (m) (C=C), 1457 (m) (C=C); 1H NMR (300 
MHz, CDCb): 09.47 (1H, brs, NH), 8.18 (1H, s, C-6), 6.92 (1H, m, H-1'), 6.74 (1H, d, 
J = 9.0 Hz, H-6"') , 6.65 (2H, m, H-3'" , H-5"'), 6.29 (1 H, dt, J = 1.6, 6.1 Hz, H-3'), 5.79 
(1 H, dq, J = 1.6, 6.1 Hz, H-2'), 5.07 (1 H, brs, NH), 4.87 (1 H, m, H-4'), 4.32 (2H, s, H-
3"), 4.04 (2H, m, CH20), 3.87 (1 H, brd, J = 12.2 Hz, H-5'), 3.79 (2H, m, CH20), 3.71 
(7H, m, 2 x CH20), OCH3), 3.66 (1 H, brd, J = 12.2 Hz, H-5'), 3.30 (2H, d, J = 6.3 Hz, 
H-2"1), 2.75 (2H, t, J= 6.3 Hz, H-1"1), 2.41 (1H, brs, OH), 1.38 (9H, s, OC(CH3h); 13C 
NMR (100 MHz, CDCb): 0 161.8 (C-4), 156.3 (NHC02), 153.8 (C-4"') , 151.0 (C-1"'), 
149.9 (C-2), 144.8 (C-6), 135.0 (C-3'), 129.4 (C-2"'), 126.0 (C-2'), 116.7 (C-3"'), 113.2 
(C-5"'), 112.0 (C-6"'), 99.2 (C-2"), 90.2 (C-1'), 89.1 (C-1"), 87.7 (C-4'), 79.0 
(02C(CH3h), 77.7 (C-5), 70.5 (OCH2), 69.8 (OCH2), 69.1 (OCH2), 68.5 (OCH2), 62.8 
(C-5'), 59.1 (C-3"), 55.6 (OCH3), 40.6 (C-2"1), 30.9 (C-1"1), 28.4 (OC(CH3h); 
FABHRMS: m/z found 624.25430 [M+Nat C30H39N3010 [M+Nat requires 
624.25332. 
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[Benzoyl-d4U]-butyne-[HI-236] (141) 
o 2'" 
1~ 
According to GP1: Alkyne 77 (0.020 g, 0.048 mmol), nucleoside 100 (0.025 g, 0.058 
mmol), Pd (0) (0.006 g, 0.005 mmol), Cui (0.004 g, 0.02 mmol), Et3N (0.01 mL, 0.010 
mmol), OMF (0.5 mL), THF (1.0 mL) to give the title compound 141 as a white solid 
(0.019 g, 54%). mp: 95-97 °c (from pet ether/CH2CI2); 1H NMR (400 MHz, COCh): 8 
11.00 (1H, brs, NH-2), 8.83 (1H, brs, NH-1), 8.11 (1H, d, J = 3.2 Hz, H-6"""), 8.02 
(2H, m, H-3""", H-4111111) , 7.67 (1 H, s, H-6), 7.53 (2H, m, H-2", H-6"), 7.43 (2H, m, H-3", 
H-5"), 7.30 (1H, m, H-4") , 7.20 (1H, brs, NH), 6.92 (1H, m, H-1'), 6.80 (1H, d, J = 2.5 
Hz, H-3""), 6.76 (1 H, d, J = 8.9 Hz, H-6""), 6.72 (1 H, dd, J = 2.5, 8.9 Hz, H-5""), 6.37 
(1 H, dt, J = 1.6, 6.0 Hz, H-3'), 6.06 (1 H, m, H-2'), 5.21 (1 H, m, H-4'), 4.67 (1 H, dd, J = 
4.0, 12.3 Hz, H-5'), 4.52 (1 H, dd, J = 3.0, 12.3 Hz, H-5'), 3.98 (2H, m, H-4111) , 3.77 
(3H, s, OCH3), 3.55 (2H, m, H-2"III), 2.95 (1 H, m, H-3111), 2.84 (1 H, m, H-3111) , 2.68 (2H, 
t, J = 6.2 Hz, H-1""'); 13C NMR (100 MHz, COCh): 8 163.7 (C-4), 155.2 (C6H50CO), 
153.9 (C-4""), 152.0 (C-2"""), 150.8 (C-1""), 149.4 (C-2), 147.2 (C-6"""), 141.8 (C-
4"""), 140.7 (C-6), 133.3 (C-4"), 133.1 (C-3'), 129.8 (C-2", C-6"), 129.5 (C-2""), 129.5 
(C-1"), 128.6 (C-3", C-5"), 127.5 (C-2'), 116.7 (C-3""), 113.7 (C-6""), 112.7 (C-5""), 
111.6 (C-3"""), 111.6 (C-5"""), 1 00.4 (C-2"'), 92.5 (C-1 III), 90.7 (C-1 '), 85.0 (C-4'), 72.1 
(C-5), 66.7 (C-4111) , 65.2 (C-5'), 55.6 (OCH3), 40.0 (C-2"III), 30.4 (C-1"III), 29.7 (C-3111). 
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[d4U]-butyne-[HI-236] (96) 
5 
1"" 2"" ~NH2 
3" A 
2'" HI 0'"'' 4" 1'~ 3'" 1 '-':: 3'"'' I 4'" I 
6'" ::::,.... 0 4"'" 
5'" OCH3 5"'" 
Br 
Trifluoroacetic acid (0.1 mL) was added to a cold solution of the nucleoside 126 
(0.020 g, 0.04 mmol) in CH2CI2 (1 mL). The mixture was stirred for 30 min at 0 °C 
and diisopropylethylamine (1.0 mL) added. The reaction mixture was stirred for 10 
min and the solvent removed in vacuo. Methanol (1.0 mL) and K2C03 (0.002 g) were 
added and the mixture stirred for an additional 10 min. Inorganic salts were removed 
by filtration through a pad of Celite and washed with large volumes of methanol. The 
solvent was removed in vacuo and the resultant amine dried under vacuum for 1 h. 
DMF (1.0 mL) and thiocarbonyl reagent 89 (0.013 g, 0.05 mmol) were added and the 
mixture was heated at 100 °C for 1 h. DMF was removed by co-evaporation with 
toluene and the product purified by column chromatography using petroleum ether I 
EtOAc (2 I 8) to give 96 as a pale yellow solid (0.012 g, 41%). mp: 200-202 °C (from 
MeOH/CH2CI2); 1H NMR (400 MHz, DMSO-ds): 8 11.04 (1 H, brt, J = 4.4 Hz, NH-1), 
10.55 (1 H, brs, NH-2), 8.04 (1 H, d, J = 2.2 Hz, H-6""'), 7.94 (1 H, s, H-6), 7.87 (1 H, 
dd, J = 2.2, 8.6 Hz, H-4""') , 7.56 (1 H, brs, NH), 7.04 (1 H, d, J = 8.6 Hz, H-3""'), 6.88 
(1H, d, J = 8.8 Hz, H-6"'), 6.75 (3H, m, H-1', H-3"', H-5111) , 6.35 (1H, dt, J = 1.6,6.0 
Hz, H-3'), 5.86 (1 H, m, H-2'), 4.74 (1 H, m, H-4'), 3.98 (2H, t, J = 6.4 Hz, H-4"), 3.78 
(2H, m, H-2'III), 3.62 (3H, s, OCH3), 3.58 (2H, m, H-5'), 2.85 (2H, t, J = 6.5 Hz, H-1""), 
2.76 (2H, t, J = 6.5 Hz, H-3"); 13C NMR (100 MHz, DMSO-ds): 8 179.0 (C=S), 162.7 
(C-4), 153.2 (C-4"'), 152.2 (C-2""'), 150.3 (C-1111), 149.8 (C-2), 145.6 (C-6""'), 141.2 
(C-6), 141.2 (C-4"III), 135.4 (C-3'), 128.6 (C-2"'), 125.5 (C-2'), 117.0 (C-3"'), 114.4 (C-
3"'''), 113.4 (C-6"'), 111.6 (C-5"'),111.6 (C-5111"), 98.4 (C-2"), 89.8 (C-1 "), 89.4 (C-1'), 
87.5 (C-4'), 73.9 (C-5), 66.8 (C-4"), 61.8 (C-5'), 55.2 (OCH3), 44.6 (C-2""), 29.1 (C-
1""), 20.1 (C-3"). 
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[d4U]-propyne-[HI-236] (97) 
Br 
OM~5'"'' 
'-':: '/" 4"'" 
3" ~o :::, N~ I 3"'" 
1'" 2'" H 2"'" 
I 
1""2",,~~H 
S 
3' 2' 
Nucleoside (0.042 g, 0.07 mmol) in methylene chloride (1.0 mL) was treated with 
trifluoroacetic acid (0.1 mL) at 0 °C. The reaction was stirred for 30 min. K2C03 and 
MeOH (1 mL) were added and the residue stirred for a further 10 min. The K2C03 
was filtered through a pad of Celite and washed with MeOH (3 x 10 mL). The solvent 
was removed in vacuo and the amine dried under vacuum. The crude amine formed 
was reacted with thiourea derivative 89 (0.029 g, 0.10 mmol) in DMF (1.0 mL) at 100 
°C for 1 h. The crude product was purified by column chromatography using ethyl 
acetate / hexane (8/2) to give a pale yellow solid (0.012 g, 49%). 
[d4U]-monoPEGpropyne-[HI-236] (98) 
S 
o 2" 
1'~ 
2"" U 
~"" tr"NH 3" 5" '" H Q"'" .!'./"-... 6':.,..0 1'" 2 V '-/ '/" 3'" '-':: 3"'" I 4'" I :::-... 04"'" OMe 
Br 
Nucleoside (0.147 g, 0.26 mmol) in methylene chloride (1.0 mL) was treated with 
trifluoroacetic acid (0.1 mL) at O°C. The reaction was stirred for 30 min. 
Diisopropylethylamine (0.4 mL) was added and the solvent evaporated. The residue 
was dissolved in MeOH (1 mL), K2C03 added and the mixture stirred for 10 min. The 
K2C03 was filtered through a pad of Celite, washed with MeOH (3 x 10 mL) and the 
solvent evaporated in vacuo. The crude amine was dried under vacuum for 1 hand 
then reacted with thiourea derivative 89 (0.097 g, 0.34 mmol) in DMF (1.0 mL) at 100 
°C for 1 h. The crude product was purified by column chromatography using ethyl 
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acetate 1 hexane (8 12) to give a pale yellow solid (0.071 g, 40%) as a mixture of two 
compounds. Repetitive column chromatography using 4% MeOH in CH2CI2 afforded 
98 (7 mg) and 98a (10 mg). 
98. mp: 79-82 °C; [a]~ +53.3 ° (c 0.10, CHCb); IR (CHCb): Ymax 3691 (m) (NH), 3607 
(w), 3385 (w), 3022 (m), 2928 (m), 2855 (w), 1719 (m) (CO), 1698 (m) (CO), 1602 
(m) (C=C), 1221 (s) (C=S) cm-1; 1H NMR (300 MHz, CDCb): 8 11.00 (1H, brt, NH), 
8.64 (2H, brs, 2 x NH), 8.18 (1 H, s, H-6), 8.03 (1 H, d, J = 2.4 Hz, H-6"III), 7.68 (1 H, 
dd, J = 2.4, 8.8, H-4111") , 6.99 (1 H, m, H-1'), 6.77 (4H, m, H-3"III, H-3111, H-5111, H-6111) , 
6.37 (1 H, dt, J = 1.6, 5.8 Hz, H-3'), 5.87 (1 H, dt, J = 1.7, 5.8 Hz, H-2'), 4.96 (1 H, m, 
H-4'), 4.40 (1 H, s, H-3"), 4.05-3.77 (8H, m, H-5', H-2111', 2 x CH20), 3.77 (3H, s, 
OCH3), 2.99 (2H, t, J = 6.4 Hz, H-1""); 13C NMR (100 MHz, CHCI3): 8 179.1 (C=S), 
161.9 (C-4), 153.4 (C-4111) , 152.2 (C-2"III), 151.2 (C-1I11), 149.7 (C-2), 146.7 (C-6"III), 
144.6 (C-6), 141.1 (C-4"III), 135.1 (C-3'), 129.2 (C-2'''), 126.1 (C-2'), 117.6 (C-3"'), 
117.6 (C-5"III), 113.5 (C-3"III), 112.9 (C-6I11), 111.7 (C-5I11), 99.7 (C-2"), 95.5 (C-1"), 
90.3 (C-1'), 87.7 (C-4'), 77.3 (C-5), 68.4 (OCH2), 68.4 (OCH2), 62.8 (C-5'), 59.3 (C-
3"), 55.6 (OCH3), 46.0 (C-2""), 30.0 (C-1 ""). 
[d4U]-diPEGpropyne-[HI-236] (98) 
Br 
4'" OMeQ"''' ~ -:?' 4 .... ' 
3" 4" 5" 6" O~~'" I .0 3'" N::,... I 3 .... ' ~ 2'" H 2 .... ' 
I 
1.... ~/NH 
2"" IT 
s 
Nucleoside (0.047 g, 0.08 mmol) in methylene chloride (1.0 mL) was treated with 
trifluoroacetic acid (0.1 mL) at O°C. The reaction was stirred for 30 min. 
Diisopropylethylamine (0.4 mL) was added and the solvent evaporated. The residue 
was dissolved in MeOH (1 mL), K2C03 added and the mixture stirred for 10 min. The 
K2C03 was filtered through a pad of Celite, washed with MeOH (3 x 10 mL) and the 
solvent evaporated in vacuo. The crude amine was reacted with thiourea derivative 
89 (0.031 g, 0.1 mmol) in DMF (1.0 mL) at 100°C for 1h. The crude product was 
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purified by column chromatography using ethyl acetate I hexane (8 I 2) to give a 
mixture of two products (0.034 g, 61 %) as a white solid. 
99: mp: 139-140 °c (from petether/CH2CI2); 1H NMR (300 MHz, COCh): 811.10 (1H, 
t, J = 5.1 Hz, NH), 8.86 (1 H, brs, NH), 8.21 (1 H, s, C-6), 8.03 (1 H, d, J = 2.4 Hz, H-
6111 '),7.69 (1H, dd, J = 2.4,8.7 Hz, H-4""), 6.97 (1H, m, H-1'), 6.84 (1H, d, J = 8.7 Hz, 
H-3""'), 6.74 (3H, m, H-3111 , H-5111, H-6111), 6.32 (1 H, dt, J = 1.6,5.9 Hz, H-3'), 5.84 (1 H, 
dq, J = 1.6, 5.9 Hz, H-2'), 4.92 (1 H, m, H-4'), 4.33 (2H, s, H-3"), 4.02 (6H, m, 3 x 
CH20), 3.84 (2H, m, CH20), 3.75 (5H, m, H-2"", OCH3), 2.98 (2H, t, J = 6.6 Hz, H-
1""); 13C NMR (100 MHz, COCh): 8179.1 (C=S), 161.6 (C-4), 153.8 (C-4I11) , 151.8 (C-
1'''),151.3 (C-2"1II), 149.8 (C-2), 146.6 (C-6"1II), 144.9 (C-6), 141.1 (C-4"III), 135.0 (C-
3'), 128.9 (C-2111), 126.1 (C-2'), 117.6 (C-3111), 113.7 (C-3"1II), 112.9 (C-5"1II), 112.7 (C-
6111),111.7 (C-5111), 99.4 (C-2"), 90.3 (C-1'), 89.4 (C-1"), 87.7 (C-4'), 76.7 (C-5), 70.7 
(CH20), 70.0 (CH20), 69.2 (CH20), 68.6 (CH20), 62.8 (C-5'), 59.2 (C-3"), 55.6 
(OCH3), 45.8 (C-2""), 30.0 (C-1 ""). 
[Uracil]-diPEGpropyne-[HI-236] (99a) 
Br 
o 
OM¢e"" -..:::::: ~ 4"" 
3' 5' 7' 9' I 4" I 
4' 6' O~ £" h3" N::,... 3"" ~ O 2,, H 2"" I 
1'" N....../NH 
2'" n 
S 
99a: mp: 119-123 °C (from pet ether/CH2CI2); 1H NMR (300 MHz, COCh): 8 11.18 
(1 H, t, J = 5.1 Hz, NH), 9.42 (1 H, brs, NH), 8.02 (1 H, d, J = 2.4 Hz, H-6""), 7.65 (1 H, 
dd, J = 2.4, 8.7 Hz, H-4""), 7.59 (1 H, s, H-6), 6.85 (1 H, d, J = 8.7 Hz, H-3""), 6.74 
(3H, m, H-3", H-5", H-6"), 4.36 (2H, s, H-3'), 4.02 (6H, m, 3 x CH20), 3.85 (2H, m, 
CH20), 3.73 (5H, m, OCH3, C-2111) , 2.98 (2H, t, J = 6.8 Hz, H-1111); 13C NMR (100 MHz, 
COCh): 8 179.0 (C=S), 163.0 (C-4), 153.7 (C-4") , 152.1 (C-2""), 151.2 (C-1"), 149.4 
(C-2), 146.5 (C-6), 144.9 (C-6""), 141.1 (C-4""), 128.9 (C-2"), 117.7 (C-3"), 113.9 (C-
3""), 112.9 (C-6"), 112.9 (C-5""), 111.6 (C-5"), 90.4 (C-2'), 87.7 (C-1'), 77.4 (C-5), 
70.7 (CH20), 69.9 (CH20), 69.2 (CH20), 68.5 (CH20), 59.2 (C-3'), 55.6 (OCH3), 45.7 
(C-2"'), 30.0 (C-1111). 
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5-[4-(2-Tetrahydropyranyloxy)-but-1-ynyl]-2' ,3'-didehydro-2' ,3'-
dideoxyuridine (140) 
o 
~ 
3 4 S ~161 
HO~ ,O~ I 
4'U1 
3' 2' 
2" 
1',,*, 
3" 
4" O~Ol 
3'VS 
4'" 
According to GP1: lodo-d4U 101 (0.100 g, 0,3 mmol), alkyne 148 (0.101 g, 0.66 
mmol), Pd(O) (0.038 g, 0.03 mmol), Cui (0.031 g, 0.16 mmol), Et3N (0.09 mL, 0.7 
mmol), DMF (2.5 mL), THF (5 mL). Purification by column chromatography using 
EtOAc / hexane (3/2) furnished 140 as a colourless oil (0.041 g, 37%). 1H NMR (400 
MHz, CDCI3): 89.10 (1 H, brs, NH), 8.02 (1 H, s, H-6), 6.96 (1 H, m, H-1'), 6.33 (1 H, dt, 
J = 1.6, 5.9 Hz, H-3'), 5.83 (1 H, dd, J = 1.6, 5.9 Hz, H-2'), 4.91 (1 H, brs, H-4'), 4.64 
(1 H, m, H-2"'), 3.83 (4H, m, 1 x H-4", 1 x H-5', 2 x H-6"'), 3.61 (1 H, m, H-4"), 3.50 
(1 H, m, H-5'), 2.64 (2H, t, J = 7.0 Hz, H-3"), 2.10 (1 H, brs, OH), 1.79 (1 H, m, CH2), 
1.70 (1 H, m, CH2), 1.56 (4H, m, 2 x CH2); 13C NMR (100 MHz, CDCI3): 8 161.8 (C-4), 
149.8 (C-2), 143.7 (C-6), 134.9 (C-3'), 126.1 (C-2'), 100.3 (C-2"), 98.9 (C-2"'), 91.5 
(C-1"), 90.2 (C-1'), 87.5 (C-4'), 72.2 (C-5), 65.7 (C-4"), 63.0 (C-6"'), 62.4 (C-5'), 30.5 
(CH 2), 25.4 (CH 2), 21.1 (C-3"), 19.4 (CH 2). 
5-(4-Hydroxybut-1-ynyl)-2' ,3'-didehydro-2' ,3'-dideoxyuridine (140a) 
2" 
3" 
4' OH 
1',,*, 
p-Toluenesulfonic acid (cat.) was added to a solution of 140 (0.041 g, 0.12 mmol) in 
MeOH (1 mL) at 0 °C. The mixture was stirred at 0 °C for 30 min. The solvent was 
removed in vacuo and the crude product purified by column chromatography 
employing EtOAc / hexane (4/1) to give 140a as a colourless oil (0.010 g, 27%). 1H 
NMR (300 MHz, CD30D): 8 8.13 (1 H, s, H-6), 6.93 (1 H, m, H-1'), 6.42 (1 H, dt, J = 
1.6, 6.2 Hz, H-3'), 5.91 (1 H, dq, J = 1.6, 6.2 Hz, H-2'), 4.88 (1 H, m, H-4'), 3.76 (2H, 
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m, H-4"), 3.67 (2H, m, H-5'), 2.56 (2H, t, J = 6.6 Hz, H-3"); 13C NMR (75 MHz, 
CD30D): 8 164.9 (C-4), 151.8 (C-2), 145.5 (C-6), 136.4 (C-3'), 127.0 (C-2'), 100.8 (C-
2"),92.1 (C-1"), 91.5 (C-1'), 89.3 (C-4'), 73.5 (C-5), 63.6 (C-4"), 61.5 (C-5'), 24.5 (C-
3"). 
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Anti-HIV Evaluation 
1 x 105 MT-2 cells per millilitre were infected with HIV-1 IIiB at a 0.1 multiplicity of 
infection (MOl). 100 Jll of this solution was mixed with each serial dilution of inhibitor 
in triplicate on a 96-well plate. Mock infected cells were also mixed with inhibitor in a 
similar manner. After five days of incubation, a cell-permeable tetrazolium dye (MTT) 
was added. The MIT reaction was stopped after 5 h by adding acidified isopropanol. 
The plates were gently shaken overnight, quantitated on a plate reader and the 
absorbance measured at 595 nm. The absorbance values were then plotted versus 
inhibitor concentration to generate ECso and CCso values. The 50% effective 
concentration (ECso) and 50% cytotoxic concentration (CCso) of the test compounds 
were defined as the compound concentrations required to inhibit cell viability (MT -2) 
by 50% or to reduce by 50% the number of viable cells in mock-infected cell cultures, 
respectively. 
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